Methods and systems for classifying a receptor protein expression status of a sample

Machine learning models on genomic data accurately classify receptor protein expression and hormone receptor status, addressing challenges of low tumor purity and ambiguous results in existing methods, enhancing diagnostic precision and treatment monitoring.

WO2026241600A1PCT designated stage Publication Date: 2026-11-19FOUNDATION MEDICINE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028301
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing methods for determining receptor protein expression status in cancer, such as IHC, face challenges with insufficient tissue samples, low tumor purity, and ambiguous results from low staining levels, necessitating a sensitive and accurate method for real-time monitoring of receptor subtype switching without chemistry-based testing.

Method used

Utilizing machine learning models trained on genomic profiling data to classify receptor protein expression status, particularly for low tumor purity samples, by identifying differentially expressed genes and incorporating tumor purity metrics, enabling accurate prediction of hormone receptor status and monitoring for subtype switching.

Benefits of technology

The method provides precise classification of receptor protein expression and hormone receptor status, even in low purity samples, improving diagnostic accuracy and enabling timely treatment decisions by detecting subtype switching.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026028301_19112026_PF_FP_ABST
    Figure US2026028301_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Methods and systems for determining a receptor expression status of a test sample and training machine learning models for the same are described. The methods may comprise, for example, receiving test gene expression data for the test sample; inputting the test gene expression data into a receptor polypeptide expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein the receptor polypeptide expression machine learning model is trained to output a protein expression marker characteristic of one or more receptor polypeptides; outputting a predicted protein expression marker characteristic of one or more receptor polypeptides for the test sample; and determining the receptor protein expression status of the test sample.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No.: 197102021140 METHODS AND SYSTEMS FOR CLASSIFYING A RECEPTOR PROTEIN EXPRESSION STATUS OF A SAMPLECROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the priority benefit of United States Provisional Patent Application Serial No. 63 / 806,209, filed May 15, 2025, the contents of which are incorporated herein by reference in their entirety.FIELD

[0002] The present disclosure relates generally to methods and systems for analyzing genomic profiling data, and more specifically to methods and systems for determining a receptor protein expression status using genomic profiling data and machine learning models.BACKGROUND

[0003] Clinical subtypes for disease, such as breast cancer, are often based on expression of receptor polypeptides. In breast cancer, expression of the estrogen receptor (ER), progesterone receptor (PR), together determine a hormone receptor (HR) status for the cancer. Along with the HER2 receptor status, the subtyping is established. For example, HR+ / HER2- subtype is the most common subtype for breast cancer. In the clinic, patients receive immunohistochemistry (IHC) testing for receptor subtype classification early in care because the subtypes play a role in diagnostic and treatment decisions. Receptor switching is a common occurrence in disease, such as breast cancer, along the course of treatment. Subtype switching may indicate resistance to therapy, such as a switch to HR- indicates a tumor may be resistant to endocrine therapy.

[0004] Tissue samples are often collected throughout treatment as they can also be important for diagnostics and treatment decisions. Often there is not sufficient tissue sample to run both genomic profiling and IHC testing at each timepoint and genomic profiling is already being performed during the normal course of case. In addition, low tumor purity samples may be difficult to analyze using chemistry based methods, such as IHC. In some cases, even with sufficient tissue and purity, low staining levels (e.g. ER l%-9%) lead to ambiguity in diagnostic testing and treatment. Thus, a sensitive, accurate and real-time method for determining receptor polypeptide expression and monitoring for subtype switching using genomic profiling data without the need for IHC (or other chemistry based method) testing is needed.1MF-369983826Docket No.: 197102021140BRIEF SUMMARY OF THE INVENTION

[0005] Disclosed herein are methods and systems for determining a receptor protein expression status for a test sample from a subject having cancer. The methods and systems use gene expression data potentially from genomic profiling data rather than chemistry based methods, such as IHC. The methods and systems utilize machine learning models trained using differentially expressed genes between samples with different receptor protein expression statuses (e.g. positive and negative). Training models with differentially expressed genes between the groups improves the accuracy of the predictions because variation that does not contribute to status differences is excluded from the model fitting. The methods and systems can be used to classify samples, diagnose patients, select treatment, and monitor for changes between receptor protein expression statuses that may indicate treatment resistance.

[0006] Also disclosed herein are methods for determining hormone receptor (HR) status in a test sample from a subject having cancer (e.g., breast cancer). The methods and systems can be used to detect HR status and monitor for subtype switching. The methods and system utilize machine learning models trained using HR characteristics (e.g. HR classifications) that are determined based on expression of the estrogen receptor (ER) and the progesterone receptor (PR) and classification labels from immunohistochemistry (IHC) staining. The machine learning models are trained using expression of genes that are differentially expressed between HR+ and HR-samples to improve predictive accuracy for predicting HR status classifications. The machine learning models are particularly effective for classification of samples with low tumor purity and / or that would have low staining percentages with IHC.

[0007] Provided herein are methods of determining a receptor protein expression status of a test sample from a subject having cancer, comprising: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein the receptor polypeptide expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein expression machine learning model a predicted2MF-369983826Docket No.: 197102021140protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

[0008] In some aspects, the receptor protein expression machine learning model has been trained using a method, comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0009] Also provided herein are methods of training a receptor protein expression machine learning model comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data, comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples 3MF-369983826Docket No.: 197102021140and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0010] In some aspects, the training data comprises tumor purity metrics for the plurality of training samples. In some aspects, the protein expression marker characteristic of one or more receptor polypeptides is a quantitative metric. In some aspects, the protein expression marker characteristic of one or more receptor polypeptides is a quantitative metric based on a percent of cells expressing the one or more receptor polypeptides in a sample of the plurality of training samples.

[0011] In some aspects, the protein expression marker characteristic of one or more receptor polypeptides is a classification of a sample of the plurality of training samples as expressing the one or more receptor polypeptides or not expressing the one or more receptor polypeptides. In some aspects, the protein expression marker characteristic of one or more receptor polypeptides is positive if the sample of the plurality of training samples expresses any of the one or more receptor polypeptides and negative if the sample of the plurality of training samples expresses none of the one or more receptor polypeptides.

[0012] In some aspects, the expression of one or more receptor polypeptides in the sample of the plurality of training samples has been measured using immunohistochemistry (IHC) staining, flow cytometry, immunofluorescence or mass spectrometry. In some aspects, a sample expresses any of the one or more receptor polypeptides if the sample has IHC staining of the one or more receptor polypeptides above a predefined threshold for the receptor polypeptide. In some aspects, the predefined threshold is about 0.01%, about 0.1%, about 1%, about 5%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99%.

[0013] In some aspects, the expanded training data comprises tumor purity metrics for the plurality of training samples.

[0014] In some aspects, the first subset of the plurality of training samples are classified as positive based on the protein expression marker characteristic for one or more of the receptor 4MF-369983826Docket No.: 197102021140polypeptides. In some aspects, the second subset of the plurality of training samples are classified as negative based on the protein expression marker characteristic for all of the one or more of the receptor polypeptides.

[0015] In some aspects, the plurality of training samples comprises a third subset of the plurality of training samples. In some aspects, the third subset of the plurality of training are classified as ambiguous based on the protein expression marker characteristic for one or more of the receptor polypeptides.

[0016] In some aspects, the predicted protein expression marker characteristic is a first predicted protein expression marker characteristic for a first receptor protein. In some aspects, the receptor protein expression status is determined based on the first predicted protein expression marker characteristic and a second predicted protein expression marker characteristic for a second receptor protein. In some aspects, the combined predicted protein expression marker characteristic is a combined quantitative metric or classification based on at least a first predicted protein expression marker characteristic for a first receptor protein and a second predicted protein expression marker characteristic for a second receptor protein. In some aspects, the receptor protein expression status is determined based on the combined predicted protein expression marker characteristic.

[0017] In some aspects, the receptor protein expression status is a quantitative metric.

[0018] In some aspects, the receptor protein expression status is a classification of the test sample as receptor protein expression status positive or receptor protein expression status negative. In some aspects, the receptor protein expression status is receptor protein expression status positive if the first predicted protein expression marker characteristic, the second predicted protein expression marker characteristic, and / or the combined predicted protein expression marker characteristic is positive. In some aspects, one or more receptor polypeptides comprise a progesterone receptor (PR) polypeptide, estrogen receptor (ER) polypeptide and / or a HER2 polypeptide. In some aspects, the receptor protein expression status relates to hormone receptor (HR) status. In some aspects, one or more receptor polypeptides comprise the one or more receptor polypeptides comprise a progesterone receptor (PR) polypeptide, estrogen receptor (ER) polypeptide, a HER2 polypeptide, and / or a polypeptide for EGFR, a PD-1 CD20, PD-1, FOLR1, CLDN18, CA-125, ADAM9, ALCAM, AXL, CA6, CD276, CD46, CEACAM5, DLL3, ENPP3, ERBB3, F3, FOLR1, GPNMB, IGF1R, IL2RA, LY75, Met, MMP14, MSLN, NCAM1, PSMA, PTK7, ROR1, ROR2, SEZ6, SLC34A2, SLC39A6, SSTR2, TFRC, TPBG, BCMA, CD22, CD33, CD79B, EGFR, HER2, NECTIN4, and / or TROP2. In some aspects, the test sample has a IHC staining percentage of less than 10% for any of the one or more receptor polypeptides.5MF-369983826Docket No.: 197102021140

[0019] Also provided herein are methods of determining a hormone receptor (HR) status in a test sample from a subject having cancer, comprising: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a HR expression machine learning model trained using training data for a plurality of training samples, the training data, comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) HR characteristic determined using a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides, wherein the HR expression machine learning model is trained to output a predicted HR characteristic for the test sample; outputting, using the one or more processors, from the HR expression machine learning model a predicted HR characteristic for the test sample; and determining the HR status of the test sample based on the predicted HR characteristic.

[0020] In some aspects, the HR status of the test sample is HR -positive or HR-negative based on the predicted HR characteristic. In some aspects, the HR status machine learning model has been trained using a method, comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) an HR characteristic determined using a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides, wherein a first subset of the plurality of training samples are HR positive and a second subset of the plurality of training samples are HR negative; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the HR characteristics for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted HR characteristic of a test sample based on the training data.

[0021] Also provided herein are methods of training a HR expression machine learning model comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data, comprising: (i) expanded training gene expression 6MF-369983826Docket No.: 197102021140data, comprising gene expression values for a plurality of differentially expressed genes, (ii) an HR characteristic determined using a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides, wherein a first subset of the plurality of training samples are HR positive and a second subset of the plurality of training samples are HR negative; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the HR characteristics for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted HR characteristic of a test sample based on the training data.

[0022] In some aspects, the HR characteristic is HR characteristic positive if the marker of expression of PR polypeptides and / or the marker of expression of ER polypeptides is positive in the training sample.

[0023] In some aspects, the test sample has an IHC staining percentage of less than 1% for ER polypeptides and / or PR polypeptides.

[0024] In some aspects, the gene expression values comprise transcripts per million (TPM) measurements. In some aspects, the plurality of differentially expressed genes are identified with DESeq2. In some aspects, the plurality of differentially expressed genes have a log2fold change in expression greater than about 1, about 2, about 3, or about 4 between the first subset of the plurality of training samples and the second subset of the plurality of training samples.

[0025] In some aspects, training the machine learning model comprises optimizing lambda in a lasso regression separately or combined with training a neural network, a Random forest model or a Ridge regression. In some aspects, training the machine learning model comprises n-fold cross validation.

[0026] In some aspects, the tumor purity of the plurality of training samples is less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%. In some aspects, the tumor purity of the test sample is less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about7MF-369983826Docket No.: 19710202114020%, less than about 10%. In some aspects, the tumor purity of the test sample is less than about 20%.

[0027] In some aspect, the method further comprising obtaining the sample from the subject.

[0028] In some aspects, the test sample is a tissue biopsy sample. In some aspects, the tissue biopsy sample comprises a heterogeneous tissue biopsy sample with a tumor portion.

[0029] In some aspects, the cancer is a B cell cancer (multiple myeloma), a melanoma, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of an oral cavity, cancer of a pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, a cancer of hematological tissue, an adenocarcinoma, an inflammatory myofibroblastic tumor, a gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia Vera, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell cancer, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familiar hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine cancers, or a carcinoid tumor. In some aspects, the cancer comprises acute lymphoblastic leukemia (Philadelphia chromosome positive), acute lymphoblastic leukemia (precursor B-cell), acute myeloid leukemia (FLT3+), acute myeloid leukemia (with an IDH2 mutation), anaplastic large cell lymphoma, basal cell carcinoma, B-cell chronic lymphocytic 8MF-369983826Docket No.: 197102021140leukemia, bladder cancer, breast cancer (HER2 overexpressed / amplified), breast cancer (HER2+), breast cancer (HR+, HER2-), cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia (with 17p deletion), chronic myelogenous leukemia, chronic myelogenous leukemia (Philadelphia chromosome positive), classical Hodgkin lymphoma, colorectal cancer, colorectal cancer (dMMR / MSI-H), colorectal cancer (KRAS wild type), cryopyrin-associated periodic syndrome, a cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, a diffuse large B-cell lymphoma, fallopian tube cancer, a follicular B-cell non-Hodgkin lymphoma, a follicular lymphoma, gastric cancer, gastric cancer (HER2+), gastroesophageal junction (GEJ) adenocarcinoma, a gastrointestinal stromal tumor, a gastrointestinal stromal tumor (KIT+), a giant cell tumor of the bone, a glioblastoma, granulomatosis with polyangiitis, a head and neck squamous cell carcinoma, a hepatocellular carcinoma, Hodgkin lymphoma, juvenile idiopathic arthritis, lupus erythematosus, a mantle cell lymphoma, medullary thyroid cancer, melanoma, a melanoma with a BRAF V600 mutation, a melanoma with a BRAF V600E or V600K mutation, Merkel cell carcinoma, multicentric Castleman’s disease, multiple hematologic malignancies including Philadelphia chromosomepositive ALL and CML, multiple myeloma, myelofibrosis, a non-Hodgkin’ s lymphoma, a nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis, a nonsmall cell lung cancer, a non-small cell lung cancer (ALK+), a non-small cell lung cancer (PD-L1+), a non-small cell lung cancer (with ALK fusion or ROS1 gene alteration), a non-small cell lung cancer (with BRAF V600E mutation), a non-small cell lung cancer (with an EGFR exon 19 deletion or exon 21 substitution (L858R) mutations), a non-small cell lung cancer (with an EGFR T790M mutation), ovarian cancer, ovarian cancer (with a BRCA mutation), pancreatic cancer, a pancreatic, gastrointestinal, or lung origin neuroendocrine tumor, a pediatric neuroblastoma, a peripheral T-cell lymphoma, peritoneal cancer, prostate cancer, a renal cell carcinoma, rheumatoid arthritis, a small lymphocytic lymphoma, a soft tissue sarcoma, a solid tumor (MSL H / dMMR), a squamous cell cancer of the head and neck, a squamous non-small cell lung cancer, thyroid cancer, a thyroid carcinoma, urothelial cancer, a urothelial carcinoma, or Waldenstrom’s macroglobulinemia. In some aspects, the cancer is breast cancer. In some aspects, the breast cancer is breast carcinoma, invasive ductal breast cancer, or invasive lobular breast cancer.

[0030] In some aspects, the plurality of training samples comprise tissue biopsy samples collected for a plurality of training subjects. In some aspects, the tissue biopsy samples comprises a heterogeneous tissue biopsy sample with a tumor portion. In some aspects, the plurality of training subject have a same cancer or different cancer from the subject.9MF-369983826Docket No.: 197102021140

[0031] In some aspects, the method further comprises obtaining test gene expression data comprising: providing a plurality of RNA molecules obtained from the test sample; generating a plurality of nucleic acid molecules form the plurality of RNA molecules; ligating one or more adapters onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying the one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing amplified nucleic acid molecules from the amplified nucleic acid molecules; sequencing, by a sequencer, the captured nucleic acid molecules to obtain a plurality of sequence reads that represent the captured nucleic acid molecules; receiving, using one or more processors, sequence read data for the plurality of sequence reads; generating the test gene expression data by quantifying, using one or more processors, genes expression values for the plurality of differentially expressed genes from the sequence read data.

[0032] In some aspects, the one or more adapters comprise amplification primers, flow cell adaptor sequences, substrate adapter sequences, or sample index sequences. In some aspects, the captured nucleic acid molecules are captured from the amplified nucleic acid molecules by hybridization to one or more bait molecules. In some aspects, the one or more bait molecules comprise one or more nucleic acid molecules, each comprising a region that is complementary to a region of a captured nucleic acid molecule. In some aspects, amplifying nucleic acid molecules comprises performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique.

[0033] In some aspects, the sequencing comprises use of an RNA sequencing technique. In some aspects, the sequencing comprises massively parallel sequencing, and the massively parallel sequencing technique comprises next generation sequencing (NGS). In some aspects, the sequencer comprises a next generation sequencer.

[0034] In some aspects, the one or more of the plurality of sequencing reads overlap one or more gene loci within one or more subgenomic intervals in the sample. In some aspects, the one or more gene loci comprises between 10 and 20 loci, between 10 and 40 loci, between 10 and 60 loci, between 10 and 80 loci, between 10 and 100 loci, between 10 and 150 loci, between 10 and 200 loci, between 10 and 250 loci, between 10 and 300 loci, between 10 and 350 loci, between 10 and 400 loci, between 10 and 450 loci, between 10 and 500 loci, between 20 and 40 loci, between 20 and 60 loci, between 20 and 80 loci, between 20 and 100 loci, between 20 and 150 loci, between 20 and 200 loci, between 20 and 250 loci, between 20 and 300 loci, between 20 and 350 loci, between 20 and 400 loci, between 20 and 500 loci, between 40 and 60 loci, between 40 and 80 loci, between 40 and 100 loci, between 40 and 150 loci, between 40 and 200 loci, between 40 and 250 loci, between 40 and 300 loci, between 40 and 350 loci, between 40 and 400 loci,10MF-369983826Docket No.: 197102021140between 40 and 500 loci, between 60 and 80 loci, between 60 and 100 loci, between 60 and 150 loci, between 60 and 200 loci, between 60 and 250 loci, between 60 and 300 loci, between 60 and 350 loci, between 60 and 400 loci, between 60 and 500 loci, between 80 and 100 loci, between 80 and 150 loci, between 80 and 200 loci, between 80 and 250 loci, between 80 and 300 loci, between 80 and 350 loci, between 80 and 400 loci, between 80 and 500 loci, between 100 and 150 loci, between 100 and 200 loci, between 100 and 250 loci, between 100 and 300 loci, between 100 and 350 loci, between 100 and 400 loci, between 100 and 500 loci, between 150 and 200 loci, between 150 and 250 loci, between 150 and 300 loci, between 150 and 350 loci, between 150 and 400 loci, between 150 and 500 loci, between 200 and 250 loci, between 200 and 300 loci, between 200 and 350 loci, between 200 and 400 loci, between 200 and 500 loci, between 250 and 300 loci, between 250 and 350 loci, between 250 and 400 loci, between 250 and 500 loci, between 300 and 350 loci, between 300 and 400 loci, between 300 and 500 loci, between 350 and 400 loci, between 350 and 500 loci, or between 400 and 500 loci.

[0035] In some aspects, the one or more gene loci comprise ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BCR, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EMSY (Cllorf30), EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESRI, ETV4, ETV5, ETV6, EWSR1, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, FAS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, IKBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D (MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, NUTM1,11MF-369983826Docket No.: 197102021140P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLDI, POLE, PPARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCHI, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAFI, RARA, RBI, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, RSPO2, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SLC34A2, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSCI, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703, or any combination thereof. In some aspects, the one or more gene loci comprise ABL, ALK, ALL, B4GALNT1, BAFF, BCL2, BRAF, BRCA, BTK, CD19, CD20, CD3, CD30, CD319, CD38, CD52, CDK4, CDK6, CML, CRACC, CS1, CTLA-4, dMMR, EGFR, ERBB1, ERBB2, FGFR1-3, FLT3, GD2, HDAC, HER1, HER2, HR, IDH2, IL-ip, IL-6, IL-6R, JAK1, JAK2, JAK3, KIT, KRAS, MEK, MET, MSLH, mTOR, PARP, PD-1, PDGFR, PDGFRa, PDGFRp, PD-L1, PI3K6, PIGF, PTCH, RAF, RANKL, RET, ROS1, SLAMF7, VEGF, VEGFA, VEGFB, or any combination thereof. In some aspects, the one or more gene loci comprise ABCB1, ABL1, ABL2, ACSL6, AFF1, AFF4, AKT1, AKT2, AKT3, ALK, APC, AR, ARHGAP26, ARHGDIA, ARID1A, ARID1B, ASXL1, ATIC, ATM, ATR, AXL, B2M, BAP1, BCL10, BCL11B, BCL2, BCL3, BCL6, BCOR, BCR, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRIP1, BTG1, BTK, CAMTAI, CBFA2T3, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD19, CD274, CD28, CD38, CD74, CDH1, CDK4, CDK6, CDKN2A, CDKN2B, CEBPA, CIC, CIITA, CLDN18, CLDN3, CLTC, CNTRL, COL1A1, CREB3L1, CREB3L2, CREBBP, CRLF2, CSF1, CUX1, CXCR4, CYLD, DDIT3, DDR1, DDR2, DDX10, DEK, DHH, DIRC2, DLC1, DNMT3A, DUSP22, EBF1, EGFR, EIF4A2, ELF4, ELL, ELN, EML4, EP300, EPOR, EPS15, ERBB2, ERBB3, ERG, ESRI, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, FBXW7, FEV, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FGR, FLU, FLT3, FOS, FOSB, FOXO1, FOXO3, FOXO4, FOXP1, FUS, GAS7, GLI1, GLIS2, HDAC 10, HERPUD1, HEY1, HIP1, HLF, HMGA1, HMGA2, IGH, IGK, IGL (IGLL5), IKZF1, IKZF2, IKZF3, INSR, IRF4, ITK, JAK1, JAK2, JAK3, JAZF1, KAT6A, KIF5B, KIT, KMT2A, LATS2, LCP1, LMNA, LMO1, LMO2, LPP, LTK, MAF, MAFB, MALT1, MAML2, MAP3K7, MAP3K8, MAST1, MDS2, MECOM, MEF2C, MEF2D, MEN1, MET, MGMT, MKL1, MKL2, MLF1, MLH1, MLLT1, MLLT10, MN1, MNX1, MSH2, MSH6, MSI2, MSMB, MTAP, MTCP1, MYB, MYC, MYH11, NAB2, NBEAP1, NCOA2, NF1, NF2, NIN, NONO, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NR4A3, NRAS, NRG1, NRG2, NSD1,12MF-369983826Docket No.: 197102021140NTRK1, NTRK2, NTRK3, NUMA1, NUP214, NUP98, NUTM1, NUTM2A, P2RY8, PALB2, PAX3, PAX5, PAX7, PBX1, PBX3, PDCD1LG2, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PICALM, PIK3CA, PIK3R1, PIK3R2, PKN1, PLAG1, PMS2, PPARG, PRDM16, PRKACA, PRKCA, PRKCB, PRMT5, PTCHI, PTEN, RAFI, RARA, RASGRF1, RBI, RELA, RET, RHOH, ROS1, RPS6KB1, RSPO2, RSPO3, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SEC31A, SEPT5, SEPT6, SEPT7, SET, SH3GL1, SLC45A3, SMAD2, SMAD4, SMARCB1, SNX29, SRC, SS18, SSX1, SSX2, SSX4, STAT6, STIL, STK11, SYK, TAF15, TALI, TAL2, TBL1XR1, TCF3, TCF4, TCL1A, TCL6, TEC, TERT, TET1, TET2, TFE3, TFEB, TFG, TFPT, THADA, TLX1, TLX3, TMPRSS2, TOPI, TP53, TP63, TPM3, TPM4, TRIM24, TRIP11, TSC1, TSC2, TTL, TYK2, USP6, VHL, WHSCI, WHSC1L1, WT1, WWTR1, YAP1, YWHAE, ZAP70, ZBTB16, ZMYM2, ZNF384, ZNF750, or any combination thereof.

[0036] In some aspects, the determination indicating the receptor protein expression or HR status of the sample is used to diagnose or confirm a diagnosis of disease in the subject.

[0037] In some aspects, the methods further comprising selecting an anti-cancer therapy to administer to the subject based on receptor protein expression or HR status of the test sample.

[0038] In some aspects, the methods further comprising determining an effective amount of an anti-cancer therapy to administer to the subject based on the receptor protein expression or HR status of the test sample.

[0039] In some aspects, the methods further comprising treating the subject with an anti-cancer therapy. In some aspects, the anti-cancer therapy comprises chemotherapy, radiation therapy, immunotherapy, a targeted therapy, or surgery. In some aspects, the targeted anti-cancer therapy comprises abemaciclib (Verzenio), abiraterone acetate (Zytiga), acalabrutinib (Calquence), ado-trastuzumab emtansine (Kadcyla), afatinib dimaleate (Gilotrif), alectinib (Alecensa), alemtuzumab (Campath), alitretinoin (Panretin), alpelisib (Piqray), amivantamab-vmjw (Rybrevant), anastrozole (Arimidex), apalutamide (Erleada), asciminib hydrochloride (Scemblix), atezolizumab (Tecentriq), avapritinib (Ayvakit), avelumab (Bavencio), axicabtagene ciloleucel (Yescarta), axitinib (Inlyta), belantamab mafodotin-blmf (Blenrep), belimumab (Benlysta), belinostat (Beleodaq), belzutifan (Welireg), bevacizumab (Avastin), bexarotene (Targretin), binimetinib (Mektovi), blinatumomab (Blincyto), bortezomib (Velcade), bosutinib (Bosulif), brentuximab vedotin (Adcetris), brexucabtagene autoleucel (Tecartus), brigatinib (Alunbrig), cabazitaxel (Jevtana), cabozantinib (Cabometyx), cabozantinib (Cabometyx, Cometriq), canakinumab (Haris), capmatinib hydrochloride (Tabrecta), carfilzomib (Kyprolis), cemiplimab-rwlc (Libtayo), ceritinib (LDK378 / Zykadia), cetuximab (Erbitux), cobimetinib 13MF-369983826Docket No.: 197102021140(Cotellic), crizotinib (Xalkori), dabrafenib (Tafinlar), dacomitinib (Vizimpro), daratumumab (Darzalex), daratumumab and hyaluronidase-fihj (Darzalex Faspro), darolutamide (Nubeqa), dasatinib (Sprycel), denileukin diftitox (Ontak), denosumab (Xgeva), dinutuximab (Unituxin), dostarlimab-gxly (Jemperli), durvalumab (Imfinzi), duvelisib (Copiktra), elotuzumab (Empliciti), enasidenib mesylate (Idhifa), encorafenib (Braftovi), enfortumab vedotin-ejfv (Padcev), entrectinib (Rozlytrek), enzalutamide (Xtandi), erdafitinib (Bal vers a), erlotinib (Tarceva), everolimus (Afinitor), exemestane (Aromasin), fam-trastuzumab deruxtecan-nxki (Enhertu), fedratinib hydrochloride (Inrebic), fulvestrant (Faslodex), gefitinib (Iressa), gemtuzumab ozogamicin (Mylotarg), gilteritinib (Xospata), glasdegib maleate (Daurismo), hyaluronidase-zzxf (Phesgo), ibrutinib (Imbruvica), ibritumomab tiuxetan (Zevalin), idecabtagene vicleucel (Abecma), idelalisib (Zydelig), imatinib mesylate (Gleevec), infigratinib phosphate (Truseltiq), inotuzumab ozogamicin (Besponsa), ipilimumab (Yervoy), isatuximab-irfc (Sarclisa), ivosidenib (Tibsovo), ixazomib citrate (Ninlaro), lanreotide acetate (Somatuline Depot), lapatinib (Tykerb), larotrectinib sulfate (Vitrakvi), lenvatinib mesylate (Lenvima), letrozole (Femara), lisocabtagene maraleucel (Breyanzi), loncastuximab tesirine-lpyl (Zynlonta), lorlatinib (Lorbrena), lutetium Lu 177-dotatate (Lutathera), margetuximab-cmkb (Margenza), midostaurin (Rydapt), mobocertinib succinate (Exkivity), mogamulizumab-kpkc (Poteligeo), moxetumomab pasudotox-tdfk (Lumoxiti), naxitamab-gqgk (Danyelza), necitumumab (Portrazza), neratinib maleate (Nerlynx), nilotinib (Tasigna), niraparib tosylate monohydrate (Zejula), nivolumab (Opdivo), obinutuzumab (Gazyva), ofatumumab (Arzerra), olaparib (Lynparza), olaratumab (Lartruvo), osimertinib (Tagrisso), palbociclib (Ibrance), panitumumab (Vectibix), pazopanib (Votrient), pembrolizumab (Keytruda), pemigatinib (Pemazyre), pertuzumab (Perjeta), pexidartinib hydrochloride (Turalio), polatuzumab vedotin-piiq (Polivy), ponatinib hydrochloride (Iclusig), pralatrexate (Folotyn), pralsetinib (Gavreto), radium 223 dichloride (Xofigo), ramucirumab (Cyramza), regorafenib (Stivarga), ribociclib (Kisqali), ripretinib (Qinlock), rituximab (Rituxan), rituximab and hyaluronidase human (Rituxan Hycela), romidepsin (Istodax), rucaparib camsylate (Rubraca), ruxolitinib phosphate (Jakafi), sacituzumab govitecan-hziy (Trodelvy), seliciclib, selinexor (Xpovio), selpercatinib (Retevmo), selumetinib sulfate (Koselugo), siltuximab (Sylvant), sirolimus protein-bound particles (Fyarro), sonidegib (Odomzo), sorafenib (Nexavar), sotorasib (Lumakras), sunitinib (Sutent), tafasitamab-cxix (Monjuvi), tagraxofusp-erzs (Elzonris), talazoparib tosylate (Talzenna), tamoxifen (Nolvadex), tazemetostat hydrobromide (Tazverik), tebentafusp-tebn (Kimmtrak), temsirolimus (Torisel), tepotinib hydrochloride (Tepmetko), tisagenlecleucel (Kymriah), tisotumab vedotin-tftv (Tivdak), tocilizumab (Actemra), tofacitinib (Xeljanz), tositumomab (Bexxar), trametinib (Mekinist), trastuzumab (Herceptin), tretinoin 14MF-369983826Docket No.: 197102021140(Vesanoid), tivozanib hydrochloride (Fotivda), toremifene (Fareston), tucatinib (Tukysa), umbralisib tosylate (Ukoniq), vandetanib (Caprelsa), vemurafenib (Zelboraf), venetoclax (Venclexta), vismodegib (Erivedge), vorinostat (Zolinza), zanubrutinib (Brukinsa), ziv-aflibercept (Zaltrap), or any combination thereof.

[0040] In some aspects, the methods further comprising generating, by the one or more processors, a report indicating the receptor protein expression or HR status of the test sample. In some aspects, the methods further comprising transmitting the report to a healthcare provider. In some aspects, the report is transmitted via a computer network or a peer-to-peer connection.

[0041] Also provided herein are methods for monitoring for switching of receptor protein expression or HR status of a cancer, the method comprising: determining a first receptor protein expression or HR status in a first test sample obtained from the subject at a first time point according to the method of any one of embodiments described herein; determining a second receptor protein expression or HR status in a second test sample obtained from the subject at a second time point according to the method of any one of embodiments described herein; and comparing the first receptor protein expression status to the second receptor protein expression status, thereby monitoring for switching of receptor protein expression status. In some aspects, the methods further comprising suggesting alternative anti-cancer treatment if a change between the first receptor protein expression or HR status and the second receptor protein expression or HR status is identified.

[0042] Also provided herein are systems comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: determine a receptor protein expression status of a test sample from a subject having cancer by: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein the receptor polypeptide expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein expression machine learning model a predicted 15MF-369983826Docket No.: 197102021140protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

[0043] Also provided herein are systems comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: receive, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identify a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generate, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides for the plurality of training samples; train, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0044] Also provided herein are non-transitory computer-readable storage mediums storing one or more programs, the one or more programs comprising instructions, which when executed by one or more processors of a system, cause the system to: determine a receptor protein expression status of a test sample from a subject having cancer by: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the16MF-369983826Docket No.: 197102021140plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein the receptor polypeptide expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein expression machine learning model a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

[0045] Also provided herein are non-transitory computer-readable storage mediums storing one or more programs, the one or more programs comprising instructions, which when executed by one or more processors of a system, cause the system to: training a receptor protein expression machine learning model by: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0046] It should be appreciated that all combinations of the foregoing concepts and additional concepts discussed in greater detail below (provided such concepts are not mutually inconsistent)17MF-369983826Docket No.: 197102021140are contemplated as being part of the inventive subject matter disclosed herein. In particular, all combinations of claimed subject matter appearing at the end of this disclosure are contemplated as being part of the inventive subject matter disclosed herein.INCORPORATION BY REFERENCE

[0047] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. In the event of a conflict between a term herein and a term in an incorporated reference, the term herein controls.BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Various aspects of the disclosed methods, devices, and systems are set forth with particularity in the appended claims. A better understanding of the features and advantages of the disclosed methods, devices, and systems will be obtained by reference to the following detailed description of illustrative embodiments and the accompanying drawings, of which:

[0049] FIG. 1 provides a non-limiting example of a method for determining a receptor protein expression status of a test sample according to various embodiments described herein.

[0050] FIG. 2 provides a non-limiting example of a method for determining a hormone receptor (HR) status in at test sample from a subject having cancer according to various embodiments described herein.

[0051] FIG. 3 provides a non-limiting example of a method for training a receptor protein expression machine learning model according to various embodiments described herein.

[0052] FIG. 4 provides a non-limiting example of a method for training a HR status machine learning model according to various embodiments described herein.

[0053] FIG. 5 depicts an exemplary computing device or system in accordance with one embodiment of the present disclosure.

[0054] FIG. 6 depicts an exemplary computer system or computer network, in accordance with some instances of the systems described herein.

[0055] FIGS. 7A and 7B demonstrate gene expression measurements follow expected pattern for receptor status. FIG. 7A demonstrates ER positive samples have significantly higher expression of ESRI than ER negative samples. FIG. 7B demonstrates PR positive samples have significantly higher expression of PGR than PR negative samples.18MF-369983826Docket No.: 197102021140

[0056] FIG. 8 shows a volcano plot highlighting genes differentially expressed between HR positive and HR negative samples. The dashed line indicates an FDR p-value (pval) of 0.01.

[0057] FIG. 9 shows a heatmap demonstrating unsupervised clustering of gene expression for samples.DETAILED DESCRIPTION

[0058] Provided herein are methods that can be used for real time profiling of receptor protein expression statuses of a sample using RNA expression data and use of the statuses for diagnosis, treating, and monitoring cancer. Receptor protein expression status, including but not limited to hormone receptor (HR) status, is a key variable for the diagnosis and treatment of cancer (e.g., breast cancer). For example, HR positive breast cancers may respond to endocrine therapy while HR negative breast cancers may be resistant to endocrine therapy. In some cases, multiple tumor biopsy samples may be collected during routine clinical care. Because receptor protein expression status changes over the progression of a cancer and / or in response to treatment, real time status updates for routinely collected samples is important for monitoring cancer and adjusting therapy recommendations.

[0059] The methods described herein are for training and using machine learning models to determine receptor protein expression statuses in samples from subjects having cancer. The methods use gene expression to generate receptor protein expression statuses rather than chemistry based methods like IHC. Chemistry based methods, such as IHC, perform poorly on low tumor purity samples because with fewer tumor derived cells in a sample, it is more difficult to assess the surface protein expression with antibodies and staining. This may result in samples being called as ambiguous and thus doctors cannot use the results for diagnosing and treating patients.

[0060] Even in high tumor purity samples, chemistry based methods like IHC do not work when available antibodies for a receptor protein have low sensitivity and additional samples are often needed for testing multiple receptor proteins. Multiple samples may be difficult to obtain in the metastatic setting.

[0061] The machine learning methods described herein can detect gene expression signatures related to receptor polypeptide statuses even from low tumor purity samples, meaning that low tumor purity samples collected from patients that would return ambiguous results from chemistry based methods can be used for diagnosis and treatment decisions. In cases where patient tumor biopsy samples are being collected for genomic profiling, the methods described herein can be used to determine receptor protein expression status without needing to collect additional material from the patient.19MF-369983826Docket No.: 197102021140

[0062] The accuracy of the machine learning models described herein and their ability to predict receptor polypeptide status for low tumor purity sample comes in part from training the machine learning models using gene expression from a subset of genes that are differentially expressed between training samples from different receptor polypeptide statuses (e.g., HR+ and HR-) or with different protein expression marker characteristics of one or more surface polypeptides. By subsetting training data to comprise differentially expressed genes, the variation in gene expression that contributes to the differences between the statuses is more easily identified by the models.

[0063] Prior studies have used gene expression data to predict RNA expression-based HR status in the context of the four intrinsic gene-expression based subtypes of breast cancer. See, e.g., Yoon et. al., Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape, 12, Cancers (2020). Rather than identifying differentially expressed genes for training using the training samples, Yoon et al., trained their model using expression of specific genes already known to be related to HR subtype. In addition, to potentially eliminate potentially helpful biologic variation from the training, the methods are limited to HR status prediction. The methods described herein do not require a priori knowledge about genes related to the receptor protein status the model is trained to determine. Thus, the methods are more flexible across receptor protein statuses and cancer types.Definitions

[0064] Unless otherwise defined, all of the technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art in the field to which this disclosure belongs.

[0065] As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Any reference to “or” herein is intended to encompass “and / or” unless otherwise stated.

[0066] “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.

[0067] As used herein, the terms “comprising” (and any form or variant of comprising, such as “comprise” and “comprises”), “having” (and any form or variant of having, such as “have” and “has”), “including” (and any form or variant of including, such as “includes” and “include”), or “containing” (and any form or variant of containing, such as “contains” and “contain”), are 20MF-369983826Docket No.: 197102021140inclusive or open-ended and do not exclude additional, un-recited additives, components, integers, elements, or method steps.

[0068] As used herein, the terms “individual,” “patient,” or “subject” are used interchangeably and refer to any single animal, e.g., a mammal (including such non-human animals as, for example, dogs, cats, horses, rabbits, zoo animals, cows, pigs, sheep, and non-human primates) for which treatment is desired. In particular embodiments, the individual, patient, or subject herein is a human.

[0069] The terms “cancer” and “tumor” are used interchangeably herein. These terms refer to the presence of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features. Cancer cells are often in the form of a tumor, but such cells can exist alone within an animal, or can be a non-tumorigenic cancer cell, such as a leukemia cell. These terms include a solid tumor, a soft tissue tumor, or a metastatic lesion. As used herein, the term “cancer” includes premalignant, as well as malignant cancers.

[0070] As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention (e.g., administration of an anti-cancer agent or anticancer therapy) in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.

[0071] As used herein, the term “subgenomic interval” (or “subgenomic sequence interval”) refers to a portion of a genomic sequence.

[0072] As used herein, the term “subject interval” refers to a subgenomic interval or an expressed subgenomic interval (e.g., the transcribed sequence of a subgenomic interval).

[0073] As used herein, the term “sequence read” is a computationally generated sequence generated by a sequencer to represent a sequence of bases of a single strand of a sequenced fragment. A sequence read can refer to a raw sequence read (e.g., a sequence read as obtained directly from a sequencing instrument), an aligned sequence read (e.g., a sequence read that has been aligned to a reference genome), a single-end sequence read, a paired-end sequence read, a merged sequence read (e.g., a sequence read based on merging a group of overlapping paired-end reads), a consensus sequence read (e.g., a sequence read based on performing error correction on21MF-369983826Docket No.: 197102021140a merged sequence read), a computationally reconstructed sequence read (e.g., a sequence read that has been computationally truncated at the 5’ and / or 3’ end), or any combination thereof.

[0074] As used herein, the terms “variant sequence” or “variant” are used interchangeably and refer to a modified nucleic acid sequence relative to a corresponding “normal” or “wild-type” sequence. In some instances, a variant sequence may be a “short variant sequence” (or “short variant”), i.e., a variant sequence of less than about 50 base pairs in length.

[0075] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0076] The figures illustrate processes according to various embodiments. In the exemplary processes, some blocks are, optionally, combined, the order of some blocks is, optionally, changed, and some blocks are, optionally, omitted. In some examples, additional steps may be performed in combination with the exemplary processes. Accordingly, the operations as illustrated (and described in greater detail below) are exemplary by nature and, as such, should not be viewed as limiting.

[0077] Finally, it is to be understood that features and preferences described in relation to “embodiments” are distinct preferences and are not limited only to that particular embodiment; they may be freely combined with features from other embodiments, where technically feasible, and may form preferred combinations of features. The description is presented to enable one of ordinary skill in the art to make and use the invention and is provided in the context of a patent application and its requirements. Various modifications to the described embodiments will be readily apparent to those persons skilled in the art and the generic principles herein may be applied to other embodiments. Thus, the present invention is not intended to be limited to the embodiment shown but is to be accorded the widest scope consistent with the principles and features described herein.Receptor polypeptides and Receptor protein expression statuses

[0078] Receptor polypeptides are polypeptides or proteins that are expressed within the nucleus, cytoplasm, or on the surface of cells. In some embodiments, receptor polypeptides are proteins that are expressed on the surface of cells. In some embodiments, receptor polypeptides are proteins that function as nuclear receptors. For example, some receptor polypeptides, such as HER2, are expressed on the surface of cells and are responsible for cells interacting with the extracellular environment, while others, such as estrogen receptor (ER) and progesterone receptor (PR), function primarily as nuclear receptors and may be detected in the nucleus, cytoplasm, or on the cell surface. The methods and systems described herein relate to receptor 22MF-369983826Docket No.: 197102021140polypeptides including but not limited to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, PD-L1, CD20, PD-1, F0LR1, CLDN18, and CA-125. In some embodiments, the receptor polypeptides comprise surface protein targets for antibody-drug conjugates, such as those described in Fang et al., The target atlas for antibody-drug conjugates across solid tumors, 31. Cancer Gene Therapy (2024). In some aspects, the receptor polypeptides include ADAM9, AECAM, AXL, CA6, CD276, CD46, CEACAM5, DLL3, ENPP3, ERBB3, F3, FOER1, GPNMB, IGF1R, IL2RA, LY75, Met, MMP14, MSEN, NCAM1, PSMA, PTK7, ROR1, ROR2, SEZ6, SLC34A2, SLC39A6, SSTR2, TFRC, TPBG, BCMA, CD22, CD33, CD79B, EGFR, HER2, NECTIN4, TROP2.

[0079] In some embodiments, the receptor polypeptide is a cell-surface polypeptide. A cellsurface polypeptide may be expressed on the surface of cells and may be responsible for mediating interactions between the cell and its extracellular environment. In some embodiments, the receptor polypeptide is a nuclear receptor polypeptide. A nuclear receptor polypeptide may be expressed predominantly within the nucleus of cells. In some embodiments, the receptor polypeptide is a cytoplasmic polypeptide. A cytoplasmic polypeptide may be expressed within the cytoplasm of cells. In some embodiments, the receptor polypeptide is expressed in more than one subcellular compartment, including, without limitation, the nucleus, cytoplasm, and / or cell surface. In some embodiments, the receptor polypeptide is HER2, which is expressed on the surface of cells. In some embodiments, the receptor polypeptide is estrogen receptor (ER) or progesterone receptor (PR), each of which functions primarily as a nuclear receptor and may be detected in the nucleus, cytoplasm, or on the cell surface depending on the detection method employed.

[0080] The expression of receptor polypeptides can be measured using chemistry based methods, such as immunohistochemistry. The expression of one or more receptor polypeptides for a sample may be characterized using a protein expression marker characteristic of one or more receptor polypeptides. The protein expression marker characteristic may be categorical, such as positive or negative for expression of the one or more receptor polypeptides. The protein expression marker characteristic may be a quantitative metric. The quantitative metric may relate to expression level of one or more receptor polypeptides. For more than one receptor polypeptides, the quantitative metric may be a combination of the expression of the receptor polypeptides in a sample. The quantitative metric may also relate to the number or proportion of cells in a sample expressing the one or more receptor polypeptides. In some instances, the quantitative metric may relate to proportion of tumor cells versus non tumor cells in a sample23MF-369983826Docket No.: 197102021140expressing the one or more receptor polypeptides. In some instances, the protein expression marker characteristic may be a quantitative metric based of FAC sorting of a sample.

[0081] Receptor protein expression statuses (e.g. HR status) may be categorical or quantitative metrics related to expression of one or more receptor polypeptides in a sample (e.g., tumor). For example, a receptor protein expression status may be positive or negative based on the expression of a receptor polypeptide. In some cases, the receptor protein expression status may be positive or negative based on expression of more than one receptor polypeptide. In some cases, a receptor protein expression status may be HR+ if tumor cells in a sample express either ER or PR and HR- if the tumor cells express neither ER nor PR. Receptor protein expression status may also be a quantitative measure that relates to the percent of cells expressing one or more receptor polypeptides or the degree of certainty tumor cells express the receptor polypeptides. The receptor protein expression status may relate to an intensity of staining in a sample, such as but not limited to the percent of cells with weak / faint staining or the percent of cells with strong / continuous staining. In some instances, the receptor protein expression status may relate to both the percent of cells expressing the one or more receptor polypeptides and the staining intensity.

[0082] For diseases such as cancer, receptor polypeptides can be used as biomarkers for diagnostics and treatments. Receptor polypeptides can also be target for therapeutics. For example, the receptor polypeptide, HER2 is overexpressed in some forms of breast cancer and is targeted by anti-cancer therapies such as trastuzumab. Thus, receptor protein expression statuses for a sample (e.g., tumor) relating to individual receptor polypeptide expression can also be used for diagnosis and treatment selection.Methods for determining receptor protein expression status

[0083] The disclosed methods are for determining a receptor protein expression status of a test sample from a subject having cancer. In some aspects, the methods for determining a receptor protein expression status may be an HR status. The methods comprise receiving test gene expression data for the test sample and using a receptor polypeptide expression machine learning model and / or a HR expression machine learning model, trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., a predicted HR characteristic) and / or a combined predicted protein expression marker characteristic. The predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic can be used in determining the receptor protein expression status of the test sample.24MF-369983826Docket No.: 197102021140

[0084] In some aspects, the methods comprise receiving test gene expression data for a test sample. The test gene expression data for the test sample comprises gene expression values for at least plurality of differentially expressed genes. The test gene expression data may comprise RN A- sequencing (RNA-seq) data. The test gene expression data may comprise RNA-seq data collected from the test sample. The RN A- sequencing data may comprise gene expression values, such as transcripts per million (TPM) for a plurality of genes. The test gene expression data may comprise RNA expression data collected from non- sequencing techniques, such as microarray data.

[0085] In some aspects, the differentially expressed genes comprise OPNIB, ROPN1, MIA, TTYH1, HORMAD1, TLX1, HIST1H1A, SFRP1, ELF5, ACTG2, VGLL1, NRG1, CXCL6, CDX2, SYCP1, PROMI, FOLR1, SOX11, KRT6A, KRT17, TLX3, ROS1, DMBT1, MAGEB17, MAGEA1, HABP2, AFP, FOXA1, AGR3, AGR2, TFF1, AFF3, TBC1D9, ESRI, SCUBE2, NAT1, BMPR1B, PGR, MAPT, GREB1, CT62, RBM24, AREG, GRM4, BCAS1, and RP1.

[0086] The test sample may be a tissue biopsy sample. The test sample may be a tissue biopsy or tumor biopsy collected from a subject with cancer. Examples of a sample include, but are not limited to, a tumor sample, a tissue sample or a biopsy sample (e.g., a tissue biopsy). In certain instances, the sample may be frozen sample or a formalin-fixed paraffin-embedded (FFPE) sample.

[0087] In some instances, the tumor purity of the test sample may be known or determined. Tumor purity of the test sample is the percent of cells in the test sample that are tumor cells. In some instances, the tumor purity of the test sample may be less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%. In some instances, the tumor purity of the test sample may be between about 90% and about 10%, between about 90% and about 20%, between about 90% and about 30%, between about 90% and about 40%, between about 90% and about 50%, between about 90% and about 60%, between about 90% and about 70%, or between about 90% and about 80%. In some instances, the tumor purity of the test sample may be between about 80% and about 10%, between about 70% and about 10%, between about 60% and about 10%, between about 50% and about 10%, between about 40% and about 10%, between about 30% and about 10%, or between about 20% and about 10%. In some instances, the tumor purity of the test sample may be less than about 20%.

[0088] In some instances, an IHC staining percentage of any of the one or more receptor polypeptides may be known or determined. IHC staining percentage may represent the25MF-369983826Docket No.: 197102021140percentage of cells in a test sample expressing any of the one or more receptor polypeptides. The IHC staining percentage may be determined by a pathologist. In some aspects, the IHC staining percentage for the sample is below a value used as a clinical cutoff for determining a receptor expression status. For example, the IHC staining percentage for ER in a sample may be less than 9%. The methods described herein may be used for determining a receptor protein expression status even when the IHC staining percentage for the one or more receptor polypeptides that contribute to the receptor protein expression status are below established cutoffs.

[0089] In some instances, the IHC staining percentage of the test sample is less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, or less than about 1% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the test sample is less than about 10% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the test sample is less than about 10% for ER. In some instances, the IHC staining percentage of the test sample is less than about 10% for PR. In some instances, the IHC staining percentage of the test sample is less than about 1% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the test sample is less than about 1% for ER. In some instances, the IHC staining percentage of the test sample is less than about 1% for PR.

[0090] In some instances, the IHC staining percentage of the test sample is between about 90% and about 1%, about 80% and about 1%, about 70% and about 1%, about 60% and about 1%, about 50% and about 1%, about 40% and about 1%, about 30% and about 1%, about 20% and about 1%, or about 10% and about 1% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the test sample is between about 90% and 1%, about 90% and about 10%, about 90% and about 20%, about 90% and about 30%, about 90% and about 40%, about 90% and about 50%, about 90% and about 60%, about 90% and about 70%, or about 90% and about 80% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the test sample is less than about 10% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the test sample is less than about 1% for any of the one or more receptor polypeptides.

[0091] In some instances, immunofluorescence, flow cytometry and / or mass spectrometry may be used to determine the expression of one or more receptor polypeptides.

[0092] In some aspect, the methods comprise inputting the test gene expression data into a machine learning model. The machine learning model may be a receptor polypeptide expression machine learning model trained to output a predicted protein expression marker characteristic for 26MF-369983826Docket No.: 197102021140the test sample. The receptor polypeptide expression machine learning model may be trained to output a predicted protein expression marker characteristic for the test sample (e.g., predicted HR characteristic). The receptor polypeptide expression machine learning model may be trained to output a combined predicted protein expression marker characteristic for the test sample. The receptor polypeptide expression machine learning model may be trained to output a predicted protein expression marker characteristic and a combined predicted protein expression marker characteristic for the test sample. A predicted combined protein express marker may be a predicted protein expression marker characteristic related to two or more receptor polypeptides.

[0093] The receptor polypeptide expression machine learning model may have been trained using training data. The training data may comprise training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, and a protein expression marker characteristic of one or more receptor polypeptides for a plurality of training samples. In some aspects the training data comprises tumor purity metrics for the training samples. In some aspects, the receptor polypeptide expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., predicted HR characteristic) and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the test sample.

[0094] In some aspects, the receptor polypeptide expression machine learning model is trained with a protein expression marker characteristic of one or more receptor polypeptides that is a categorical variable, such as a protein expression marker characteristic positive and or protein expression marker characteristic negative (e.g., HR characteristic positive or HR characteristic negative). The predicted protein expression marker characteristic may also be a categorical representation of the sample as protein expression marker characteristic positive or protein expression marker characteristic negative. The combined predicted protein expression marker characteristic may be categorical metric for a combination of protein expression marker characteristics as positive or negative. In some instances, the protein expression marker characteristic of one or more receptor polypeptides that is a categorical variable related to patient outcome upon treatment with a targeted therapy for the one or more receptor polypeptides.

[0095] In some aspects, the receptor polypeptide expression machine learning model is trained with a protein expression marker characteristic of one or more receptor polypeptides that is a quantitative value. The value may be, for example, an expression level of a marker, the percent of cells in a sample expressing the receptor polypeptide. The value may be a weighted value related to expression of two or more receptor polypeptides (e.g., ER and PR). The predicted protein expression marker characteristic and / or combined predicted protein expression marker27MF-369983826Docket No.: 197102021140characteristic may also be a quantitative value representing expression of one or more markers or a predicted percent of cells in a sample expressing the one or more receptor polypeptides. In some instances, the protein expression marker characteristic of one or more receptor polypeptides that is a quantitative variable related to patient outcome upon treatment with a targeted therapy for the one or more receptor polypeptides. The quantitative variable may relate to survival.

[0096] In some instances, the methods comprise outputting the predicted protein expression marker characteristic of one or more receptor polypeptides and / or the combined predicted protein expression marker characteristic from the machine learning model. The output may be used in determining a receptor protein expression status.

[0097] The receptor protein expression status (e.g. HR status) may be categorical such as receptor protein expression positive or receptor protein expression negative. In some instances, the receptor protein expression status may be receptor protein expression ambiguous. In some instances, the receptor protein expression status may be positive if the predicted protein expression marker characteristic for one or more receptor polypeptides and / or the combined predicted protein expression marker characteristics are positive. In some instances, the receptor protein expression status may be negative if the predicted protein expression marker characteristic for all the one or more receptor polypeptides and / or the combined predicted protein expression marker characteristics are negative. In some instances, the receptor protein expression status may be ambiguous if the predicted protein expression marker characteristic for all the one or more receptor polypeptides and / or the combined predicted protein expression marker characteristics are ambiguous. If the predicted values (e.g., predicted protein expression marker characteristics for one or more receptor polypeptides and / or the combined predicted protein expression marker characteristic) are quantitative, the receptor protein expression marker characteristic may be positive if the quantitative metrics are above a predefined threshold. In some instances, the predicted metric relates to the predicted percent of cells in a sample expressing one or more receptor polypeptides (e.g., ER or PR). In some instances, the predefined threshold may be about 0.01%, about 0.1%, about 1%, about 5%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99%.

[0098] The determined receptor protein expression marker characteristic status, may be used for any of the uses described herein, including but not limited to diagnosing the subject, selecting a treatment for a subject, monitoring for status switching for a subject and / or generating a report for a subject.28MF-369983826Docket No.: 197102021140

[0099] FIG. 1 provides a non-limiting example of a method for determining a receptor protein expression status of a test sample from a subject having cancer according to various embodiments described herein.

[0100] At block 102, test gene expression data for a test sample is received. The test gene expression data for the test sample comprises gene expression values for a plurality of differentially expressed genes. At 102, the plurality of differentially expressed genes may be genes that have been identified as differentially expressed between samples classified as from different receptor protein expression statuses.

[0101] At block 104, the test gene expression received at block 102, may be input into a receptor polypeptide expression machine learning model.

[0102] At block 106, the predicted protein expression marker characteristic of one or more receptor polypeptides may be output from the machine learning model at block 104. In some instances, at block 106, the combined predicted protein expression marker characteristic of one or more receptor polypeptides may be output from the machine learning model at block 104. In some instances, at block 106, the combined predicted protein expression marker characteristic of one or more receptor polypeptides and the combined predicted protein expression marker characteristic may be output from the machine learning model at block 104.

[0103] At block 108, a receptor protein expression status may be determined using the predicted protein expression marker characteristic of one or more receptor polypeptides and / or the combined predicted protein expression marker characteristic from block 106.

[0104] FIG. 2 provides embodiments for determining a HR status of a test sample from a subject having cancer.

[0105] At block 202, test gene expression data for a test sample is received. The test gene expression data for the test sample comprises gene expression values for a plurality of differentially expressed genes. At 202, the plurality of differentially expressed genes may be genes that have been identified as differentially expressed between samples classified as from different HR statuses. In some instances, the test gene expression data comprises gene expression values for a full transcriptome and / or a subset of baited genes.

[0106] In a specific embodiment, at block 204, the test gene expression received at block 202, may be input into a HR expression machine learning model. The HR expression machine learning model may be a machine learning model according to the embodiments described herein. The HR expression machine learning model may be trained to output a predicted HR characteristic for the test sample. The predicted HR characteristic may be related to predicted expression of estrogen receptor (ER) and / or progesterone receptor (PR) in the test sample.29MF-369983826Docket No.: 197102021140

[0107] In some aspects, the machine learning model may be a HR expression machine learning model trained to output a predicted HR characteristic for the test sample. The HR expression machine learning model may have been trained using training data as described herein. The training data may comprise training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, and a HR characteristic determined using a marker of expression of PR polypeptides and / or a marker of expression of ER polypeptides for a plurality of training samples. The HR characteristic may be a classification, wherein the HR characteristic is positive if the marker of expression of ER polypeptides and / or PR polypeptides is positive and the HR characteristic is negative if the marker of expression of ER polypeptides and PR polypeptides is negative. In some instances, the HR characteristic may be unknown or ambiguous if the marker of expression of ER polypeptides and / or PR polypeptides is ambiguous. The HR characteristic may be a quantitative metric related to the marker of expression for ER polypeptides and / or PR polypeptides. For example, the metric may be a combination of a percent of cells expressing ER polypeptides and the percent of cells expressing PR polypeptides, or a combination of the expression level of ER polypeptides and PR polypeptides in a sample. The marker of expression for ER polypeptides and / or PR polypeptides may be based on a chemistry technique such as IHC. In some aspects the training data comprises tumor purity metrics for the training samples.

[0108] In some aspects, the HR expression machine learning model is trained with a categorical variable, such as a HR characteristic positive or HR characteristic negative. The predicted PR metric may also be a categorical representation of the sample as HR positive or HR negative.

[0109] In some aspects, the HR expression machine learning model is trained with a quantitative value. The value may be, for example, an expression level of a marker or the percent of cells in a sample expressing the ER polypeptides and / or PR polypeptides. The value may be a weighted value related to expression of ER polypeptides and PR polypeptides. The predicted HR characteristic may also be a quantitative value representing expression of HR polypeptides as a combination of the predicted expression of ER polypeptides and predicted expression of PR polypeptides. The quantitative variable may be quantitative variable related to staining intensity, e.g. weak or strong.

[0110] In some aspects, the HR expression machine learning model is trained with a categorical variable and a quantitative variable.

[0111] At block 206, the predicted HR characteristic may be output from the HR expression machine learning at block 204. At block 208, a HR status may be determined using the predicted HR characteristic from block 206.30MF-369983826Docket No.: 197102021140

[0112] In some instances, the predicted HR characteristic is used to determine the HR status of the test sample. In some instances, the HR status of the test sample is HR-positive or HRnegative based on the predicted HR characteristic. In some instances, the HR status may be positive if the predicted HR characteristic is positive or if the predicted HR characteristic is above a predefined threshold and HR status negative if the predicted HR characteristic is below the predefined threshold. In some instances, the predicted HR characteristic represents the percent of cells expressing ER and / or PR. The predefined threshold may be about 0.01%, about 0.1%, about 1%, about 5%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99%. The HR status may be a quantitative metric. For example, based on a quantitative predicted HR characteristic or a predicted HR characteristic weighted by additional variables such as certainty in the prediction.

[0113] The HR status may be a quantitative metric. The quantitative metric may be based on a combination of the predicted HR characteristic and another characteristic. In some instances, the quantitative metric may be based on a predicted protein expression marker for one or more receptor polypeptides, such as for ER and PR or a combined prediction related to ER and PR.Methods for training a receptor protein expression machine learning model

[0114] Disclosed are methods for training a machine learning model (e.g. receptor protein expression machine learning model and or HR expression machine learning model) to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g. predicted HR characteristic) and / or a combined predicted protein expression marker characteristic of a test sample. The predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic can be used for determining receptor protein expression status (e.g. HR status). The training methods comprise identifying differentially expressed genes between a first subset of training samples and a second subset of training sample. In some aspects, the training methods comprise identifying differentially expressed genes between HR positive and HR negative training samples. Identifying the differentially expressed genes allows for training of the machine learning model with biologically relevant features but does not require a priori knowledge of the biological mechanisms. Training the machine learning models with differentially expressed genes improves the prediction by focusing the optimization on biologically relevant values.

[0115] The methods described herein comprise receiving expanded training data for a plurality of training samples. The training samples comprise samples as described herein collected from a plurality of training subjects with cancer (e.g., breast cancer). The expanded training data31MF-369983826Docket No.: 197102021140comprises training gene expression data. The training gene expression data comprises gene expression values for a plurality of differentially expressed genes. The training gene expression data may also comprise gene expression values for the full transcriptome and / or for a plurality of baited genes as described herein.

[0116] The expanded training data further comprises a protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic) for the plurality of training samples. The protein expression marker characteristic of one or more receptor polypeptides may be a categorical variable such as protein expression marker characteristic positive or protein expression marker characteristic negative. The one or more receptor polypeptides may be ER and / or PR. In some aspects, the protein expression marker characteristic of one or more receptor polypeptides may be positive is one or more receptor polypeptides are expressed in the training sample and negative if all of the one or more receptor polypeptides are not expressed in the training sample.

[0117] In some aspects the protein expression marker characteristic of one or more receptor polypeptides is a quantitative metric. The protein expression marker characteristic of one or more receptor polypeptides may be a value representing the level of expression of the one or more receptor polypeptides or a percentage of cells expressing the one or more receptor polypeptides. In some aspects, the expression of the one or more receptor polypeptides may have been detected or quantified with immunohistochemistry (IHC). The value may be a weighted value related to expression of two or more receptor polypeptides (e.g., ER and PR).

[0118] In some aspects, the plurality training samples comprise tumor biopsy samples. The training sample of the plurality of training samples may be a tissue biopsy or tumor biopsy collected from a training subject with cancer. Examples of a training sample include, but are not limited to, a tumor sample, a tissue sample or a biopsy sample (e.g., a tissue biopsy). In certain instances, the training sample may be frozen sample or a formalin-fixed paraffin-embedded (FFPE) sample.

[0119] In some instances, the tumor purity of the training samples may be known or determined. Tumor purity is the percent of cells in the training sample that are tumor cells. In some instances, the tumor purity of a training sample in the plurality of training samples may be less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%. In some instances, the tumor purity of a training sample in the plurality of training samples may be between about 90% and about 10%, between about 90% and about 20%, between about 90% and about 30%, between about 90% and about 40%, between about 90% and about 50%, between about 90% and 32MF-369983826Docket No.: 197102021140about 60%, between about 90% and about 70%, or between about 90% and about 80%. In some instances, the tumor purity of a training sample in the plurality of training samples may be between about 80% and about 10%, between about 70% and about 10%, between about 60% and about 10%, between about 50% and about 10%, between about 40% and about 10%, between about 30% and about 10%, or between about 20% and about 10%. In some instances, the tumor purity of a training sample in the plurality of training samples may be less than about 20%.Training the machine learning models with gene expression data collected from training samples with a variety of tumor purities including low tumor purities may improve the machine learning model’s ability to make accurate predictions for test samples with low tumor purity.

[0120] The expanded training data comprises data for a plurality of training samples. The plurality of training samples comprise at least a first subset and a second subset of the plurality of training samples. The first plurality of training samples and the second plurality of training samples are based on the protein expression marker characteristic of one or more receptor polypeptides. In a non-limiting example, the protein expression marker characteristic of one or more receptor polypeptides (e.g. HR characteristic) is a categorical variable that is positive if cells from the training sample express the one or more receptor polypeptides (e.g., ER +, PR+, ER+PR-, or ER-PR+) and negative if cells from the training sample do not express the one or more receptor polypeptides (e.g., ER-PR-). The first subset of the plurality of training samples may have a positive protein expression marker characteristic and the second subset of the plurality of training samples may have a negative protein expression marker characteristic.

[0121] In some aspects, the plurality of training samples comprise more than two subsets of training samples. In some aspects, the plurality of training samples comprise a first subset of the plurality of training samples, a second subset of the plurality of training samples, and a third subset of the plurality of training samples. The third plurality of training samples may comprise samples with an unknown or ambiguous protein expression marker characteristic of one or more receptor polypeptides (e.g. HR ambiguous, ER ambiguous, PR ambiguous).

[0122] In some aspects, the methods comprise identifying a plurality of differentially expressed genes between the first subset of the plurality of training samples and the second subset of the plurality of training samples.

[0123] In some aspects, the training gene expression data comprises RNA-seq data. In some aspects, the RNA-seq data comprises gene expression values, such as transcripts per million (TPM) for a plurality of genes. Software such as DESeq2 may be used to identify differentially expressed genes. Other methods known in the art for identifying differentially expressed genes33MF-369983826Docket No.: 197102021140between gene expression data from two subsets of samples may be used to identify differentially expressed genes.

[0124] In some aspects, the differentially expressed genes comprise OPNIB, ROPN1, MIA, TTYH1, HORMAD1, TLX1, HIST1H1A, SFRP1, ELF5, ACTG2, VGLL1, NRG1, CXCL6, CDX2, SYCP1, PROMI, FOLR1, SOX11, KRT6A, KRT17, TLX3, ROS1, DMBT1, MAGEB17, MAGEA1, HABP2, AFP, FOXA1, AGR3, AGR2, TFF1, AFF3, TBC1D9, ESRI, SCUBE2, NAT1, BMPR1B, PGR, MAPT, GREB1, CT62, RBM24, AREG, GRM4, BCAS1, and RP1.

[0125] In some aspects, differentially expressed genes may be identified based on the identification of a significant difference in gene expression for a gene between the training gene expression data for the first subset of training samples and the training gene expression data for the second subset of training samples (e.g., between HR positive and HR negative). In some aspects, differentially expressed gene have an FDR p-value of less than 0.01.

[0126] In some aspects, differentially expressed genes may be identified based on the identification of a significant difference in gene expression for a gene between the training gene expression data for the first subset of training samples and the training gene expression data for the second subset of training samples and a log2fold change in gene expression between the two subsets greater than about 2. In some aspects, the plurality of differentially expressed gene have a log2fold change in expression greater than about 1, about 2, about 3, or about 4 between the first subset of the plurality of training samples and the second subset of the plurality of training samples. In some aspects, the plurality of differentially expressed gene have a log2fold change in expression greater than about 2 between the first subset of the plurality of training samples and the second subset of the plurality of training samples.

[0127] In some aspects, the methods comprise generating training data by subsetting the expanded training gene expression data based on the differentially expressed genes. The subset of the expanded training gene expression data consists of the expanded training gene expression data for the plurality of differentially expressed genes (e.g., between HR positive and HR negative). The training data comprises the protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic) for the plurality of training samples. In some aspects, the training data comprises tumor purity metrics for the plurality of training samples.

[0128] In some aspects, the methods comprise training a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides or a combined predicted protein expression marker characteristic.34MF-369983826Docket No.: 197102021140

[0129] The machine learning model may be a receptor protein expression machine learning model trained to output a combined predicted protein expression marker characteristic of a test sample based on the training data. The machine learning model may be a receptor protein expression machine learning model trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0130] In some aspects, the methods comprise training a lasso regression model. A lasso regression model may be used to compare the training gene expression values for the plurality of differentially expressed genes based on the protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic) for the training sample. In some aspects, training the machine learning model may comprise optimizing a lambda value for in a lasso regression. Lasso regression may be used for variable selection in the machine learning model training, for example, selecting the plurality of genes from the plurality of differentially expressed genes that are most informative for predicting the protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic) of a sample that is not part of the training samples (e.g. a test sample of the current disclosure). In some aspects, the methods comprise training a ridge regression model. In some aspects, the methods comprise training a Random Forest model. In some aspects, the methods comprise training a neural network model. In some aspects, the machine learning model comprises training a lasso regression and a ridge regression, Random Forest model, or neural network.

[0131] In some aspects, training the machine learning model may comprise 5-fold cross validation. In some aspect, training the machine learning model may comprise n-fold cross validation, wherein n increases as the sample size increases. In some aspects, n-fold cross validation may be 10-fold cross validation.

[0132] The machine learning model may be trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides or a combined protein expression marker character for a test sample. The predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., predicted HR characteristic) and / or a combined predicted protein expression marker characteristic may be a categorical or a quantitative variable based on the protein expression marker characteristic of one or more receptor polypeptides in the training data.

[0133] In some aspects, the predicted protein expression marker characteristic may be a categorical representation of the sample as protein expression marker characteristic positive or protein expression marker characteristic negative. The combined predicted protein expression 35MF-369983826Docket No.: 197102021140marker characteristic may be categorical metric for a combination of protein expression marker characteristics as positive or negative. In some aspects, the predicted protein expression marker characteristic and / or combined predicted protein expression marker characteristic may be a quantitative value representing expression of one or more markers or a predicted percent of cells in a sample expressing the one or more receptor polypeptides.

[0134] FIG. 3 provides a non-limiting example of a method for training a receptor protein expression machine learning model according to various embodiments described herein.

[0135] At block 302, expanded training data for a plurality of training samples is received.

[0136] The expanded training data at block 302 comprises data for a plurality of training samples. The plurality of training samples comprise at least a first subset and a second subset of the plurality of training samples. The first plurality of training samples and the second plurality of training samples are based on the protein expression marker characteristic of one or more receptor polypeptides.

[0137] At block 304, the expanded training data from block 302 is used to identify a plurality of differentially expressed genes between the first subset of the plurality of training samples and the second subset of the plurality of training samples. The methods comprise identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples.

[0138] At block 306, training data is generated from the expanded training data at 302, using the differentially expressed genes identified at block 304. Generating the training data at block 306 comprises subsetting the expanding training gene expression data based on the differentially expressed genes.

[0139] At block 308, a machine learning model, e.g., a receptor protein expression machine learning model, respectively is trained using the training data generated at block 306. The machine learning model may be a receptor protein expression machine learning model trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides. The machine learning model may be a receptor protein expression machine learning model trained to output a combined predicted protein expression marker characteristic of a test sample based on the training data. The machine learning model may be a receptor protein expression machine learning model trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data. Training the machine learning model at block 308 may comprise training a lasso regression model.36MF-369983826Docket No.: 197102021140

[0140] FIG. 4 provides embodiments for training a HR expression machine learning model. At block 402, expanded training data for a plurality of training samples is received. According to process 400, the expanded training data comprises training gene expression data and HR characteristics. In some aspects, the HR characteristic is determined using a marker of expression for PR polypeptides and / or a marker of expression for ER polypeptides In some aspects, the expanded training data comprises tumor purity metrics for the plurality of training samples.

[0141] The expanded training data at block 402 comprises data for a plurality of training samples. In a non-limiting example, the protein expression marker characteristic of one or more receptor polypeptides (e.g. HR characteristic) is a categorical variable that is positive if cells from the training sample express the one or more receptor polypeptides (e.g., ER +, PR+, ER+PR-, or ER-PR+) and negative if cells from the training sample do not express the one or more receptor polypeptides (e.g., ER-PR-). The first subset of the plurality of training samples may have a positive protein expression marker characteristic and the second subset of the plurality of training samples may have a negative protein expression marker characteristic.

[0142] At block 404, the expanded training data from block 402 is used to identify a plurality of differentially expressed genes between the first subset of the plurality of training samples and the second subset of the plurality of training samples. At block 404, the differentially expressed gene are differentially expressed between HR positive and HR negative samples.

[0143] At block 406, training data is generated from the expanded training data at 402, using the differentially expressed genes identified at block 404. Generating the training data at block 406 comprises subsetting the expanding training gene expression data based on the differentially expressed genes.

[0144] At block 408, a machine learning model, e.g., a HR expression machine learning model, is trained using the training data generated at block 406. The machine learning model may be a HR expression machine learning model trained to output a predicted HR characteristic. Training the machine learning model at block 408 may comprise training a lasso regression model.Methods of use

[0145] In some instances, the disclosed methods may further comprise one or more of the steps of: (i) obtaining the sample from the subject (e.g., a subject suspected of having or determined to have cancer), (ii) extracting nucleic acid molecules (e.g., RNA molecules) from the sample, (iii) ligating one or more adapters to the nucleic acid molecules extracted from the sample (e.g., one or more amplification primers, flow cell adaptor sequences, substrate adapter sequences, or sample index sequences), (iv) amplifying the nucleic acid molecules (e.g., using a polymerase 37MF-369983826Docket No.: 197102021140chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique), (v) capturing nucleic acid molecules from the amplified nucleic acid molecules (e.g., by hybridization to one or more bait molecules, where the bait molecules each comprise one or more nucleic acid molecules that each comprising a region that is complementary to a region of a captured nucleic acid molecule), (vi) sequencing the nucleic acid molecules extracted from the sample (or library proxies derived therefrom) using, e.g., a next-generation (massively parallel) sequencing technique, a whole genome sequencing (WGS) technique, a whole exome sequencing technique, a targeted sequencing technique, a direct sequencing technique, or a Sanger sequencing technique) using, e.g., a next- generation (massively parallel) sequencer, (viii) combining the nucleic acid sequence data (including, e.g., variant data, copy number data, methylation status data, etc., of the sequenced nucleic acid molecules) with other biomarker data modalities including, but not limited to, proteomics-based biomarker data (e.g., the detection of specific polypeptides, such as proteins) or fragmentomics-based biomarker data (e.g., the detection of certain attributes related to nucleic acid fragments, such as fragment size or the sequences of fragment ends), to determine, for example, the presence of ctDNA in the sample and / or to determine a diagnostic, prognostic, and / or treatment response prediction for the subject, and (ix) generating, displaying, transmitting, and / or delivering a report (e.g., an electronic, web-based, or paper report) to the subject (or patient), a caregiver, a healthcare provider, a physician, an oncologist, an electronic medical record system, a hospital, a clinic, a third-party payer, an insurance company, or a government office. In some instances, the report comprises output from the methods described herein. In some instances, all or a portion of the report may be displayed in the graphical user interface of an online or web-based healthcare portal. In some instances, the report is transmitted via a computer network or peer-to-peer connection.

[0146] The disclosed methods may be used with any of a variety of samples. For example, in some instances, the sample may comprise a tissue biopsy sample or a normal control.

[0147] In some instances, the nucleic acid molecules extracted from a sample may comprise a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules. In some instances, the tumor nucleic acid molecules may be derived from a tumor portion of a heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecules may be derived from a normal portion of the heterogeneous tissue biopsy sample. In some instances, the nucleic acid molecules extracted from a sample may comprise RNA (e.g., mRNA).

[0148] In some instances, the disclosed methods for determining a receptor protein expression status and / or HR status may be used to diagnose (or as part of a diagnosis of) the presence of 38MF-369983826Docket No.: 197102021140cancer, in a subject (e.g., a patient). In some instances, the disclosed methods may be applicable to diagnosis of any of a variety of cancers as described elsewhere herein.

[0149] In some instances, the disclosed methods for determining a receptor protein expression status and / or HR status may be used to select a subject (e.g., a patient) for a clinical trial based on the receptor protein expression status and / or HR status. In some instances, patient selection for clinical trials based on, e.g., determination of a receptor protein expression status and / or HR status, may accelerate the development of targeted therapies and improve the healthcare outcomes for treatment decisions.

[0150] In some instances, the disclosed methods for determining a receptor protein expression status and / or HR status may be used to select an appropriate therapy or treatment (e.g., an anticancer therapy or anti-cancer treatment) for a subject. In some instances, for example, the anticancer therapy or treatment may comprise use of a poly (ADP-ribose) polymerase inhibitor (PARPi), a platinum compound, chemotherapy, radiation therapy, a targeted therapy, an immunotherapy, a neoantigen-based therapy, surgery, or any combination thereof. In some aspects, the anti-cancer therapy may comprise an endocrine therapy. In some aspects, the anticancer therapy or treatment may comprise an antibody-drug conjugate (ADC). In some aspects, the ADC may comprise an antibody that targets the one or more receptor polypeptides.

[0151] In some instances, the anti-cancer therapy or treatment may comprise a targeted anticancer therapy or treatment (e.g., a monoclonal antibody-based therapy, an enzyme inhibitorbased therapy, an antibody-drug conjugate therapy, a hormone therapy, and / or a targeted radiotherapy) that targets specific molecules required for cancer cell growth, division, and spreading. In some instances, the targeted anti-cancer therapy or treatment may comprise abemaciclib (Verzenio), abiraterone acetate (Zytiga), acalabrutinib (Calquence), ado-trastuzumab emtansine (Kadcyla), afatinib dimaleate (Gilotrif), alectinib (Alecensa), alemtuzumab (Campath), alitretinoin (Panretin), alpelisib (Piqray), amivantamab-vmjw (Rybrevant), anastrozole (Arimidex), apalutamide (Erleada), asciminib hydrochloride (Scemblix), atezolizumab (Tecentriq), avapritinib (Ayvakit), avelumab (Bavencio), axicabtagene ciloleucel (Yescarta), axitinib (Inlyta), belantamab mafodotin-blmf (Blenrep), belimumab (Benlysta), belinostat (Beleodaq), belzutifan (Welireg), bevacizumab (Avastin), bexarotene (Targretin), binimetinib (Mektovi), blinatumomab (Blincyto), bortezomib (Velcade), bosutinib (Bosulif), brentuximab vedotin (Adcetris), brexucabtagene autoleucel (Tecartus), brigatinib (Alunbrig), cabazitaxel (Jevtana), cabozantinib (Cabometyx), cabozantinib (Cabometyx, Cometriq), canakinumab (Haris), capmatinib hydrochloride (Tabrecta), carfilzomib (Kyprolis), cemiplimab-rwlc (Libtayo), ceritinib (LDK378 / Zykadia), cetuximab (Erbitux), cobimetinib (Cotellic), crizotinib (Xalkori),39MF-369983826Docket No.: 197102021140dabrafenib (Tafinlar), dacomitinib (Vizimpro), daratumumab (Darzalex), daratumumab and hyaluronidase-fihj (Darzalex Faspro), darolutamide (Nubeqa), dasatinib (Sprycel), denileukin diftitox (Ontak), denosumab (Xgeva), dinutuximab (Unituxin), dostarlimab-gxly (Jemperli), durvalumab (Imfinzi), duvelisib (Copiktra), elotuzumab (Empliciti), enasidenib mesylate (Idhifa), encorafenib (Braftovi), enfortumab vedotin-ejfv (Padcev), entrectinib (Rozlytrek), enzalutamide (Xtandi), erdafitinib (Balversa), erlotinib (Tarceva), everolimus (Afinitor), exemestane (Aromasin), fam-trastuzumab deruxtecan-nxki (Enhertu), fedratinib hydrochloride (Inrebic), fulvestrant (Faslodex), gefitinib (Iressa), gemtuzumab ozogamicin (Mylotarg), gilteritinib (Xospata), glasdegib maleate (Daurismo), hyaluronidase-zzxf (Phesgo), ibrutinib (Imbruvica), ibritumomab tiuxetan (Zevalin), idecabtagene vicleucel (Abecma), idelalisib (Zydelig), imatinib mesylate (Gleevec), infigratinib phosphate (Truseltiq), inotuzumab ozogamicin (Besponsa), ipilimumab (Yervoy), isatuximab-irfc (Sarclisa), ivosidenib (Tibsovo), ixazomib citrate (Ninlaro), lanreotide acetate (Somatuline Depot), lapatinib (Tykerb), larotrectinib sulfate (Vitrakvi), lenvatinib mesylate (Lenvima), letrozole (Femara), lisocabtagene maraleucel (Breyanzi), loncastuximab tesirine-lpyl (Zynlonta), lorlatinib (Lorbrena), lutetium Lu 177-dotatate (Lutathera), margetuximab-cmkb (Margenza), midostaurin (Rydapt), mobocertinib succinate (Exkivity), mogamulizumab-kpkc (Poteligeo), moxetumomab pasudotox-tdfk (Lumoxiti), naxitamab-gqgk (Danyelza), necitumumab (Portrazza), neratinib maleate (Nerlynx), nilotinib (Tasigna), niraparib tosylate monohydrate (Zejula), nivolumab (Opdivo), obinutuzumab (Gazyva), ofatumumab (Arzerra), olaparib (Lynparza), olaratumab (Lartruvo), osimertinib (Tagrisso), palbociclib (Ibrance), panitumumab (Vectibix), pazopanib (Votrient), pembrolizumab (Keytruda), pemigatinib (Pemazyre), pertuzumab (Perjeta), pexidartinib hydrochloride (Turalio), polatuzumab vedotin-piiq (Polivy), ponatinib hydrochloride (Iclusig), pralatrexate (Folotyn), pralsetinib (Gavreto), radium 223 dichloride (Xofigo), ramucirumab (Cyramza), regorafenib (Stivarga), ribociclib (Kisqali), ripretinib (Qinlock), rituximab (Rituxan), rituximab and hyaluronidase human (Rituxan Hycela), romidepsin (Istodax), rucaparib camsylate (Rubraca), ruxolitinib phosphate (Jakafi), sacituzumab govitecan-hziy (Trodelvy), seliciclib, selinexor (Xpovio), selpercatinib (Retevmo), selumetinib sulfate (Koselugo), siltuximab (Sylvant), sirolimus protein-bound particles (Fyarro), sonidegib (Odomzo), sorafenib (Nexavar), sotorasib (Lumakras), sunitinib (Sutent), tafasitamab-cxix (Monjuvi), tagraxofusp-erzs (Elzonris), talazoparib tosylate (Talzenna), tamoxifen (Nolvadex), tazemetostat hydrobromide (Tazverik), tebentafusp-tebn (Kimmtrak), temsirolimus (Torisel), tepotinib hydrochloride (Tepmetko), tisagenlecleucel (Kymriah), tisotumab vedotin-tftv (Tivdak), tocilizumab (Actemra), tofacitinib (Xeljanz), tositumomab (Bexxar), trametinib (Mekinist), trastuzumab (Herceptin), tretinoin 40MF-369983826Docket No.: 197102021140(Vesanoid), tivozanib hydrochloride (Fotivda), toremifene (Fareston), tucatinib (Tukysa), umbralisib tosylate (Ukoniq), vandetanib (Caprelsa), vemurafenib (Zelboraf), venetoclax (Venclexta), vismodegib (Erivedge), vorinostat (Zolinza), zanubrutinib (Brukinsa), ziv-aflibercept (Zaltrap), or any combination thereof.

[0152] In some instances, the anti-cancer therapy or treatment may comprise an immunotherapy (e.g., a cancer treatment that acts by stimulating the immune system to fight cancer). In some instances, the immunotherapy can be, for example, an immune system modulator (e.g., a cytokine, such as an interferon or interleukin), an immune checkpoint inhibitor (such as an anti-PD-1 or anti-PD-Ll antibody), a T-cell transfer therapy (e.g., a tumor infiltrating lymphocyte (TIL) therapy in lymphocytes extracted from a patient’ s tumor are selected for their ability to recognize tumor cells and propagated prior to reintroduction into the patient, or a CAR T-cell therapy in which a patient’s T-cells are modified to express the CAR protein prior to reintroduction into the patient), a monoclonal antibody-based therapy (e.g., a monoclonal antibody that binds to receptor markers on cancer cells to facilitate recognition by the immune system), or a cancer treatment vaccine (e.g., a vaccine based on tumor cells, tumor-associated neoantigens, or dendritic cells, etc., that stimulates the immune system to fight cancer).

[0153] In some instances, the anti-cancer therapy or treatment may comprise a neoantigen-based therapy. Non-limiting examples of neoantigen-based therapies include T-cell receptor (TCR) engineered T-cell (TCR-T) therapies, chimeric antigen receptor T-cell (CAR-T) therapies, TCR bispecific antibody therapies, and cancer vaccines. TCR-T therapies are produced by genetically engineering a patient’s T-cells to express T-cell receptors that are specific to neoantigens of interest, and then infusing them back into the patient. CAR-T therapies are produced by genetically engineering a patient’s T-cells to express chimeric antigen receptor molecules which contain an intracellular signaling and co-signaling domain as well as an extracellular antigenbinding domain; CAR-T therapies don’t always rely on neoantigen presentation, but can be designed to be directed towards neoantigens. TCR bispecific antibody therapies are small, engineered antibody molecules that comprise a neoantigen- specific TCR on one end and a CD3-directed single-chain variable fragment on the other end. Cancer vaccines can include RNA molecules, DNA molecules, peptides, or a combination thereof that are designed to boost the immune system’s ability to find and destroy neoantigen-presenting cells.

[0154] In some instances, the disclosed methods for or determining a receptor protein expression status and / or HR status may be used in treating a cancer (e.g., breast cancer) in a subject. For example, in response to determining the receptor protein expression status and / or HR status using41MF-369983826Docket No.: 197102021140any of the methods disclosed herein, an effective amount of an anti-cancer therapy or anti-cancer treatment may be administered to the subject.

[0155] In some instances, the disclosed methods for determining a receptor protein expression status and / or HR status may be used for monitoring cancer progression or recurrence in a subject. For example, in some instances, the methods may be used to determine a receptor protein expression status and / or HR status in a first sample obtained from the subject at a first time point, and used to determine a receptor protein expression status and / or HR status in a second sample obtained from the subject at a second time point, where comparison of the first determination of the receptor protein expression status and / or HR status and the second determination of a receptor protein expression status and / or HR status allows one to monitor cancer progression or recurrence. In some instances, the first time point is chosen before the subject has been administered a therapy or treatment, and the second time point is chosen after the subject has been administered the therapy or treatment.

[0156] In some instances, the disclosed method may be used to monitor for switching of receptor protein expression status and / or HR status of a cancer in a subject. In some instances, the methods may be used to determine a first receptor protein expression status and / or HR status in a first test sample obtained from the subject a first time point and used to determine a second receptor protein expression status and / or HR status in a second test sample obtained from the subject a second time point, where comparison of the first and second receptor protein expression status and / or HR status allows for monitoring of switching of receptor protein expression status and / or HR status. Monitoring switching may be used to suggest alternative anti-cancer therapy or treatments. In some instances, the first time point is chosen before the subject has been administered a therapy or treatment, and the second time point is chosen after the subject has been administered the therapy or treatment.

[0157] In some instances, the disclosed methods may be used for adjusting a therapy or treatment (e.g., an anti-cancer treatment or anti-cancer therapy) for a subject, e.g., by adjusting a treatment dose and / or selecting a different treatment in response to a change in the determination of the receptor protein expression status and / or HR status or switching of the receptor protein expression status and / or HR status between two timepoints.

[0158] In some instances, the value of a receptor protein expression status and / or HR status determined using the disclosed methods may be used as a prognostic or diagnostic indicator associated with the sample. For example, in some instances, the prognostic or diagnostic indicator may comprise an indicator of the presence of cancer in the sample, an indicator of the probability that a cancer is present in the sample, an indicator of the probability that the subject 42MF-369983826Docket No.: 197102021140from which the sample was derived will develop a cancer (i.e., a risk factor), or an indicator of the likelihood that the subject from which the sample was derived will respond to a particular therapy or treatment.

[0159] In some instances, the disclosed methods for determining a receptor protein expression status and / or HR status may be implemented as part of a genomic profiling process that comprises identification of the presence of variant sequences at one or more gene loci in a sample derived from a subject as part of detecting, monitoring, predicting a risk factor, or selecting a treatment for a particular disease, e.g., cancer. In some instances, the variant panel selected for genomic profiling may comprise the detection of variant sequences at a selected set of gene loci. In some instances, the variant panel selected for genomic profiling may comprise detection of variant sequences at a number of gene loci through comprehensive genomic profiling (CGP), which is a next-generation sequencing (NGS) approach used to assess hundreds of genes (including relevant cancer biomarkers) in a single assay. Inclusion of the disclosed methods for determining a receptor protein expression status and / or HR status as part of a genomic profiling process (or inclusion of the output from the disclosed methods for determining a receptor protein expression status and / or HR status as part of the genomic profile of the subject) can improve the validity of, e.g., disease detection calls and treatment decisions, made on the basis of the genomic profile by, for example, independently confirming the receptor protein expression status and / or HR status in a given patient sample.

[0160] In some instances, a genomic profile may comprise information on the presence of genes (or variant sequences thereof), copy number variations, epigenetic traits, proteins (or modifications thereof), and / or other biomarkers in an individual’s genome and / or proteome, as well as information on the individual’s corresponding phenotypic traits and the interaction between genetic or genomic traits, phenotypic traits, and environmental factors.

[0161] In some instances, a genomic profile for the subject may comprise results from a comprehensive genomic profiling (CGP) test, a nucleic acid sequencing-based test, a gene expression profiling test, a cancer hotspot panel test, a DNA methylation test, a DNA fragmentation test, an RNA fragmentation test, or any combination thereof.

[0162] In some instances, the method can further include administering or applying a treatment or therapy (e.g., an anti-cancer agent, anti-cancer treatment, or anti-cancer therapy) to the subject based on the generated genomic profile. An anti-cancer agent or anti-cancer treatment may refer to a compound that is effective in the treatment of cancer cells. Examples of anti-cancer agents or anti-cancer therapies include, but not limited to, alkylating agents, antimetabolites, natural products, hormones, chemotherapy, radiation therapy, immunotherapy, surgery, or a therapy 43MF-369983826Docket No.: 197102021140configured to target a defect in a specific cell signaling pathway, e.g., a defect in a DNA mismatch repair (MMR) pathway.

[0163] In some embodiments, the methods provided herein comprise generating a report, and / or providing a report to party. In some embodiments, a report according to the present disclosure comprises information about one or more of: receptor protein expression status of a test sample from a subject, HR status of a test sample from a subject, or a treatment, a therapy, or one or more treatment options for an individual having a cancer, such as a cancer of the disclosure. In some embodiments, the report includes information on the role of the receptor protein expression status and / or HR status in disease, such as cancer. Such information can include one or more of: information on prognosis of a cancer, such as a cancer provided herein, information on resistance of a cancer, such as a cancer provided herein, to one or more treatments; information on potential or suggested therapeutic options (e.g., such as an anti-cancer therapy provided herein, or a treatment selected or identified according to the methods provided herein); or information on therapeutic options that should be avoided. In some embodiments, the report includes information on the likely effectiveness, acceptability, and / or advisability of applying a therapeutic option (e.g., such as an anti-cancer therapy provided herein, or a treatment selected or identified according to the methods provided herein) to an individual having a cancer. In some embodiments, the report includes information or a recommendation on the administration of a treatment (e.g., an anti-cancer therapy provided herein, or a treatment selected or identified according to the methods provided herein). In some embodiments, the information or recommendation includes the dosage of the treatment and / or a treatment regimen (e.g., in combination with other treatments, such as a second therapeutic agent). In some embodiments, the report comprises information or a recommendation for at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more treatments.

[0164] Also provided herein are methods of generating a report according to the present disclosure. In some embodiments, a report according to the present disclosure is generated by a method comprising one or more of the following steps: obtaining a sample, such as a sample described herein, from an individual, e.g., an individual having a cancer, such as a cancer provided herein; determining a receptor protein expression status of the sample, HR status of the sample, and generating a report.

[0165] A report according to the present disclosure may be in an electronic, web-based, or paper form. The report may be provided to an individual or a patient (e.g., an individual or a patient with a cancer, such as a cancer provided herein), or to an individual or entity other than the 44MF-369983826Docket No.: 197102021140individual or patient (e.g., other than the individual or patient with the cancer), such as one or more of a caregiver, a physician, an oncologist, a hospital, a clinic, a third party payor, an insurance company, or a government entity. In some embodiments, the report is provided or delivered to the individual or entity within any of about 1 day or more, about 7 days or more, about 14 days or more, about 21 days or more, about 30 days or more, about 45 days or more, or about 60 days or more from obtaining a sample from an individual (e.g., an individual having a cancer). In some embodiments, the report is provided or delivered to an individual or entity within any of about 1 day or more, about 7 days or more, about 14 days or more, about 21 days or more, about 30 days or more, about 45 days or more, or about 60 days or more from determining the receptor protein expression status or HR status of a sample obtained from an individual (e.g., an individual having a cancer).

[0166] The method steps of the methods described herein are intended to include any suitable method of causing one or more other parties or entities to perform the steps, unless a different meaning is expressly provided or otherwise clear from the context. Such parties or entities need not be under the direction or control of any other party or entity, and need not be located within a particular jurisdiction. Thus, for example, a description or recitation of “adding a first number to a second number” includes causing one or more parties or entities to add the two numbers together. For example, if person X engages in an arm’s length transaction with person Y to add the two numbers, and person Y indeed adds the two numbers, then both persons X and Y perform the step as recited: person Y by virtue of the fact that he actually added the numbers, and person X by virtue of the fact that he caused person Y to add the numbers. Furthermore, if person X is located within the United States and person Y is located outside the United States, then the method is performed in the United States by virtue of person X’s participation in causing the step to be performed.Samples

[0167] The disclosed methods and systems may be used with any of a variety of samples (also referred to herein as specimens) comprising nucleic acids (e.g., DNA or RNA) that are collected from a subject (e.g., a patient). Examples of a sample include, but are not limited to, a tumor sample, a tissue sample or a biopsy sample (e.g., a tissue biopsy). In certain instances, the sample may be frozen sample or a formalin-fixed paraffin-embedded (FFPE) sample.

[0168] In some instances, the sample may be collected by tissue resection (e.g., surgical resection), needle biopsy, bone marrow biopsy, bone marrow aspiration, skin biopsy, endoscopic45MF-369983826Docket No.: 197102021140biopsy, fine needle aspiration, oral swab, nasal swab, vaginal swab or a cytology smear, scrapings, washings or lavages (such as a ductal lavage or bronchoalveolar lavage), etc.

[0169] In some instances, the sample may comprise one or more premalignant or malignant cells. Premalignant, as used herein, refers to a cell or tissue that is not yet malignant but is poised to become malignant. In certain instances, the sample may be acquired from a solid tumor, a soft tissue tumor, or a metastatic lesion. In certain instances, the sample may be acquired from a hematologic malignancy or pre-malignancy. In other instances, the sample may comprise a tissue or cells from a surgical margin. In certain instances, the sample may comprise tumor-infiltrating lymphocytes. In some instances, the sample may comprise one or more non-malignant cells. In some instances, the sample may be, or is part of, a primary tumor or a metastasis (e.g., a metastasis biopsy sample). In some instances, the sample may be obtained from a site (e.g., a tumor site) with the highest percentage of tumor (e.g., tumor cells) as compared to adjacent sites (e.g., sites adjacent to the tumor). In some instances, the sample may be obtained from a site (e.g., a tumor site) with the largest tumor focus (e.g., the largest number of tumor cells as visualized under a microscope) as compared to adjacent sites (e.g., sites adjacent to the tumor).

[0170] In some instances, the disclosed methods may further comprise analyzing a primary control (e.g., a normal tissue sample). In some instances, the disclosed methods may further comprise determining if a primary control is available and, if so, isolating a control nucleic acid (e.g., DNA) from said primary control. In some instances, the sample may comprise any normal control (e.g., a normal adjacent tissue (NAT)) if no primary control is available. In some instances, the sample may be or may comprise histologically normal tissue. In some instances, the method includes evaluating a sample, e.g., a histologically normal sample (e.g., from a surgical tissue margin) using the methods described herein. In some instances, the disclosed methods may further comprise acquiring a sub-sample enriched for non-tumor cells, e.g., by macro-dissecting non-tumor tissue from said NAT in a sample not accompanied by a primary control. In some instances, the disclosed methods may further comprise determining that no primary control and no NAT is available, and marking said sample for analysis without a matched control. In some aspects, analysis of the NAT may improve the understanding of the tumor microenvironment. Such an understanding may improve prognostic or treatment decisions.

[0171] In some instances, samples obtained from histologically normal tissues (e.g., otherwise histologically normal surgical tissue margins) may still comprise a genetic alteration such as a variant sequence as described herein. The methods may thus further comprise re-classifying a sample based on the presence of the detected genetic alteration. In some instances, multiple samples (e.g., from different subjects) are processed simultaneously. In some instances, analysis 46MF-369983826Docket No.: 197102021140of histologically normal tissue may be used to analyze patients with non-cancer malignancies and / or autoimmune diseases.

[0172] The disclosed methods and systems may be applied to the analysis of nucleic acids extracted from any of variety of tissue samples (or disease states thereof), e.g., solid tissue samples, soft tissue samples, or metastatic lesions. Examples of tissues include, but are not limited to, connective tissue, muscle tissue, nervous tissue, epithelial tissue, and blood. Tissue samples may be collected from any of the organs within an animal or human body. Examples of human organs include, but are not limited to, the brain, heart, lungs, liver, kidneys, pancreas, spleen, thyroid, mammary glands, uterus, prostate, large intestine, small intestine, bladder, bone, skin, etc.

[0173] In some instances, the nucleic acids extracted from the sample may comprise deoxyribonucleic acid (DNA) molecules. Examples of DNA that may be suitable for analysis by the disclosed methods include, but are not limited to, genomic DNA or fragments thereof, mitochondrial DNA or fragments thereof, cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA). Cell-free DNA (cfDNA) is comprised of fragments of DNA that are released from normal and / or cancerous cells during apoptosis and necrosis, and circulate in the blood stream and / or accumulate in other bodily fluids. Circulating tumor DNA (ctDNA) is comprised of fragments of DNA that are released from cancerous cells and tumors that circulate in the blood stream and / or accumulate in other bodily fluids.

[0174] In some instances, DNA is extracted from nucleated cells from the sample. In some instances, a sample may have a low nucleated cellularity, e.g., when the sample is comprised mainly of erythrocytes, lesional cells that contain excessive cytoplasm, or tissue with fibrosis. In some instances, a sample with low nucleated cellularity may require more, e.g., greater, tissue volume for DNA extraction.

[0175] In some instances, the nucleic acids extracted from the sample may comprise ribonucleic acid (RNA) molecules. Examples of RNA that may be suitable for analysis by the disclosed methods include, but are not limited to, total cellular RNA, total cellular RNA after depletion of certain abundant RNA sequences (e.g., ribosomal RNAs), cell-free RNA (cfRNA), messenger RNA (mRNA) or fragments thereof, the poly(A)-tailed mRNA fraction of the total RNA, ribosomal RNA (rRNA) or fragments thereof, transfer RNA (tRNA) or fragments thereof, and mitochondrial RNA or fragments thereof. In some instances, RNA may be extracted from the sample and converted to complementary DNA (cDNA) using, e.g., a reverse transcription reaction. In some instances, the cDNA is produced by random-primed cDNA synthesis methods. In other instances, the cDNA synthesis is initiated at the poly(A) tail of mature mRNAs by 47MF-369983826Docket No.: 197102021140priming with oligo(dT)-containing oligonucleotides. Methods for depletion, poly(A) enrichment, and cDNA synthesis are well known to those of skill in the art.

[0176] In some instances, the sample may comprise a tumor content (e.g., comprising tumor cells or tumor cell nuclei), or a non-tumor content (e.g., immune cells, fibroblasts, and other nontumor cells). In some instances, the tumor content of the sample may constitute a sample metric. In some instances, the sample may comprise a tumor content of at least 5-50%, 10-40%, 15-25%, or 20-30% tumor cell nuclei. In some instances, the sample may comprise a tumor content of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% tumor cell nuclei. In some instances, the percent tumor cell nuclei (e.g., sample fraction) is determined (e.g., calculated) by dividing the number of tumor cells in the sample by the total number of all cells within the sample that have nuclei. In some instances, for example when the sample is a liver sample comprising hepatocytes, a different tumor content calculation may be required due to the presence of hepatocytes having nuclei with twice, or more than twice, the DNA content of other, e.g., non-hepatocyte, somatic cell nuclei. In some instances, the sensitivity of detection of a genetic alteration, e.g., a variant sequence, or a determination of, e.g., micro satellite instability, may depend on the tumor content of the sample. For example, a sample having a lower tumor content can result in lower sensitivity of detection for a given size sample.

[0177] In some instances, the tumor purity of the sample may be known or determined. Tumor purity of the sample is the percent of cells in the sample that are tumor cells. In some instances, the tumor purity of the sample (e.g., test sample or training sample) may be less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%. In some instances, the tumor purity of the sample (e.g., test sample or training sample) may be between about 90% and about 10%, between about 90% and about 20%, between about 90% and about 30%, between about 90% and about 40%, between about 90% and about 50%, between about 90% and about 60%, between about 90% and about 70%, or between about 90% and about 80%. In some instances, the tumor purity of the sample (e.g., test sample or training sample) may be between about 80% and about 10%, between about 70% and about 10%, between about 60% and about 10%, between about 50% and about 10%, between about 40% and about 10%, between about 30% and about 10%, or between about 20% and about 10%. In some instances, the tumor purity of the test sample may be less than about 20%.

[0178] In some instances, as noted above, the sample comprises nucleic acid (e.g., DNA, RNA (or a cDNA derived from the RNA), or both), e.g., from a tumor or from normal tissue. In certain48MF-369983826Docket No.: 197102021140instances, the sample may further comprise a non-nucleic acid component, e.g., cells, protein, carbohydrate, or lipid, e.g., from the tumor or normal tissue.

[0179] In some instances, an IHC staining percentage of any of the one or more receptor polypeptides may be known or determined. IHC staining percentage may represent the percentage of cells in a sample expressing any of the one or more receptor polypeptides. The IHC staining percentage may be determined by a pathologist. In some aspects, the ICH staining percentage for the sample is below a value used as a clinical cutoff for determining a receptor expression status. For example, the IHC staining percentage for ER in a sample may be less than 10% or the IHC staining may be less than 9%, or the IHC staining may be less than 1%. The methods described herein may be used for determining a receptor protein expression status even when the IHC staining percentage for the one or more receptor polypeptides that contribute to the receptor protein expression status are below established cutoffs.

[0180] In some instances, the IHC staining percentage of the sample is less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%, or less than about 1% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the sample is less than about 10% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the sample is less than about 10% for ER. In some instances, the IHC staining percentage of the sample is less than about 10% for PR. In some instances, the IHC staining percentage of the sample is less than about 1% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the sample is less than about 1% for ER. In some instances, the IHC staining percentage of the sample is less than about 1% for PR.

[0181] In some instances, the IHC staining percentage of the sample is between about 90% and about 1%, about 80% and about 1%, about 70% and about 1%, about 60% and about 1%, about 50% and about 1%, about 40% and about 1%, about 30% and about 1%, about 20% and about 1% or about 10% and 1% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the sample is between about 90% and about 1%, about 90% and about 10%, about 90% and about 20%, about 90% and about 30%, about 90% and about 40%, about 90% and about 50%, about 90% and about 60%, about 90% and about 70%, or about 90% and about 80% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the sample is less than about 10% for any of the one or more receptor polypeptides. In some instances, the IHC staining percentage of the sample is less than about 1% for any of the one or more receptor polypeptides.49MF-369983826Docket No.: 197102021140Subjects

[0182] In some aspects, the method comprise test samples collected from subjects. The test samples may be any of the samples described herein. In some aspects, the methods comprise collecting a test sample from a subject. In some aspects, the method comprise training samples collected from training subjects. The training samples may be any of the samples described herein. In some aspect, the methods comprise collecting training samples from training subjects.

[0183] In some instances, the sample is obtained (e.g., collected) from a subject (e.g., patient) with a condition or disease (e.g., a hyperproliferative disease or a non-cancer indication) or suspected of having the condition or disease. In some instances, the hyperproliferative disease is a cancer. In some instances, the cancer is a solid tumor or a metastatic form thereof. In some instances, the cancer is a hematological cancer, e.g., a leukemia or lymphoma. In some instances, the subject has a non-cancer malignancy. In some instances, the subject has an autoimmune disease.

[0184] In some instances, the subject has a cancer or is at risk of having a cancer. In some aspects, the subject has the same cancer as the training subjects. In some aspects, the subject has a different cancer as the training subjects. For example, in some instances, the subject has a genetic predisposition to a cancer (e.g., having a genetic mutation that increases his or her baseline risk for developing a cancer). In some instances, the subject has been exposed to an environmental perturbation (e.g., radiation or a chemical) that increases his or her risk for developing a cancer. In some instances, the subject is in need of being monitored for development of a cancer. In some instances, the subject is in need of being monitored for cancer progression or regression, e.g., after being treated with an anti-cancer therapy (or anti-cancer treatment). In some instances, the subject is in need of being monitored for relapse of cancer. In some instances, the subject is in need of being monitored for minimum residual disease (MRD). In some instances, the subject has been, or is being treated, for cancer. In some instances, the subject has not been treated with an anti-cancer therapy (or anti-cancer treatment).

[0185] In some instances, the subject (e.g., a patient) is being treated, or has been previously treated, with one or more targeted therapies. In some instances, e.g., for a patient who has been previously treated with a targeted therapy, a post-targeted therapy sample (e.g., specimen) is obtained (e.g., collected). In some instances, the post-targeted therapy sample is a sample obtained after the completion of the targeted therapy.

[0186] In some instances, the patient has not been previously treated with a targeted therapy. In some instances, e.g., for a patient who has not been previously treated with a targeted therapy,50MF-369983826Docket No.: 197102021140the sample comprises a resection, e.g., an original resection, or a resection following recurrence (e.g., following a disease recurrence post-therapy).Cancers

[0187] In some instances, the sample is acquired from a subject having a cancer. Exemplary cancers include, but are not limited to, B cell cancer (e.g., multiple myeloma), melanomas, breast cancer, lung cancer (such as non-small cell lung carcinoma or NSCLC), bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of hematological tissues, adenocarcinomas, inflammatory myofibroblastic tumors, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia Vera, Hodgkin lymphoma, nonHodgkin lymphoma (NHL), soft-tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell cancers, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familiar hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine cancers, carcinoid tumors, and the like.

[0188] In some instances, the cancer comprises acute lymphoblastic leukemia (Philadelphia chromosome positive), acute lymphoblastic leukemia (precursor B-cell), acute myeloid leukemia (FLT3+), acute myeloid leukemia (with an IDH2 mutation), anaplastic large cell lymphoma,51MF-369983826Docket No.: 197102021140basal cell carcinoma, B-cell chronic lymphocytic leukemia, bladder cancer, breast cancer (HER2 overexpressed / amplified), breast cancer (HER2+), breast cancer (HR+, HER2-), cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia (with 17p deletion), chronic myelogenous leukemia, chronic myelogenous leukemia (Philadelphia chromosome positive), classical Hodgkin lymphoma, colorectal cancer, colorectal cancer (dMMR and MSI-H), colorectal cancer (KRAS wild type), cryopyrin-associated periodic syndrome, a cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, a diffuse large B-cell lymphoma, fallopian tube cancer, a follicular B-cell non-Hodgkin lymphoma, a follicular lymphoma, gastric cancer, gastric cancer (HER2+), a gastroesophageal junction (GEJ) adenocarcinoma, a gastrointestinal stromal tumor, a gastrointestinal stromal tumor (KIT+), a giant cell tumor of the bone, a glioblastoma, granulomatosis with polyangiitis, a head and neck squamous cell carcinoma, a hepatocellular carcinoma, Hodgkin lymphoma, juvenile idiopathic arthritis, lupus erythematosus, a mantle cell lymphoma, medullary thyroid cancer, melanoma, a melanoma with a BRAF V600 mutation, a melanoma with a BRAF V600E or V600K mutation, Merkel cell carcinoma, multicentric Castleman’s disease, multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML, multiple myeloma, myelofibrosis, a non-Hodgkin’ s lymphoma, a nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis, a non-small cell lung cancer, a non-small cell lung cancer (ALK+), a nonsmall cell lung cancer (PD-L1+), a non-small cell lung cancer (with ALK fusion or ROS1 gene alteration), a non-small cell lung cancer (with BRAF V600E mutation), a non-small cell lung cancer (with an EGFR exon 19 deletion or exon 21 substitution (L858R) mutations), a non-small cell lung cancer (with an EGFR T790M mutation), ovarian cancer, ovarian cancer (with a BRCA mutation), pancreatic cancer, a pancreatic, gastrointestinal, or lung origin neuroendocrine tumor, a pediatric neuroblastoma, a peripheral T-cell lymphoma, peritoneal cancer, prostate cancer, a renal cell carcinoma, rheumatoid arthritis, a small lymphocytic lymphoma, a soft tissue sarcoma, a solid tumor (MSLH / dMMR), a squamous cell cancer of the head and neck, a squamous non-small cell lung cancer, thyroid cancer, a thyroid carcinoma, urothelial cancer, a urothelial carcinoma, or Waldenstrom’s macroglobulinemia.

[0189] In some instances, the cancer is a hematologic malignancy (or premaligancy). As used herein, a hematologic malignancy refers to a tumor of the hematopoietic or lymphoid tissues, e.g., a tumor that affects blood, bone marrow, or lymph nodes. Exemplary hematologic malignancies include, but are not limited to, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic52MF-369983826Docket No.: 197102021140myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma (e.g., classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma), mycosis fungoides, non-Hodgkin lymphoma (e.g., B-cell nonHodgkin lymphoma (e.g., Burkitt lymphoma, small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma) or T-cell non-Hodgkin lymphoma (mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma)), primary central nervous system lymphoma, Sezary syndrome, Waldenstrom macroglobulinemia), chronic myeloproliferative neoplasm, Langerhans cell histiocytosis, multiple myeloma / plasma cell neoplasm, myelodysplastic syndrome, or myelodysplastic / myeloproliferative neoplasm.

[0190] In some aspect, the cancer is breast cancer. In some aspects, the breast cancer is breast carcinoma, invasive ductal breast cancer, or invasive lobular breast cancer.Nucleic acid extraction and processing

[0191] DNA or RNA may be extracted from tissue samples, biopsy samples, blood samples, or other bodily fluid samples using any of a variety of techniques known to those of skill in the art (see, e.g., Example 1 of International Patent Application Publication No. WO 2012 / 092426; Tan, et al. (2009), “DNA, RNA, and Protein Extraction: The Past and The Present”, J. Biomed.Biotech. 2009:574398; the technical literature for the Maxwell® 16 LEV Blood DNA Kit (Promega Corporation, Madison, WI); and the Maxwell 16 Buccal Swab LEV DNA Purification Kit Technical Manual (Promega Literature #TM333, January 1, 2011, Promega Corporation, Madison, WI)). Protocols for RNA isolation are disclosed in, e.g., the Maxwell® 16 Total RNA Purification Kit Technical Bulletin (Promega Literature #TB351, August 2009, Promega Corporation, Madison, WI).

[0192] A typical DNA extraction procedure, for example, comprises (i) collection of the fluid sample, cell sample, or tissue sample from which DNA is to be extracted, (ii) disruption of cell membranes (i.e., cell lysis), if necessary, to release DNA and other cytoplasmic components, (iii) treatment of the fluid sample or lysed sample with a concentrated salt solution to precipitate proteins, lipids, and RNA, followed by centrifugation to separate out the precipitated proteins, lipids, and RNA, and (iv) purification of DNA from the supernatant to remove detergents, proteins, salts, or other reagents used during the cell membrane lysis step.

[0193] Disruption of cell membranes may be performed using a variety of mechanical shear (e.g., by passing through a French press or fine needle) or ultrasonic disruption techniques. The cell 53MF-369983826Docket No.: 197102021140lysis step often comprises the use of detergents and surfactants to solubilize lipids the cellular and nuclear membranes. In some instances, the lysis step may further comprise use of proteases to break down protein, and / or the use of an RNase for digestion of RNA in the sample.

[0194] Examples of suitable techniques for DNA purification include, but are not limited to, (i) precipitation in ice-cold ethanol or isopropanol, followed by centrifugation (precipitation of DNA may be enhanced by increasing ionic strength, e.g., by addition of sodium acetate), (ii) phenolchloroform extraction, followed by centrifugation to separate the aqueous phase containing the nucleic acid from the organic phase containing denatured protein, and (iii) solid phase chromatography where the nucleic acids adsorb to the solid phase (e.g., silica or other) depending on the pH and salt concentration of the buffer.

[0195] In some instances, cellular and histone proteins bound to the DNA may be removed either by adding a protease or by having precipitated the proteins with sodium or ammonium acetate, or through extraction with a phenol-chloroform mixture prior to a DNA precipitation step.

[0196] In some instances, DNA may be extracted using any of a variety of suitable commercial DNA extraction and purification kits. Examples include, but are not limited to, the QIAamp (for isolation of genomic DNA from human samples) and DNAeasy (for isolation of genomic DNA from animal or plant samples) kits from Qiagen (Germantown, MD) or the Maxwell® and ReliaPrep™ series of kits from Promega (Madison, WI).

[0197] As noted above, in some instances the sample may comprise a formalin-fixed (also known as formaldehyde-fixed, or paraformaldehyde-fixed), paraffin-embedded (FFPE) tissue preparation. For example, the FFPE sample may be a tissue sample embedded in a matrix, e.g., an FFPE block. Methods to isolate nucleic acids (e.g., DNA) from formaldehyde- or paraformaldehyde-fixed, paraffin-embedded (FFPE) tissues are disclosed in, e.g., Cronin, et al., (2004) Am J Pathol. 164(l):35-42; Masuda, et al., (1999) Nucleic Acids Res. 27(22):4436-4443; Specht, et al., (2001) Am J Pathol. 158(2):419-429; the Ambion RecoverAll™ Total Nucleic Acid Isolation Protocol (Ambion, Cat. No. AM1975, September 2008); the Maxwell® 16 FFPE Plus EEV DNA Purification Kit Technical Manual (Promega Literature #TM349, February 2011); the E.Z.N.A.® FFPE DNA Kit Handbook (OMEGA bio-tek, Norcross, GA, product numbers D3399-00, D3399-01, and D3399-02, June 2009); and the QIAamp® DNA FFPE Tissue Handbook (Qiagen, Cat. No. 37625, October 2007). For example, the RecoverAll™ Total Nucleic Acid Isolation Kit uses xylene at elevated temperatures to solubilize paraffin-embedded samples and a glass-fiber filter to capture nucleic acids. The Maxwell® 16 FFPE Plus LEV DNA Purification Kit is used with the Maxwell® 16 Instrument for purification of genomic DNA from 1 to 10 pm sections of FFPE tissue. DNA is purified using silica-clad paramagnetic particles 54MF-369983826Docket No.: 197102021140(PMPs), and eluted in low elution volume. The E.Z.N.A.® FFPE DNA Kit uses a spin column and buffer system for isolation of genomic DNA. QIAamp® DNA FFPE Tissue Kit uses QIAamp® DNA Micro technology for purification of genomic and mitochondrial DNA.

[0198] In some instances, the disclosed methods may further comprise determining or acquiring a yield value for the nucleic acid extracted from the sample and comparing the determined value to a reference value. For example, if the determined or acquired value is less than the reference value, the nucleic acids may be amplified prior to proceeding with library construction. In some instances, the disclosed methods may further comprise determining or acquiring a value for the size (or average size) of nucleic acid fragments in the sample, and comparing the determined or acquired value to a reference value, e.g., a size (or average size) of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 base pairs (bps). In some instances, one or more parameters described herein may be adjusted or selected in response to this determination.

[0199] After isolation, the nucleic acids are typically dissolved in a slightly alkaline buffer, e.g., Tris-EDTA (TE) buffer, or in ultra-pure water. In some instances, the isolated nucleic acids (e.g., genomic DNA) may be fragmented or sheared by using any of a variety of techniques known to those of skill in the art. For example, genomic DNA can be fragmented by physical shearing methods, enzymatic cleavage methods, chemical cleavage methods, and other methods known to those of skill in the art. Methods for DNA shearing are described in Example 4 in International Patent Application Publication No. WO 2012 / 092426. In some instances, alternatives to DNA shearing methods can be used to avoid a ligation step during library preparation.Library preparation

[0200] In some instances, the nucleic acids isolated from the sample may be used to construct a library (e.g., a nucleic acid library as described herein). In some instances, the nucleic acids are fragmented using any of the methods described above, optionally subjected to repair of chain end damage, and optionally ligated to synthetic adapters, primers, and / or barcodes (e.g., amplification primers, sequencing adapters, flow cell adapters, substrate adapters, sample barcodes or indexes, and / or unique molecular identifier sequences), size-selected (e.g., by preparative gel electrophoresis), and / or amplified (e.g., using PCR, a non-PCR amplification technique, or an isothermal amplification technique). In some instances, the fragmented and adapter-ligated group of nucleic acids is used without explicit size selection or amplification prior to hybridizationbased selection of target sequences. In some instances, the nucleic acid is amplified by any of a variety of specific or non-specific nucleic acid amplification methods known to those of skill in the art. In some instances, the nucleic acids are amplified, e.g., by a whole-genome amplification 55MF-369983826Docket No.: 197102021140method such as random-primed strand-displacement amplification. Examples of nucleic acid library preparation techniques for next- generation sequencing are described in, e.g., van Dijk, et al. (2014), Exp. Cell Research 322:12 - 20, and Illumina’s genomic DNA sample preparation kit.

[0201] In some instances, the nucleic acids isolated from the sample are RNA (mRNA) and are used to construct a library for RNA sequencing (RNAseq). In addition to the methods described above, library preparation may comprise generating a plurality of nucleic acid molecules form the plurality of RNA molecules. The plurality of nucleic acid molecules may be cDNA molecules. Examples of RNAseq preparation techniques for next-generation sequencing may comprise the techniques described in Illumina’s NextSeq or TruSeq mRNA library prep kits.

[0202] In some instances, the resulting nucleic acid library may contain all or substantially all of the complexity of the genome. The term “substantially all” in this context refers to the possibility that there can in practice be some unwanted loss of genome complexity during the initial steps of the procedure. The methods described herein also are useful in cases where the nucleic acid library comprises a portion of the genome, e.g., where the complexity of the genome is reduced by design. In some instances, any selected portion of the genome can be used with a method described herein. For example, in certain embodiments, the entire exome or a subset thereof is isolated. In some instances, the library may include at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the genomic DNA. In some instances, the library may consist of cDNA copies of genomic DNA that includes copies of at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% of the genomic DNA. In certain instances, the amount of nucleic acid used to generate the nucleic acid library may be less than 5 micrograms, less than 1 microgram, less than 500 ng, less than 200 ng, less than 100 ng, less than 50 ng, less than 10 ng, less than 5 ng, or less than 1 ng.

[0203] In some instances, a library (e.g., a nucleic acid library) includes a collection of nucleic acid molecules. As described herein, the nucleic acid molecules of the library can include a target nucleic acid molecule (e.g., a tumor nucleic acid molecule, a reference nucleic acid molecule and / or a control nucleic acid molecule; also referred to herein as a first, second and / or third nucleic acid molecule, respectively). The nucleic acid molecules of the library can be from a single subject or individual. In some instances, a library can comprise nucleic acid molecules derived from more than one subject (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30 or more subjects). For example, two or more libraries from different subjects can be combined to form a library having nucleic acid molecules from more than one subject (where the nucleic acid molecules derived from each subject are optionally ligated to a unique sample barcode corresponding to a specific subject). In some instances, the subject is a human having, or at risk of having, a cancer or tumor.56MF-369983826Docket No.: 197102021140

[0204] In some instances, the library (or a portion thereof) may comprise one or more subgenomic intervals. In some instances, a subgenomic interval can be a single nucleotide position, e.g., a nucleotide position for which a variant at the position is associated (positively or negatively) with a tumor phenotype. In some instances, a subgenomic interval comprises more than one nucleotide position. Such instances include sequences of at least 2, 5, 10, 50, 100, 150, 250, or more than 250 nucleotide positions in length. Subgenomic intervals can comprise, e.g., one or more entire genes (or portions thereof), one or more exons or coding sequences (or portions thereof), one or more introns (or portion thereof), one or more microsatellite region (or portions thereof), or any combination thereof. A subgenomic interval can comprise all or a part of a fragment of a naturally occurring nucleic acid molecule, e.g., a genomic DNA molecule. For example, a subgenomic interval can correspond to a fragment of genomic DNA which is subjected to a sequencing reaction. In some instances, a subgenomic interval is a continuous sequence from a genomic source. In some instances, a subgenomic interval includes sequences that are not contiguous in the genome, e.g., subgenomic intervals in cDNA can include exonexon junctions formed as a result of splicing. In some instances, the subgenomic interval comprises a tumor nucleic acid molecule. In some instances, the subgenomic interval comprises a non-tumor nucleic acid molecule.Targeting gene loci for analysis

[0205] The methods described herein can be used in combination with, or as part of, a method for evaluating a plurality or set of subject intervals (e.g., target sequences), e.g., from a set of genomic loci (e.g., gene loci or fragments thereof), as described herein.

[0206] In some instances, the set of genomic loci evaluated by the disclosed methods comprises a plurality of, e.g., genes, which in mutant form, are associated with an effect on cell division, growth or survival, or are associated with a cancer, e.g., a cancer described herein.

[0207] In some instances, the set of gene loci evaluated by the disclosed methods comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, or more than 100 gene loci.

[0208] In some instances, the selected gene loci (also referred to herein as target gene loci or target sequences), or fragments thereof, may include subject intervals comprising non-coding sequences, coding sequences, intragenic regions, or intergenic regions of the subject genome. For example, the subject intervals can include a non-coding sequence or fragment thereof (e.g., a promoter sequence, enhancer sequence, 5’ untranslatedregion (5’ UTR), 3’ untranslatedregion 57MF-369983826Docket No.: 197102021140(3’ UTR), or a fragment thereof), a coding sequence of fragment thereof, an exon sequence or fragment thereof, an intron sequence or a fragment thereof.Target capture reagents

[0209] The methods described herein may comprise contacting a nucleic acid library with a plurality of target capture reagents in order to select and capture a plurality of specific target sequences (e.g., gene sequences or fragments thereof) for analysis. In some instances, a target capture reagent (i.e., a molecule which can bind to and thereby allow capture of a target molecule) is used to select the subject intervals to be analyzed. For example, a target capture reagent can be a bait molecule, e.g., a nucleic acid molecule (e.g., a DNA molecule or RNA molecule) which can hybridize to (i.e., is complementary to) a target molecule, and thereby allows capture of the target nucleic acid. In some instances, the target capture reagent, e.g., a bait molecule (or bait sequence), is a capture oligonucleotide (or capture probe). In some instances, the target nucleic acid is a genomic DNA molecule, an RNA molecule, a cDNA molecule derived from an RNA molecule, a micro satellite DNA sequence, and the like. In some instances, the target capture reagent is suitable for solution-phase hybridization to the target. In some instances, the target capture reagent is suitable for solid-phase hybridization to the target. In some instances, the target capture reagent is suitable for both solution-phase and solid-phase hybridization to the target. The design and construction of target capture reagents is described in more detail in, e.g., International Patent Application Publication No. WO 2020 / 236941, the entire content of which is incorporated herein by reference.

[0210] The methods described herein provide for optimized sequencing of a large number of genomic loci (e.g., genes or gene products (e.g., mRNA), microsatellite loci, etc.) from samples (e.g., cancerous tissue specimens, liquid biopsy samples, and the like) from one or more subjects by the appropriate selection of target capture reagents to select the target nucleic acid molecules to be sequenced. In some instances, a target capture reagent may hybridize to a specific target locus, e.g., a specific target gene locus or fragment thereof. In some instances, a target capture reagent may hybridize to a specific group of target loci, e.g., a specific group of gene loci or fragments thereof. In some instances, a plurality of target capture reagents comprising a mix of target-specific and / or group-specific target capture reagents may be used.

[0211] In some instances, the number of target capture reagents (e.g., bait molecules) in the plurality of target capture reagents (e.g., a bait set) contacted with a nucleic acid library to capture a plurality of target sequences for nucleic acid sequencing is greater than 10, greater than 50, greater than 100, greater than 200, greater than 300, greater than 400, greater than 500,58MF-369983826Docket No.: 197102021140greater than 600, greater than 700, greater than 800, greater than 900, greater than 1,000, greater than 1,250, greater than 1,500, greater than 1,750, greater than 2,000, greater than 3,000, greater than 4,000, greater than 5,000, greater than 10,000, greater than 25,000, or greater than 50,000.

[0212] In some instances, the overall length of the target capture reagent sequence can be between about 70 nucleotides and 1000 nucleotides. In one instance, the target capture reagent length is between about 100 and 300 nucleotides, 110 and 200 nucleotides, or 120 and 170 nucleotides, in length. In addition to those mentioned above, intermediate oligonucleotide lengths of about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides in length can be used in the methods described herein. In some embodiments, oligonucleotides of about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, or 230 bases can be used.

[0213] In some instances, each target capture reagent sequence can include: (i) a target- specific capture sequence (e.g., a gene locus or micro satellite locus- specific complementary sequence), (ii) an adapter, primer, barcode, and / or unique molecular identifier sequence, and (iii) universal tails on one or both ends. As used herein, the term “target capture reagent” can refer to the targetspecific target capture sequence or to the entire target capture reagent oligonucleotide including the target-specific target capture sequence.

[0214] In some instances, the target-specific capture sequences in the target capture reagents are between about 40 nucleotides and 1000 nucleotides in length. In some instances, the targetspecific capture sequence is between about 70 nucleotides and 300 nucleotides in length. In some instances, the target- specific sequence is between about 100 nucleotides and 200 nucleotides in length. In yet other instances, the target- specific sequence is between about 120 nucleotides and 170 nucleotides in length, typically 120 nucleotides in length. Intermediate lengths in addition to those mentioned above also can be used in the methods described herein, such as target-specific sequences of about 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides in length, as well as target- specific sequences of lengths between the above-mentioned lengths.

[0215] In some instances, the target capture reagent may be designed to select a subject interval containing one or more rearrangements, e.g., an intron containing a genomic rearrangement. In such instances, the target capture reagent is designed such that repetitive sequences are masked to increase the selection efficiency. In those instances where the rearrangement has a known juncture sequence, complementary target capture reagents can be designed to recognize the juncture sequence to increase the selection efficiency.59MF-369983826Docket No.: 197102021140

[0216] In some instances, the disclosed methods may comprise the use of target capture reagents designed to capture two or more different target categories, each category having a different target capture reagent design strategy. In some instances, the hybridization-based capture methods and target capture reagent compositions disclosed herein may provide for the capture and homogeneous coverage of a set of target sequences, while minimizing coverage of genomic sequences outside of the targeted set of sequences. In some instances, the target sequences may include the entire exome of genomic DNA or a selected subset thereof. In some instances, the target sequences may include, e.g., a large chromosomal region (e.g., a whole chromosome arm). The methods and compositions disclosed herein provide different target capture reagents for achieving different sequencing depths and patterns of coverage for complex sets of target nucleic acid sequences.

[0217] Typically, DNA molecules are used as target capture reagent sequences, although RNA molecules can also be used. In some instances, a DNA molecule target capture reagent can be single stranded DNA (ssDNA) or double- stranded DNA (dsDNA). In some instances, an RNA-DNA duplex is more stable than a DNA-DNA duplex and therefore provides for potentially better capture of nucleic acids.

[0218] In some instances, the disclosed methods comprise providing a selected set of nucleic acid molecules (e.g., a library catch) captured from one or more nucleic acid libraries. For example, the method may comprise: providing one or a plurality of nucleic acid libraries, each comprising a plurality of nucleic acid molecules (e.g., a plurality of target nucleic acid molecules and / or reference nucleic acid molecules) extracted from one or more samples from one or more subjects; contacting the one or a plurality of libraries (e.g., in a solution-based hybridization reaction) with one, two, three, four, five, or more than five pluralities of target capture reagents (e.g., oligonucleotide target capture reagents) to form a hybridization mixture comprising a plurality of target capture reagent / nucleic acid molecule hybrids; separating the plurality of target capture reagent / nucleic acid molecule hybrids from said hybridization mixture, e.g., by contacting said hybridization mixture with a binding entity that allows for separation of said plurality of target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, thereby providing a library catch (e.g., a selected or enriched subgroup of nucleic acid molecules from the one or a plurality of libraries).

[0219] In some instances, the disclosed methods may further comprise amplifying the library catch (e.g., by performing PCR). In other instances, the library catch is not amplified.

[0220] In some instances, the target capture reagents can be part of a kit which can optionally comprise instructions, standards, buffers or enzymes or other reagents.60MF-369983826Docket No.: 197102021140Hybridization conditions

[0221] As noted above, the methods disclosed herein may include the step of contacting the library (e.g., the nucleic acid library) with a plurality of target capture reagents to provide a selected library target nucleic acid sequences (i.e., the library catch). The contacting step can be effected in, e.g., solution-based hybridization. In some instances, the method includes repeating the hybridization step for one or more additional rounds of solution-based hybridization. In some instances, the method further includes subjecting the library catch to one or more additional rounds of solution-based hybridization with the same or a different collection of target capture reagents.

[0222] In some instances, the contacting step is effected using a solid support, e.g., an array. Suitable solid supports for hybridization are described in, e.g., Albert, T.J. et al. (2007) Nat. Methods 4(ll):903-5; Hodges, E. etal. (2007) Nat. Genet. 39(12): 1522-7; and Okou, D.T. et al. (2007) Nat. Methods 4(11 ):907-9, the contents of which are incorporated herein by reference in their entireties.

[0223] Hybridization methods that can be adapted for use in the methods herein are described in the art, e.g., as described in International Patent Application Publication No. WO 2012 / 092426. Methods for hybridizing target capture reagents to a plurality of target nucleic acids are described in more detail in, e.g., International Patent Application Publication No. WO 2020 / 236941, the entire content of which is incorporated herein by reference.Sequencing methods

[0224] The methods and systems disclosed herein can be used in combination with, or as part of, a method or system for sequencing nucleic acids (e.g., a next- generation sequencing system) to generate a plurality of sequence reads that overlap one or more gene loci within a subgenomic interval in the sample and thereby determine, e.g., gene allele sequences at a plurality of gene loci. “Next-generation sequencing” (or “NGS”) as used herein may also be referred to as “massively parallel sequencing” (or “MPS”), and refers to any sequencing method that determines the nucleotide sequence of either individual nucleic acid molecules (e.g., as in single molecule sequencing) or clonally expanded proxies for individual nucleic acid molecules in a high throughput fashion (e.g., wherein greater than 103, 104, 105or more than 105molecules are sequenced simultaneously).

[0225] Next-generation sequencing methods are known in the art, and are described in, e.g., Metzker, M. (2010) Nature Biotechnology Reviews 11:31-46, which is incorporated herein by 61MF-369983826Docket No.: 197102021140reference. Other examples of sequencing methods suitable for use when implementing the methods and systems disclosed herein are described in, e.g., International Patent Application Publication No. WO 2012 / 092426. In some instances, the sequencing may comprise, for example, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, or direct sequencing. In some instances, sequencing may be performed using, e.g., Sanger sequencing. In some instances, the sequencing may comprise a paired-end sequencing technique that allows both ends of a fragment to be sequenced and generates high-quality, alignable sequence data for detection of, e.g., genomic rearrangements, repetitive sequence elements, gene fusions, and novel transcripts.

[0226] The disclosed methods and systems may be implemented using sequencing platforms such as the Roche / 454 Genome Sequencer (GS) FLX System, Illumina / Solexa Genome Analyzer (GA), Illumina’s HiSeq® 2500, HiSeq® 3000, HiSeq® 4000 and NovaSeq® 6000 Sequencing Systems, Life / APG’s Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator’s G.007 system, Helicos BioSciences’ HeliScope Gene Sequencing system, or Pacific Biosciences’ PacBio® RS platform. In some instances, sequencing may comprise Illumina MiSeqO sequencing. In some instances, sequencing may comprise Illumina HiSeq® sequencing. In some instances, sequencing may comprise Illumina NovaSeq® sequencing. Optimized methods for sequencing a large number of target genomic loci in nucleic acids extracted from a sample are described in more detail in, e.g., International Patent Application Publication No. WO 2020 / 236941, the entire content of which is incorporated herein by reference.

[0227] In certain instances, the disclosed methods comprise one or more of the steps of: (a) acquiring a library comprising a plurality of normal and / or tumor nucleic acid molecules from a sample; (b) simultaneously or sequentially contacting the library with one, two, three, four, five, or more than five pluralities of target capture reagents under conditions that allow hybridization of the target capture reagents to the target nucleic acid molecules, thereby providing a selected set of captured normal and / or tumor nucleic acid molecules (i.e., a library catch); (c) separating the selected subset of the nucleic acid molecules (e.g., the library catch) from the hybridization mixture, e.g., by contacting the hybridization mixture with a binding entity that allows for separation of the target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, (d) sequencing the library catch to acquiring a plurality of reads (e.g., sequence reads) that overlap one or more subject intervals (e.g., one or more target sequences) from said library catch that may comprise a mutation (or alteration), e.g., a variant sequence comprising a somatic mutation or germline mutation; (e) aligning said sequence reads using an alignment method as described elsewhere herein; and / or (f) assigning a nucleotide value for a nucleotide position in 62MF-369983826Docket No.: 197102021140the subject interval (e.g., calling a mutation using, e.g., a Bayesian method or other method described herein) from one or more sequence reads of the plurality.

[0228] In some instances, acquiring sequence reads for one or more subject intervals may comprise sequencing at least 1, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, at least 1,000, at least 1,250, at least 1,500, at least 1,750, at least 2,000, at least 2,250, at least 2,500, at least 2,750, at least 3,000, at least 3,500, at least 4,000, at least 4,500, or at least 5,000 loci, e.g., genomic loci, gene loci, microsatellite loci, etc. In some instances, acquiring a sequence read for one or more subject intervals may comprise sequencing a subject interval for any number of loci within the range described in this paragraph, e.g., for at least 2,850 gene loci.

[0229] In some instances, acquiring sequence reads for one or more subject intervals may comprise between 10 and 20 loci, between 10 and 40 loci, between 10 and 60 loci, between 10 and 80 loci, between 10 and 100 loci, between 10 and 150 loci, between 10 and 200 loci, between 10 and 250 loci, between 10 and 300 loci, between 10 and 350 loci, between 10 and 400 loci, between 10 and 450 loci, between 10 and 500 loci, between 20 and 40 loci, between 20 and 60 loci, between 20 and 80 loci, between 20 and 100 loci, between 20 and 150 loci, between 20 and 200 loci, between 20 and 250 loci, between 20 and 300 loci, between 20 and 350 loci, between 20 and 400 loci, between 20 and 500 loci, between 40 and 60 loci, between 40 and 80 loci, between 40 and 100 loci, between 40 and 150 loci, between 40 and 200 loci, between 40 and 250 loci, between 40 and 300 loci, between 40 and 350 loci, between 40 and 400 loci, between 40 and 500 loci, between 60 and 80 loci, between 60 and 100 loci, between 60 and 150 loci, between 60 and 200 loci, between 60 and 250 loci, between 60 and 300 loci, between 60 and 350 loci, between 60 and 400 loci, between 60 and 500 loci, between 80 and 100 loci, between 80 and 150 loci, between 80 and 200 loci, between 80 and 250 loci, between 80 and 300 loci, between 80 and 350 loci, between 80 and 400 loci, between 80 and 500 loci, between 100 and 150 loci, between 100 and 200 loci, between 100 and 250 loci, between 100 and 300 loci, between 100 and 350 loci, between 100 and 400 loci, between 100 and 500 loci, between 150 and 200 loci, between 150 and 250 loci, between 150 and 300 loci, between 150 and 350 loci, between 150 and 400 loci, between 150 and 500 loci, between 200 and 250 loci, between 200 and 300 loci, between 200 and 350 loci, between 200 and 400 loci, between 200 and 500 loci, between 250 and 300 loci, between 250 and 350 loci, between 250 and 400 loci, between 250 and 500 loci, between63MF-369983826Docket No.: 197102021140300 and 350 loci, between 300 and 400 loci, between 300 and 500 loci, between 350 and 400 loci, between 350 and 500 loci, or between 400 and 500 loci.

[0230] In some aspects, the plurality of sequencing reads overlap one or more gene loci. In some aspects, the one or more gene loci comprise ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BCR, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EMSY (Cllorf30), EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESRI, ETV4, ETV5, ETV6, EWSR1, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, FAS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, IKBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D (MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, NUTM1, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLDI, POLE, PPARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCHI, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAFI, RARA, RBI, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, RSPO2, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SLC34A2, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSCI, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703, or any combination thereof.64MF-369983826Docket No.: 197102021140

[0231] In some aspects, the plurality of sequencing reads overlap one or more gene loci. In some aspects, the one or more gene loci comprise ABL, ALK, ALL, B4GALNT1, BAFF, BCL2, BRAF, BRCA, BTK, CD19, CD20, CD3, CD30, CD319, CD38, CD52, CDK4, CDK6, CML, CRACC, CS1, CTLA-4, dMMR, EGFR, ERBB1, ERBB2, FGFR1-3, FLT3, GD2, HDAC, HER1, HER2, HR, IDH2, IL-ip, IL-6, IL-6R, JAK1, JAK2, JAK3, KIT, KRAS, MEK, MET, MSLH, mTOR, PARP, PD-1, PDGFR, PDGFRa, PDGFRp, PD-L1, PI3K6, PIGF, PTCH, RAF, RANKL, RET, ROS1, SLAMF7, VEGF, VEGFA, VEGFB, or any combination thereof.

[0232] In some aspects, the one or more gene loci comprise ABCB1, ABL1, ABL2, ACSL6, AFF1, AFF4, AKT1, AKT2, AKT3, ALK, APC, AR, ARHGAP26, ARHGDIA, ARID1A, ARID1B, ASXL1, ATIC, ATM, ATR, AXL, B2M, BAP1, BCL10, BCL11B, BCL2, BCL3, BCL6, BCOR, BCR, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRIP1, BTG1, BTK, CAMTAI, CBFA2T3, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD19, CD274, CD28, CD38, CD74, CDH1, CDK4, CDK6, CDKN2A, CDKN2B, CEBPA, CIC, CIITA, CLDN18, CLDN3, CLTC, CNTRL, COL1A1, CREB3L1, CREB3L2, CREBBP, CRLF2, CSF1, CUX1, CXCR4, CYLD, DDIT3, DDR1, DDR2, DDX10, DEK, DHH, DIRC2, DLC1, DNMT3A, DUSP22, EBF1, EGFR, EIF4A2, ELF4, ELL, ELN, EML4, EP300, EPOR, EPS15, ERBB2, ERBB3, ERG, ESRI, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, FBXW7, FEV, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FGR, FLU, FLT3, FOS, FOSB, FOXO1, FOXO3, FOXO4, FOXP1, FUS, GAS7, GLI1, GLIS2, HDAC10, HERPUD1, HEY1, HIP1, HLF, HMGA1, HMGA2, IGH, IGK, IGL (IGLL5), IKZF1, IKZF2, IKZF3, INSR, IRF4, ITK, JAK1, JAK2, JAK3, JAZF1, KAT6A, KIF5B, KIT, KMT2A, LATS2, LCP1, LMNA, LMO1, LMO2, LPP, LTK, MAF, MAFB, MALT1, MAML2, MAP3K7, MAP3K8, MAST1, MDS2, MECOM, MEF2C, MEF2D, MEN1, MET, MGMT, MKL1, MKL2, MLF1, MLH1, MLLT1, MLLT10, MN1, MNX1, MSH2, MSH6, MSI2, MSMB, MTAP, MTCP1, MYB, MYC, MYH11, NAB2, NBEAP1, NCOA2, NF1, NF2, NIN, NONO, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NR4A3, NRAS, NRG1, NRG2, NSD1, NTRK1, NTRK2, NTRK3, NUMA1, NUP214, NUP98, NUTM1, NUTM2A, P2RY8, PALB2, PAX3, PAX5, PAX7, PBX1, PBX3, PDCD1LG2, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PICALM, PIK3CA, PIK3R1, PIK3R2, PKN1, PLAG1, PMS2, PPARG, PRDM16, PRKACA, PRKCA, PRKCB, PRMT5, PTCHI, PTEN, RAFI, RARA, RASGRF1, RBI, RELA, RET, RHOH, ROS1, RPS6KB1, RSPO2, RSPO3, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SEC31A, SEPT5, SEPT6, SEPT7, SET, SH3GL1, SLC45A3, SMAD2, SMAD4, SMARCB1, SNX29, SRC, SSI 8, SSX1, SSX2, SSX4, STAT6, STIL, STK11, SYK, TAF15, TALI, TAL2, TBL1XR1, TCF3, TCF4, TCL1A, TCL6, TEC, TERT, TET1, TET2, TFE3, TFEB, TFG, TFPT, THADA, TLX1, TLX3, TMPRSS2, TOPI, TP53, TP63, TPM3,65MF-369983826Docket No.: 197102021140TPM4, TRIM24, TRIP11, TSC1, TSC2, TTL, TYK2, USP6, VHL, WHSCI, WHSC1L1, WT1, WWTR1, YAP1, YWHAE, ZAP70, ZBTB16, ZMYM2, ZNF384, ZNF750, or any combination thereof.

[0233] In some aspects, the one or more gene loci comprise A2M, ABCA6, ABCB1, ABCC2, ABCC9, ABH, ABL1, ABL2, ACACA, ACLY, ACRBP, ACSL3, ACSL6, ACTA2, ACTG1, ACTG2, ACTN1, ACTR3B, ACVR1, ACVR1C, ACVRL1, ADAM12, ADAM19, ADAM2, ADCY7, ADGRB1, ADGRB3, ADGRF5, ADGRL4, ADRB2, AFF1, AFF3, AFF4, AFP, AGR2, AGR3, AHR, AIFM3, AKT1, AKT2, AKT3, ALDH2, ALK, ALOX12, AMER1, AMZ1, ANGPT1, ANGPT2, ANLN, ANPEP, ANXA1, ANXA2, APC, APCDD1, APEX2, APH1A, APLN, APOBEC3A, APOBEC3B, APOBR, APOL6, APP, APPBP2, AR, AREG, ARF1, ARG2, ARHGAP15, ARHGAP26, ARHGDIA, ARID1A, ARID1B, ARID3A, ARNT, ARNT2, ASAP2, ASB13, ASCL2, ASGR2, ASTE1, ASXL1, ATAD2, ATIC, ATM, ATP2C1, ATP8A1, ATP8B2, ATR, AURKA, AURKB, AVPR1A, AXIN2, AXL, B2M, B3GNT5, BAALC, BAG1, BAG2, BAGE4, BAK1, BAMBI, BAP1, BASP1, BATE, BATF3, BAX, BAZ2B, BCAM, BCAR1, BCAR3, BCAS1, BCL10, BCL11A, BCL11B, BCL2, BCL2A1, BCL2L1, BCL2L11, BCL3, BCL6, BCL7A, BCL9, BCOR, BCR, BIN2, BIRC3, BIRC5, BLK, BLM, BLNK, BLVRA, BMF, BMP2, BMP4, BMPR1A, BMPR1B, BNC2, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRDT, BRINP3, BRIP1, BRPF1, BTG1, BTG3, BTK, BTLA, BUB1, BUB1B, C10orf35, C15orf48, C1RL, C3, C5, C5AR2, CA4, CAGE1, CALB2, CALML3, CALR, CAMTAI, CANX, CASP1, CASP3, CASP8, CASP9, CBFA2T3, CBFB, CBL, CBLC, CCDC140, CCDC50, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL3, CCL4, CCL5, CCL8, CCNA2, CCNB1, CCNB2, CCND1, CCND2, CCND3, CCNE1, CCNE2, CCNG2, CCR4, CCR5, CCR7, CCR8, CCRL2, CCSER2, CD14, CD163, CD19, CD1A, CD1B, CD1D, CD1E, CD2, CD209, CD22, CD226, CD244, CD247, CD248, CD27, CD274, CD276, CD28, CD33, CD34, CD36, CD38, CD3D, CD3E, CD3G, CD4, CD40, CD40LG, CD44, CD46, CD47, CD5, CD6, CD63, CD68, CD7, CD70, CD74, CD79A, CD79B, CD80, CD81, CD84, CD86, CD8A, CD8B, CD9, CD93, CD96, CDC20, CDC25C, CDC45, CDC6, CDCA3, CDCA5, CDCA7, CDCA7L, CDCA8, CDH1, CDH3, CDH5, CDHR1, CDK2, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2AIP, CDKN2B, CDKN2B-AS1, CDKN2D, CDKN3, CDT1, CDX2, CEACAM1, CEACAM3, CEACAM5, CEACAM8, CEBPA, CEBPB, CELSR2, CENPA, CENPF, CENPM, CEP55, CES1, CES2, CFD, CHAF1B, CHEK1, CHEK2, CHN1, CHUK, CIC, CIITA, CITED4, CLCA2, CLDN18, CLDN3, CLDN4, CLDN5, CLDN6, CLDN7, CLEC10A, CLEC14A, CLEC4C, CLEC5A, CLEC9A, CLIC2, CLIC4, CLTC, CMKLR1, CMPK2, CNN1, CNTNAP2, CNTRL, COL15A1,66MF-369983826Docket No.: 197102021140C0L18A1, C0L1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL6A3, COL7A1, COPB2, CPA3, CRAT, CREB1, CREB3L1, CREB3L2, CREBBP, CRKL, CRLF2, CRNDE, CRYAB, CSF1, CSF1R, CSF2, CSF3R, CSMD1, CSNK1E, CSNK1G2, CST7, CT45A1, CT45A2, CT45A3, CT62, CTAG1A, CTAG1B, CTAG2, CTAGE1, CTGF, CTLA4, CTNNB1, CTNNBIP1, CTPS1, CTPS2, CTSV, CTSW, CUX1, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL2, CXCL3, CXCL6, CXCL8, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXXC5, CYB5R2, CYBB, CYLD, CYP4F3, DCAF12, DCLK1, DCN, DDB2, DDIT3, DDIT4, DDR1, DDR2, DDX10, DDX21, DDX4, DDX58, DDX6, DEK, DENND3, DEPTOR, DHH, DHX58, DIDOI, DIRC2, DKK1, DKK2, DKK4, DLC1, DLL3, DLL4, DMBT1, DMD, DNMT1, DNMT3A, DOCK5, DOT1L, DRAM1, DSC2, DSCR8, DTL, DTX1, DTX2, DTX3L, DUSP1, DUSP18, DUSP22, DUSP6, DVL1, E2F1, E2F4, E2F5, EBF1, ECSCR, ECT2, EDNRB, EGF, EGFR, EGLN3, EGR1, EGR2, EIF4A2, ELF4, ELF5, ELK4, ELL, ELN, EMCN, EMEI, EML4, EML6, EMSY, ENTPD1, EOMES, EP300, EP400, EPCAM, EPHA4, EPHA7, EPOR, EPS15, ERAP1, ERAP2, ERBB2, ERBB3, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EREG, ERG, ERN2, ESMI, ESRI, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, EXO1, EZH2, FUR, FAM101B, FAM171B, FAM26F, FAM46A, FAM64A, FANCA, FANCB, FANCC, FANCD2, FAP, FAS, FASN, FAT2, FBXW11, FBXW7, FCAR, FCGR2B, FCGR3B, FCRL2, FCRL5, FEV, FGF9, FGFBP2, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FGR, FKBP4, FLU, FLNA, FLT1, FLT3, FLT3LG, FLT4, FMN1, FMN2, FMOD, FN1, FNBP1, FNIP2, FOLH1, FOLR1, FOS, FOSB, FOXA1, FOXCI, FOXM1, FOXO1, FOXO3, FOXO4, FOXO6, FOXP1, FOXP3, FPR1, FPR3, FSTL3, FUCA1, FUS, FUT4, FUT8, FZD1, FZD10, FZD2, FZD5, FZD6, FZD7, GABBR2, GADD45A, GADD45B, GAGE1, GAGE2E, GAGE6, GAGE8, GALNT10, GALNT12, GAS1, GAS7, GBP5, GIMAP5, GIMAP7, GINS2, GJA4, GLI1, GLIS2, GMFG, GMNN, GMPS, GNA12, GNG11, GNLY, GOLM1, GPA33, GPC4, GPC6, GPI, GPR143, GPR146, GPR160, GRB7, GREB1, GRM4, GSK3B, GSTA1, GSTM1, GUSB, GZMA, GZMB, GZMH, GZMK, H2AFX, HABP2, HAMP, HAP1, HAVCR2, HBEGF, HCLS1, HCST, HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDC, HELZ2, HERPUD1, HES1, HES2, HES4, HES5, HES6, HEY1, HEY2, HEYL, HGF, HHIP, HIF1A, HIP1, HIST1H1A, HIST1H1E, HIST1H2AG, HIST1H2AI, HIST1H2BL, HIST1H3B, HIST2H2BF, HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-E, HLF, HMGA1, HMGA2, HMGCS2, HMMR, HOPX, HORMAD1, HOXA11, HOXB2, HPCAL1, HRAS, HRASLS, HSD11B1, HSP90AA1, HSP90AB1, HSPA4L, HSPB1, ICAM1, ICAM2, ICOS, ID1, ID2, IDO1, IFI16, IFI27, IFI35, IFI6, IFIT1, IFIT2, IFIT3,67MF-369983826Docket No.: 197102021140IFITM2, IFITM3, IFNG, IFNL2, IGF1, IGF1R, IGFBP1, IGFBP3, IGFBP4, IGLL5, IHH, IKBKE, IKZF1, IKZF2, IKZF3, IL10, IL11, IL12A, IL13, IL13RA2, IL15, IL16, IL17RA, ILIA, IL1B, IL1R1, IL1RN, IL21R, IL23A, IL2RA, IL3, IL33, IL3RA, IL4R, IL6, IL6R, IL6ST, IL7, IL7R, IMPDH1, INPPI, INSR, INSRR, IPO8, IQGAP3, IRF1, IRF4, IRF7, IRF8, IRGM, IRS2, IRX4, ISG20, ISY1, ITGAM, ITGAV, ITGAX, ITGB1, ITGB2, ITGB4, ITK, ITM2A, ITPKB, JAK1, JAK2, JAK3, J AML, JAZF1, JUN, KAT6A, KCNE3, KCNJ15, KCNK5, KCNMA1, KDM1A, KDM3B, KDM4C, KDM5C, KDM5D, KDR, KDSR, KIAA0040, KIAA0125, KIAA0319L, KIAA1462, KIAA1804, KIF13B, KIF23, KIF2B, KIF2C, KIF5B, KIFC1, KIR2DL1, KIR2DL3, KIR3DL1, KIR3DL2, KIR3DS1, KIT, KLF2, KLF4, KLK3, KLRB1, KLRC3, KLRC4, KLRD1, KLRK1, KMT2A, KMT2C, KMT2D, KMT5A, KRAS, KRT14, KRT17, KRT31, KRT5, KRT6A, KRTCAP3, KYNU, LAG3, LAIR1, LAMB1, LASPI, LATS1, LATS2, LCK, LCN2, LCP1, LDHB, LEF1, LGALS2, LGALS3, LILRB5, LIMD1, LIMK2, LINC-ROR, LINC00598, LIPH, LIPI, LMNA, LMO1, LMO2, LMO3, LMO4, LOC100506207, LOC100507346, LOC100507424, LPP, LRMP, LRP1, LRP8, LRRC15, LTF, LTK, LUZP4, LY6E, LY6G6D, LYL1, LZTR1, MACC1, MAF, MAFB, MAGEA1, MAGEA10, MAGEA11, MAGEA12, MAGEA2B, MAGEA3, MAGEA4, MAGEA5, MAGEA6, MAGEA8, MAGEA9B, MAGEB1, MAGEBIO, MAGEB16, MAGEB17, MAGEB18, MAGEB2, MAGEB3, MAGEB4, MAGEB5, MAGEB6, MAGECI, MAGEC2, MAGEC3, MALAT1, MALT1, MAML2, MAML3, MAP2, MAP2K1, MAP2K3, MAP3K7, MAP3K8, MAP4K4, MAPK1, MAPK3, MAPKAPK2, MAPT, MARK1, MASP2, MAST1, MAST2, MASTL, MB21D1, MBTD1, MCAM, MCL1, MCM10, MCM2, MCM4, MCM6, MDC1, MDM2, MDS2, MECOM, MEF2C, MEF2D, MEG3, MEGF9, MELK, MEN1, MEST, MET, METRNL, MFAP4, MFAP5, MGA, MGMT, MGST2, MIA, MIAT, MICB, MIR100, MITF, MKI67, MKL1, MKL2, MLF1, MLH1, MLLT1, MLLT10, MLPH, MME, MMP11, MN1, MNX1, MOCOS, MPZL3, MRAS, MRE11A, MRVI1, MS4A1, MS4A2, MS4A4A, MSH2, MSH6, MSI2, MSMB, MSN, MST1R, MTAP, MTCP1, MTHFD1L, MTOR, MUC1, MUC16, MUTYH, MVP, MX1, MX2, MYB, MYBL2, MYC, MYCL, MYCN, MYCT1, MYD88, MYH11, MYH9, NAB2, NAT1, NAV3, NBEA, NBEAP1, NBN, NCAM1, NCOA2, NCOR1, NCR1, NDC80, NDE1, NDRG1, NEAT1, NECTIN1, NECTIN2, NECTIN3, NEK1, NEK2, NEK6, NELL2, NF1, NF2, NFATC2, NFE2L2, NFIC, NFKB2, NID2, NIN, NKD1, NKG7, NKX3-1, NLK, NONO, NOS1, NOS1AP, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPAS2, NPM1, NR4A3, NRAP, NRARP, NRAS, NRG1, NRG2, NRP1, NRP2, NRTN, NSD1, NT5C3A, NT5E, NTRK1, NTRK2, NTRK3, NUF2, NUMA1, NUMBL, NUP214, NUP98, NUTM1, NUTM2A, NXF2B, NXPH3, OAS3, OASL, ODC1, OGN, OLFM1, OLFM4, OLIG2,68MF-369983826Docket No.: 1971020211400RAI2, 0RC6, P2RY8, PADI2, PAFAH1B2, PAGE5, PAK2, PAK4, PALB2, PAMR1, PARP1, PARP12, PARP14, PAX3, PAX5, PAX7, PAX8, PBK, PBX1, PBX3, PCDH17, PCSK1, PDCD1, PDCD1LG2, PDGFA, PDGFB, PDGFD, PDGFRA, PDGFRB, PDIA3, PDZK1IP1, PECAM1, PFN2, PGR, PHF1, PHF11, PHGDH, PHLPP1, PICALM, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIM2, PIM3, PKN1, PLA2G7, PLAC8, PLAG1, PLAGL2, PLCB4, PLEK2, PLEKHA4, PLEKHB1, PLK2, PLPP3, PLVAP, PMEPA1, PML, PMS1, PMS2, PNOC, PNPLA7, PODXL, POLDI, POLE, POU2F2, POU5F1, PPARG, PPM1J, PPP1R13L, PRDM15, PRDM16, PRF1, PRKACA, PRKACB, PRKACG, PRKCA, PRKCB, PRMT1, PRMT5, PRND, PR0M1, PRPF6, PRPF8, PSAT1, PSCA, PSD3, PSENEN, PSIP1, PSMB10, PSMB8, PSMB9, PSME1, PTCHI, PTCH2, PTCRA, PTEN, PTGDS, PTGER2, PTGER4, PTGS2, PTPN1, PTPN11, PTPN22, PTPRB, PTPRC, PTPRK, PTPRO, PTPRZ1, PTRF, PTTG1, PUM1, PVR, PVRIG, PXDC1, R3HDM1, RAB23, RAB27A, RAB29, RAC1, RAD50, RAD51, RAD51AP1, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAFI, RAPGEFL1, RARA, RASGRF1, RASIP1, RASSF6, RBI, RBL1, RBM24, RBP7, RBX1, RECQL4, REG4, RELA, RERG, RET, RGCC, RGS10, RGS16, RGS2, RHOA, RHOH, RHOJ, RIT1, RNF13, ROBO4, ROCK2, ROPN1, ROPN1B, ROR1, RORA, RORC, ROS1, RP1, RPL23, RPL39L, RPS26, RPS6KA1, RPS6KB1, RPSAP52, RRAGC, RRAS, RRM2, RSAD2, RSPO2, RSPO3, RUNX1, RUNX1T1, RUNX2, RUNX3, S100A12, S100A8, S1PR2, SAA1, SAGE1, SAMD9L, SAP30, SCD, SCD5, SCML4, SCUBE2, SDC1, SDHA, SDHB, SDHC, SDHD, SEC31A, SELL, SELP, SEMA3E, SEMA4B, SEMA4C, SEMA6D, SEMA7A, SEPT12, SEPT5, SEPT6, SEPT9, SEPW1, SERPINA9, SERPINB13, SERPINB2, SERPINB5, SERPINE1, SERPINF1, SESN1, SESN2, SESN3, SET, SF3B1, SFRP1, SGK3, SH2D1A, SH2D1B, SH2D2A, SH3BP5, SH3GL1, SH3PXD2A, SHCBP1, SHISA5, SHISA8, SHOC2, SIGLEC5, SKP1, SLAMF1, SLC16A3, SLC1A2, SLC22A8, SLC39A6, SLC40A1, SLC45A3, SLC7A8, SLC9A3R1, SLCO2A1, SLFN11, SLIT2, SMAD2, SMAD3, SMAD4, SMAD9, SMARCB1, SMURF2, SNAI1, SNRNP70, SNW1, SNX29, SOCS1, SOS1, SOS2, SOX11, SOX17, SOX18, SOX9, SP2, SPANXA1, SPANXB1, SPANXC, SPARC, SPARCL1, SPIB, SPINK1, SPN, SPP1, SPRY4, SRC, SRD5A1, SREBF1, SRSF3, SS18, SSPO, SSX1, SSX2, SSX2B, SSX3, SSX4, SSX5, ST3GAL2, STAT1, STAT3, STAT4, STAT6, STAU2, STEAP1, STEAP4, STIL, STK11, STON1, SULF2, SULT1A1, SUV39H2, SYCP1, SYCP3, SYK, TACSTD2, TAF15, TAGAP, TAGLN, TALI, TAL2, TAPI, TAP2, TAPBP, TBC1D10C, TBC1D4, TBC1D9, TBL1XR1, TBX21, TCF12, TCF3, TCF4, TCF7L1, TCF7L2, TCL1A, TCL6, TDG, TDGF1, TDRD7, TEAD1, TEC, TEK, TENM3, TERC, TERT, TET1, TET2, TET3, TFCP2L1, TFE3, TFEB, TFF1, TFG, TFPT, TFRC, TGFB1, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBR2, THADA,69MF-369983826Docket No.: 197102021140THBD, THBS1, THY1, TIAM1, TIE1, TIGIT, TIMP3, TLL1, TLR2, TLR3, TLX1, TLX3, TMEM173, TMEM38A, TMEM45B, TMEM55B, TMPRSS2, TNF, TNFRSF10C, TNFRSF11A, TNFRSF14, TNFRSF17, TNFRSF1A, TNFRSF1B, TNFRSF25, TNFRSF8, TNFRSF9, TNFSF1O, TNFSF11, TNFSF12, TNFSF13B, TNFSF4, TNFSF9, TNKS, TNKS2, TNS1, TOPI, TOP2A, TP53, TP53BP1, TP53INP1, TP53INP2, TP63, TP73, TPM1, TPM2, TPM3, TPM4, TPSAB1, TPSB2, TPST1, TPX2, TRAT1, TREM2, TREX1, TRIM2, TRIM24, TRIM56, TRIP11, TRPS1, TSC1, TSC2, TSHR, TTC39B, TTK, TTE, TTTY14, TTYH1, TWIST1, TYK2, TYMS, UBA7, UBE2C, UBE2T, UBXN4, UGT8, UNC5B, UPK1A, UPP1, USP44, USP6, USP8, VAV3, VCAM1, VCE, VEGFA, VEGFB, VEGFC, VGEE1, VHE, VIM, VNN3, VPREB1, VWF, WASH5P, WBSCR17, WHSCI, WHSC1E1, WIFI, WNT11, WNT16, WNT2, WNT5B, WNT7A, WNT7B, WNT8B, WT1, WWTR1, XCE1, XCE2, XIST, XPA, XPO1, YAP1, YWHAE, YY1, ZAP70, ZBP1, ZBTB16, ZBTB46, ZC3H13, ZC3HAV1, ZEB1, ZEB2, ZIC2, ZMAT3, ZMYM2, ZNF384, ZNF521, ZNF608, ZNF703, ZNF750, ZNRF3, or any combination thereof.

[0234] In some instances, acquiring a sequence read for one or more subject intervals comprises sequencing a subject interval with a sequencing method that provides a sequence read length (or average sequence read length) of at least 20 bases, at least 30 bases, at least 40 bases, at least 50 bases, at least 60 bases, at least 70 bases, at least 80 bases, at least 90 bases, at least 100 bases, at least 120 bases, at least 140 bases, at least 160 bases, at least 180 bases, at least 200 bases, at least 220 bases, at least 240 bases, at least 260 bases, at least 280 bases, at least 300 bases, at least 320 bases, at least 340 bases, at least 360 bases, at least 380 bases, or at least 400 bases. In some instances, acquiring a sequence read for the one or more subject intervals may comprise sequencing a subject interval with a sequencing method that provides a sequence read length (or average sequence read length) of any number of bases within the range described in this paragraph, e.g., a sequence read length (or average sequence read length) of 56 bases.

[0235] In some instances, acquiring a sequence read for one or more subject intervals may comprise sequencing with at least lOOx or more coverage (or depth) on average. In some instances, acquiring a sequence read for one or more subject intervals may comprise sequencing with at least lOOx, at least 150x, at least 200x, at least 250x, at least 500x, at least 750x, at least l,000x, at least 1,500 x, at least 2,000x, at least 2,500x, at least 3,000x, at least 3,500x, at least 4,000x, at least 4,500x, at least 5,000x, at least 5,500x, or at least 6,000x or more coverage (or depth) on average. In some instances, acquiring a sequence read for one or more subject intervals may comprise sequencing with an average coverage (or depth) having any value within the range of values described in this paragraph, e.g., at least 160x.70MF-369983826Docket No.: 197102021140

[0236] In some instances, acquiring a read for the one or more subject intervals comprises sequencing with an average sequencing depth having any value ranging from at least lOOx to at least 6,000x for greater than about 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% of the gene loci sequenced. For example, in some instances acquiring a read for the subject interval comprises sequencing with an average sequencing depth of at least 125x for at least 99% of the gene loci sequenced. As another example, in some instances acquiring a read for the subject interval comprises sequencing with an average sequencing depth of at least 4,100x for at least 95% of the gene loci sequenced.

[0237] In some instances, the relative abundance of a nucleic acid species in the library can be estimated by counting the relative number of occurrences of their cognate sequences (e.g., the number of sequence reads for a given cognate sequence) in the data generated by the sequencing experiment.

[0238] In some instances, the disclosed methods and systems provide nucleotide sequences for a set of subject intervals (e.g., gene loci), as described herein. In certain instances, the sequences are provided without using a method that includes a matched normal control (e.g., a wild-type control) and / or a matched tumor control (e.g., primary versus metastatic).

[0239] In some instances, the level of sequencing depth as used herein (e.g., an X-fold level of sequencing depth) refers to the number of reads (e.g., unique reads) obtained after detection and removal of duplicate reads (e.g., PCR duplicate reads). In other instances, duplicate reads are evaluated, e.g., to support detection of copy number alteration (CNAs).Alignment

[0240] Alignment is the process of matching a read with a location, e.g., a genomic location or locus. In some instances, NGS reads may be aligned to a known reference sequence (e.g., a wildtype sequence). In some instances, NGS reads may be assembled de novo. Methods of sequence alignment for NGS reads are described in, e.g., Trapnell, C. and Salzberg, S.L. Nature Biotech., 2009, 27:455-457. Examples of de novo sequence assemblies are described in, e.g., Warren R., et al., Bioinformatics, 2007, 23:500-501; Butler, J. et al., Genome Res., 2008, 18:810-820; and Zerbino, D.R. and Birney, E., Genome Res., 2008, 18:821-829. Optimization of sequence alignment is described in the art, e.g., as set out in International Patent Application Publication No. WO 2012 / 092426. Additional description of sequence alignment methods is provided in, e.g., International Patent Application Publication No. WO 2020 / 236941, the entire content of which is incorporated herein by reference.71MF-369983826Docket No.: 197102021140

[0241] Misalignment (e.g., the placement of base-pairs from a short read at incorrect locations in the genome), e.g., misalignment of reads due to sequence context (e.g., the presence of repetitive sequence) around an actual cancer mutation can lead to reduction in sensitivity of mutation detection, can lead to a reduction in sensitivity of mutation detection, as reads for the alternate allele may be shifted off the histogram peak of alternate allele reads. Other examples of sequence context that may cause misalignment include short-tandem repeats, interspersed repeats, low complexity regions, insertions - deletions (indels), and paralogs. If the problematic sequence context occurs where no actual mutation is present, misalignment may introduce artifactual reads of “mutated” alleles by placing reads of actual reference genome base sequences at the wrong location. Because mutation-calling algorithms for multigene analysis should be sensitive to even low-abundance mutations, sequence misalignments may increase false positive discovery rates and / or reduce specificity.

[0242] In some instances, the methods and systems disclosed herein may integrate the use of multiple, individually-tuned, alignment methods or algorithms to optimize base-calling performance in sequencing methods, particularly in methods that rely on massively parallel sequencing (MPS) of a large number of diverse genetic events at a large number of diverse genomic loci. In some instances, the disclosed methods and systems may comprise the use of one or more global alignment algorithms. In some instances, the disclosed methods and systems may comprise the use of one or more local alignment algorithms. Examples of alignment algorithms that may be used include, but are not limited to, the Burrows-Wheeler Alignment (BWA) software bundle (see, e.g., Li, et al. (2009), “Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform”, Bioinformatics 25:1754-60; Li, et al. (2010), Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform", Bioinformatics epub. PMID:20080505), the Smith-Waterman algorithm (see, e.g., Smith, et al. (1981), ’’Identification of Common Molecular Subsequences", J. Molecular Biology 147(1): 195-197), the Striped Smith-Waterman algorithm (see, e.g., Farrar (2007), ’’Striped Smith-Waterman Speeds Database Searches Six Times Over Other SIMD Implementations", Bioinformatics 23(2): 156-161), the Needleman-Wunsch algorithm (Needleman, et al. (1970) ”A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Molecular Biology 48(3):443-53), or any combination thereof.

[0243] In some instances, the methods and systems disclosed herein may also comprise the use of a sequence assembly algorithm, e.g., the Arachne sequence assembly algorithm (see, e.g., Batzoglou, et al. (2002), “ARACHNE: A Whole-Genome Shotgun Assembler”, Genome Res.12:177-189).72MF-369983826Docket No.: 197102021140

[0244] In some aspects, the methods and systems disclosed herein may integrate the use of alignment methods optimized or useful for quantification of gene expression values. Methods known in the art for aligning and quantifying RNA seq reads may be used. In some aspects, gene expression values are expressed as transcripts per million for a gene loci such as any of the loci described herein or the full transcriptome. Methods for alignment and quantification may include but are not limited to BWA, Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 25(14) bioinformatics. (2009); Salmon, Patro R. et. al., Salmon provides fast and bias-aware quantification of transcript expression. 14(4) Nat Methods. (2017); Kallisto, Bray N.L et. al., Near optimal probabilistic RNA-seq quantification, 34 Nature Biotechnology (2016); and STAR, Dobin A. et. al., STAR: ultrafast universal RNA-seq aligner.29(l)Bioinformatics. (2013).

[0245] In some instances, the alignment method used to analyze sequence reads is not individually customized or tuned for detection of different variants (e.g., point mutations, insertions, deletions, and the like) at different genomic loci. In some instances, different alignment methods are used to analyze reads that are individually customized or tuned for detection of at least a subset of the different variants detected at different genomic loci. In some instances, different alignment methods are used to analyze reads that are individually customized or tuned to detect each different variant at different genomic loci. In some instances, tuning can be a function of one or more of: (i) the genetic locus (e.g., gene loci, micro satellite locus, or other subject interval) being sequenced, (ii) the tumor type associated with the sample, (iii) the variant being sequenced, or (iv) a characteristic of the sample or the subject. The selection or use of alignment conditions that are individually tuned to a number of specific subject intervals to be sequenced allows optimization of speed, sensitivity, and specificity. The method is particularly effective when the alignment of reads for a relatively large number of diverse subject intervals are optimized.

[0246] In some instances, the method includes the use of an alignment method optimized for rearrangements in combination with other alignment methods optimized for subject intervals not associated with rearrangements.

[0247] In some instances, the methods disclosed herein further comprise selecting or using an alignment method for analyzing, e.g., aligning, a sequence read, wherein said alignment method is a function of, is selected responsive to, or is optimized for, one or more of: (i) tumor type, e.g., the tumor type in the sample; (ii) the location (e.g., a gene locus) of the subject interval being sequenced; (iii) the type of variant (e.g., a point mutation, insertion, deletion, substitution, copy number variation (CNV), rearrangement, or fusion) in the subject interval being sequenced; (iv)73MF-369983826Docket No.: 197102021140the site (e.g., nucleotide position) being analyzed; (v) the type of sample (e.g., a sample described herein); and / or (vi) adjacent sequence(s) in or near the subject interval being evaluated (e.g., according to the expected propensity thereof for misalignment of the subject interval due to, e.g., the presence of repeated sequences in or near the subject interval). In some instances, the methods comprise selecting or using an alignment method for analyzing transcript-specific variation and / or alternative spicing.

[0248] In some instances, the methods disclosed herein allow for the rapid and efficient alignment of troublesome reads, e.g., a read having a rearrangement. Thus, in some instances where a read for a subject interval comprises a nucleotide position with a rearrangement, e.g., a translocation, the method can comprise using an alignment method that is appropriately tuned and that includes: (i) selecting a rearrangement reference sequence for alignment with a read, wherein said rearrangement reference sequence aligns with a rearrangement (in some instances, the reference sequence is not identical to the genomic rearrangement); and (ii) comparing, e.g., aligning, a read with said rearrangement reference sequence.

[0249] In some instances, alternative methods may be used to align troublesome reads. These methods are particularly effective when the alignment of reads for a relatively large number of diverse subject intervals is optimized. By way of example, a method of analyzing a sample can comprise: (i) performing a comparison (e.g., an alignment comparison) of a read using a first set of parameters (e.g., using a first mapping algorithm, or by comparison with a first reference sequence), and determining if said read meets a first alignment criterion (e.g., the read can be aligned with said first reference sequence, e.g., with less than a specific number of mismatches); (ii) if said read fails to meet the first alignment criterion, performing a second alignment comparison using a second set of parameters, (e.g., using a second mapping algorithm, or by comparison with a second reference sequence); and (iii) optionally, determining if said read meets said second criterion (e.g., the read can be aligned with said second reference sequence, e.g., with less than a specific number of mismatches), wherein said second set of parameters comprises use of, e.g., said second reference sequence, which, compared with said first set of parameters, is more likely to result in an alignment with a read for a variant (e.g., a rearrangement, insertion, deletion, or translocation).

[0250] In some instances, the alignment of sequence reads in the disclosed methods may be combined with a mutation calling method as described elsewhere herein. As discussed herein, reduced sensitivity for detecting actual mutations may be addressed by evaluating the quality of alignments (manually or in an automated fashion) around expected mutation sites in the genes or genomic loci (e.g., gene loci) being analyzed. In some instances, the sites to be evaluated can be 74MF-369983826Docket No.: 197102021140obtained from databases of the human genome (e.g., the HG19 human reference genome) or cancer mutations (e.g., COSMIC). Regions that are identified as problematic can be remedied with the use of an algorithm selected to give better performance in the relevant sequence context, e.g., by alignment optimization (or re-alignment) using slower, but more accurate alignment algorithms such as Smith-Waterman alignment. In cases where general alignment algorithms cannot remedy the problem, customized alignment approaches may be created by, e.g., adjustment of maximum difference mismatch penalty parameters for genes with a high likelihood of containing substitutions; adjusting specific mismatch penalty parameters based on specific mutation types that are common in certain tumor types (e.g. CaT in melanoma); or adjusting specific mismatch penalty parameters based on specific mutation types that are common in certain sample types (e.g. substitutions that are common in FFPE).

[0251] Reduced specificity (increased false positive rate) in the evaluated subject intervals due to misalignment can be assessed by manual or automated examination of all mutation calls in the sequencing data. Those regions found to be prone to spurious mutation calls due to misalignment can be subjected to alignment remedies as discussed above. In cases where no algorithmic remedy is found possible, “mutations” from the problem regions can be classified or screened out from the panel of targeted loci.Systems

[0252] Also disclosed herein are systems designed to implement any of the disclosed methods for determining a receptor protein expression status and / or HR status in a sample from a subject. The systems may comprise, e.g., one or more processors, and a memory unit communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: determine a receptor protein expression status (e.g., HR status) of a test sample from a subject having cancer by: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide (e.g., HR) expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic), wherein the receptor polypeptide expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., predicted HR75MF-369983826Docket No.: 197102021140characteristic) and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein (e.g., HR) expression machine learning model a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., predicted HR characteristic) and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein expression status (e.g., HR status) of the test sample based on the predicted protein expression marker characteristic (e.g., predicted HR characteristic) and / or a combined predicted protein expression marker characteristic for the test sample.

[0253] The systems may be designed to implement any of the disclosed methods for training the machine learning models (e.g. receptor polypeptide expression machine learning model and / or HR expression machine learning model) described herein. The systems may comprise, e.g., one or more processors, and a memory unit communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: receive, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic), wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identify a plurality of differentially expressed genes between the gene expression data for the first subset of the plurality of training samples and the gene expression data for the second subset of the plurality of training samples; generate, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides (e.g., HR characteristic) for the plurality of training samples; train, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., predicted HR characteristic) and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0254] In some instances, the systems may be designed to implement the processes of any one of FIGS. 1-4. The processes can be performed, for example, using one or more electronic devices 76MF-369983826Docket No.: 197102021140implementing a software platform. In some examples, the process can be performed using a client-server system, and the blocks of the process divided up in any manner between the server and a client device. In other examples, the blocks of the processes are divided up between the server and multiple client devices. Thus, while portions of processes are described herein as being performed by particular devices of a client-server system, it will be appreciated that the processes are not so limited. In other examples, the processes is performed using only a client device or only multiple client devices. In the processes, some blocks are, optionally, combined, the order of some blocks is, optionally, changed, and some blocks are, optionally, omitted. In some examples, additional steps may be performed in combination with the processes.Accordingly, the operations as illustrated (and described in greater detail below) are exemplary by nature and, as such, should not be viewed as limiting.

[0255] In some instances, the disclosed systems may further comprise a sequencer, e.g., a next generation sequencer (also referred to as a massively parallel sequencer). Examples of next generation (or massively parallel) sequencing platforms include, but are not limited to, Roche / 454’s Genome Sequencer (GS) FLX system, Illumina / Solexa’s Genome Analyzer (GA), Illumina’s HiSeq® 2500, HiSeq® 3000, HiSeq® 4000 and NovaSeq® 6000 sequencing systems, Life / APG’s Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator’s G.007 system, Helicos BioSciences’ HeliScope Gene Sequencing system, ThermoFisher Scientific’s Ion Torrent Genexus system, or Pacific Biosciences’ PacBio® RS system.

[0256] In some instances, the disclosed systems may be used for determining a receptor protein expression status and / or HR status in any of a variety of samples as described herein (e.g., a tissue sample or biopsy sample,).

[0257] In some instances, the plurality of gene loci for which sequencing data is processed to determine receptor protein expression status and / or HR status may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 0, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000 or more than 3500 gene loci (or any number of gene loci within the range of 1 to more than 1000 gene loci).

[0258] In some instance, the nucleic acid sequence data is acquired using a next generation sequencing technique (also referred to as a massively parallel sequencing technique) having a read-length of less than 400 bases, less than 300 bases, less than 200 bases, less than 150 bases, less than 100 bases, less than 90 bases, less than 80 bases, less than 70 bases, less than 60 bases, less than 50 bases, less than 40 bases, or less than 30 bases. In some instances, the nucleic acid sequence data is RNA expression data.77MF-369983826Docket No.: 197102021140

[0259] In some instances, the determination of receptor protein expression status and / or HR status is used to select, initiate, adjust, or terminate a treatment for cancer in the subject (e.g., a patient) from which the sample was derived, as described elsewhere herein.

[0260] In some instances, the disclosed systems may further comprise sample processing and library preparation workstations, microplate-handling robotics, fluid dispensing systems, temperature control modules, environmental control chambers, additional data storage modules, data communication modules (e.g., Bluetooth®, WiFi, intranet, or internet communication hardware and associated software), display modules, one or more local and / or cloud-based software packages (e.g., instrument / system control software packages, sequencing data analysis software packages), etc., or any combination thereof. In some instances, the systems may comprise, or be part of, a computer system or computer network as described elsewhere herein.Machine learning

[0261] Any of a variety of machine learning approaches & algorithms (where a machine learning model, as referred to herein, comprises a trained machine learning algorithm) may be used in implementing the disclosed methods. For example, the machine learning model (e.g., receptor polypeptide expression machine learning model and / or HR status machine learning model) may comprise a supervised learning model (i.e., a model trained using labeled sets of training data), an unsupervised learning model (i.e., a model trained using unlabeled sets of training data), a semi-supervised learning model (i.e., a model trained using a combination of labeled and unlabeled training data), a self-supervised learning model, or any combination thereof. In some examples, the machine learning model can comprise a deep learning model (i.e., a model comprising many layers of coupled “nodes” that may be trained in a supervised, unsupervised, or semi-supervised manner).

[0262] In some instances, one or more machine learning models (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 machine learning models), or a combination thereof, may be utilized to implement the disclosed methods.

[0263] In some instances, the one or more machine learning models may comprise statistical methods for analyzing data. The machine learning models may be used for classification and / or regression of data. The machine learning models can include, for example, neural networks, support vector machines, decision trees, ensemble learning (e.g., bagging-based learning, such as random forest, and / or boosting-based learning), / .-nearest neighbors algorithms, linear regressionbased models, Least Absolute Shrinkage and Selection Operator regression (LASSO), and / or logistic regression-based models. The machine learning models can comprise regularization, such 78MF-369983826Docket No.: 197102021140as LI regularization and / or L2 regularization. The machine learning models can include the use of dimensionality reduction techniques (e.g., principal component analysis, matrix factorization techniques, and / or autoencoders) and / or clustering techniques (e.g., hierarchical clustering, k-means clustering, distribution-based clustering, such as Gaussian mixture models, or densitybased clustering, such as DBSCAN or OPTICS). The one or more machine learning models can comprise solving, e.g., optimizing, an objective function over multiple iterations based on a training data set. The iterative solving approach can be used to minimize and / or optimize a penalty term, e.g., lambda. The iterative solving approach can be used even when the machine learning model comprises a model for which there exists a closed-form solution (e.g., linear regression).

[0264] In some instances, training the machine learning models comprise cross-validation. In some aspects, training the machine learning models comprise n-fold cross-validation. In some aspects, n-fold cross-validation is used to optimize a penalty term, e.g., lambda in a LASSO model. In some instances, n-fold cross-validation is 5-fold cross-validation. In some instances n-fold cross-validation is 10-fold cross-validation. The n may be selected based on the number of training samples.

[0265] In some instances, the machine learning models are classification models. In some instances, the machine learning models are regression models.

[0266] In some instances, the machine learning models can comprise artificial neural networks (ANNs), e.g., deep learning models. For example, the one or more machine learning models / algorithms used for implementing the disclosed methods may include an ANN which can comprise any of a variety of computational motifs / architectures known to those of skill in the art, including, but not limited to, feedforward connections (e.g., skip connections), recurrent connections, fully connected layers, convolutional layers, and / or pooling functions (e.g., attention, including self-attention). The artificial neural networks can comprise differentiable non-linear functions trained by backpropagation.

[0267] Artificial neural networks, e.g., deep learning models, generally comprise an interconnected group of nodes organized into multiple layers of nodes. For example, the ANN architecture may comprise at least an input layer, one or more hidden layers (i.e., intermediate layers), and an output layer. The ANN or deep learning model may comprise any total number of layers (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more than 20 layers in total), and any number of hidden layers (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more than 20 hidden layers), where the hidden layers function as trainable feature extractors that allow mapping of a set of input data to a preferred output value or set of output values. Each layer of the neural network comprises a 79MF-369983826Docket No.: 197102021140plurality of nodes (e.g., at least 10, 25, 50, 75 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000, or more than 10,000 nodes). A node receives input data (e.g., genomic feature data (such as variant sequence data, methylation status data, etc.), non-genomic feature data (e.g., digital pathology image feature data), or other types of input data (e.g., patient- specific clinical data)) that comes either directly from one or more input data nodes or from the output of one or more nodes in previous layers, and performs a specific operation, e.g., a summation operation. In some cases, a connection from an input to a node is associated with a weight (or weighting factor). In some cases, the node may, for example, sum up the products of all pairs of inputs, Xi, and their associated weights, Wt. In some cases, the weighted sum is offset with a bias, b. In some cases, the output of a node may be gated using a threshold or activation function, / , where / may be a linear or non-linear function. The activation function may be, for example, a rectified linear unit (ReLU) activation function or other function such as a saturating hyperbolic tangent, identity, binary step, logistic, arcTan, softsign, parameteric rectified linear unit, exponential linear unit, softPlus, bent identity, softExponential, Sinusoid, Sine, Gaussian, or sigmoid function, or any combination thereof.

[0268] The weighting factors, bias values, and threshold values, or other computational parameters of the neural network (or other machine learning architecture), can be “taught” or “learned” in a training phase using one or more sets of training data (e.g., 1, 2, 3, 4, 5, or more than 5 sets of training data) and a specified training approach configured to solve, e.g., minimize, a loss function. For example, the adjustable parameters for an ANN (e.g., deep learning model) may be determined based on input data from a training data set using an iterative solver (such as a gradient-based method, e.g., backpropagation), so that the output value(s) that the ANN computes (e.g., a classification of a sample or a prediction of a disease outcome) are consistent with the examples included in the training data set. The training of the model (i.e., determination of the adjustable parameters of the model using an iterative solver) may or may not be performed using the same hardware as that used for deployment of the trained model.

[0269] In some instances, the disclosed methods may comprise retraining any of the machine learning models (e.g., iteratively retraining a previously trained model using one or more training data sets that differ from those used to train the model initially). In some instances, retraining the machine learning model may comprise using a continuous, e.g., online, machine learning model, i.e., where the model is periodically or continuously updated or retrained based on new training data. The new training data may be provided by, e.g., a single deployed local operational system, a plurality of deployed local operational systems, or a plurality of deployed, geographically-distributed operational systems. In some instances, the disclosed methods may employ, for 80MF-369983826Docket No.: 197102021140example, pre-trained ANNs, and the pre-trained ANNs can be fine-tuned according to an additional dataset that is inputted into the pre-trained ANN.

[0270] In some instances, performance metrics may be used to assess the precision and accuracy of the machine learning models described herein. Performance metrics may comprise sensitivity, specificity, proportion of true positive (PPV), proportion of true negative (NPV), Kappa, and / or Fl scored. Kappa may be a metric related to how well the model performed compared to random chance. An Fl metric may be related to the performance of a classification model that comprises precision and recall.Computer systems and networks

[0271] FIG. 5 illustrates an example of a computing device or system in accordance with one embodiment. Device 500 can be a host computer connected to a network. Device 500 can be a client computer or a server. As shown in FIG. 5, device 500 can be any suitable type of microprocessor-based device, such as a personal computer, workstation, server or handheld computing device (portable electronic device) such as a phone or tablet. The device can include, for example, one or more processor(s) 510, input devices 520, output devices 530, memory or storage devices 540, communication devices 560, and nucleic acid sequencers 570. Software 550 residing in memory or storage device 540 may comprise, e.g., an operating system as well as software for executing the methods described herein. Input device 520 and output device 530 can generally correspond to those described herein, and can either be connectable or integrated with the computer.

[0272] Input device 520 can be any suitable device that provides input, such as a touch screen, keyboard or keypad, mouse, or voice-recognition device. Output device 530 can be any suitable device that provides output, such as a touch screen, haptics device, or speaker.

[0273] Storage 540 can be any suitable device that provides storage (e.g., an electrical, magnetic or optical memory including a RAM (volatile and non-volatile), cache, hard drive, or removable storage disk). Communication device 560 can include any suitable device capable of transmitting and receiving signals over a network, such as a network interface chip or device. The components of the computer can be connected in any suitable manner, such as via a wired media (e.g., a physical system bus 580, Ethernet connection, or any other wire transfer technology) or wirelessly (e.g., Bluetooth®, Wi-Fi®, or any other wireless technology).

[0274] Software module 550, which can be stored as executable instructions in storage 540 and executed by processor(s) 510, can include, for example, an operating system and / or the processes81MF-369983826Docket No.: 197102021140that embody the functionality of the methods of the present disclosure (e.g., as embodied in the devices as described herein).

[0275] Software module 550 can also be stored and / or transported within any non-transitory computer-readable storage medium for use by or in connection with an instruction execution system, apparatus, or device, such as those described herein, that can fetch instructions associated with the software from the instruction execution system, apparatus, or device and execute the instructions. In the context of this disclosure, a computer-readable storage medium can be any medium, such as storage 540, that can contain or store processes for use by or in connection with an instruction execution system, apparatus, or device. Examples of computer-readable storage media may include memory units like hard drives, flash drives and distribute modules that operate as a single functional unit. Also, various processes described herein may be embodied as modules configured to operate in accordance with the embodiments and techniques described above. Further, while processes may be shown and / or described separately, those skilled in the art will appreciate that the above processes may be routines or modules within other processes.

[0276] Software module 550 can also be propagated within any transport medium for use by or in connection with an instruction execution system, apparatus, or device, such as those described above, that can fetch instructions associated with the software from the instruction execution system, apparatus, or device and execute the instructions. In the context of this disclosure, a transport medium can be any medium that can communicate, propagate or transport programming for use by or in connection with an instruction execution system, apparatus, or device. The transport readable medium can include, but is not limited to, an electronic, magnetic, optical, electromagnetic or infrared wired or wireless propagation medium.

[0277] Device 500 may be connected to a network (e.g., network 604, as shown in FIG. 6 and / or described below), which can be any suitable type of interconnected communication system. The network can implement any suitable communications protocol and can be secured by any suitable security protocol. The network can comprise network links of any suitable arrangement that can implement the transmission and reception of network signals, such as wireless network connections, T1 or T3 lines, cable networks, DSE, or telephone lines.

[0278] Device 500 can be implemented using any operating system, e.g., an operating system suitable for operating on the network. Software module 550 can be written in any suitable programming language, such as C, C++, Java or Python. In various embodiments, application software embodying the functionality of the present disclosure can be deployed in different configurations, such as in a client / server arrangement or through a Web browser as a Web-based82MF-369983826Docket No.: 197102021140application or Web service, for example. In some embodiments, the operating system is executed by one or more processors, e.g., processor(s) 510.

[0279] Device 500 can further include a sequencer 570, which can be any suitable nucleic acid sequencing instrument.

[0280] FIG. 6 illustrates an example of a computing system in accordance with one embodiment. In system 600, device 500 (e.g., as described above and illustrated in FIG. 5) is connected to network 604, which is also connected to device 606. In some embodiments, device 606 is a sequencer. Exemplary sequencers can include, without limitation, Roche / 454’s Genome Sequencer (GS) FLX System, Illumina / Solexa’s Genome Analyzer (GA), Illumina’s HiSeq® 2500, HiSeq® 3000, HiSeq® 4000 and NovaSeq® 6000 Sequencing Systems, Life / APG’s Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator’s G.007 system, Helicos BioSciences’ HeliScope Gene Sequencing system, Pacific Biosciences’ PacBio® RS system, Ultima Genomics UG 100™ platform, or the Illumina NovaSeq X series platform.

[0281] Devices 500 and 606 may communicate, e.g., using suitable communication interfaces via network 604, such as a Local Area Network (LAN), Virtual Private Network (VPN), or the Internet. In some embodiments, network 604 can be, for example, the Internet, an intranet, a virtual private network, a cloud network, a wired network, or a wireless network. Devices 500 and 606 may communicate, in part or in whole, via wireless or hardwired communications, such as Ethernet, IEEE 802.11b wireless, or the like. Additionally, devices 500 and 606 may communicate, e.g., using suitable communication interfaces, via a second network, such as a mobile / cellular network. Communication between devices 500 and 606 may further include or communicate with various servers such as a mail server, mobile server, media server, telephone server, and the like. In some embodiments, Devices 500 and 606 can communicate directly (instead of, or in addition to, communicating via network 604), e.g., via wireless or hardwired communications, such as Ethernet, IEEE 802.11b wireless, or the like. In some embodiments, devices 500 and 606 communicate via communications 608, which can be a direct connection or can occur via a network (e.g., network 604).

[0282] One or all of devices 500 and 606 generally include logic (e.g., http web server logic) or are programmed to format data, accessed from local or remote databases or other sources of data and content, for providing and / or receiving information via network 604 according to various examples described herein.83MF-369983826Docket No.: 197102021140EXEMPLARY IMPLEMENTATIONS

[0283] Exemplary implementations of the methods and systems described herein include:

[0284] Embodiment 1. A method of determining a receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status of a test sample from a subject having cancer, comprising: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2 polypeptide) expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides), wherein the receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2 polypeptide) expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression machine learning model a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

[0285] Embodiment 2. The method of embodiment 1, where the receptor protein (e.g., a cellsurface protein, ER protein, PR protein or HER2 protein) expression machine learning model has been trained using a method, comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER284MF-369983826Docket No.: 197102021140polypeptides), wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides); using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0286] Embodiment 3. A method of training a receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression machine learning model comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data, comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides), wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides); using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker85MF-369983826Docket No.: 197102021140characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0287] Embodiment 4. The method of any of embodiments 1-3, wherein the training data comprising tumor purity metrics for the plurality of training samples.

[0288] Embodiment 5. The method of any of embodiments 1-4, wherein the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) is a quantitative metric.

[0289] Embodiment 6. The method of any of embodiments 1-5, wherein the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) is a quantitative metric based on a percent of cells expressing the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) in a sample of the plurality of training samples.

[0290] Embodiment 7. The method of any of embodiments 1-4, wherein the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) is a classification of a sample of the plurality of training samples as expressing the one or more receptor polypeptides (e.g., cellsurface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) or not expressing the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides).

[0291] Embodiment 8. The method of embodiment 7, wherein the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) a positive if the sample of the plurality of training samples expresses any of the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and negative if the sample of the plurality of training samples expresses none of the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides).

[0292] Embodiment 9. The method of any of embodiments 1-7 wherein the expression of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or 86MF-369983826Docket No.: 197102021140HER2 polypeptides) in the sample of the plurality of training samples has been measured using immunohistochemistry (IHC) staining, flow cytometry, immunofluorescence or mass spectrometry.

[0293] Embodiment 10. The method of embodiment 9, wherein a sample expresses any of the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) if the sample has IHC staining of the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) above a predefined threshold for the receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2 polypeptide).

[0294] Embodiment 11. The method of embodiment 10, wherein the predefined threshold is about 0.01%, about 0.1%, about 1%, about 5%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 99%.

[0295] Embodiment 12. The method of any of embodiments 2-11, wherein the expanded training data comprising tumor purity metrics for the plurality of training samples.

[0296] Embodiment 13. The method of any of embodiments 2-12, wherein the first subset of the plurality of training samples are classified as positive based on the protein expression marker characteristic for one or more of the receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides).

[0297] Embodiment 14. The method any of embodiments 2-13, wherein the second subset of the plurality of training samples are classified as negative based on the protein expression marker characteristic for all of the one or more of the receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides).

[0298] Embodiment 15. The method of any of embodiments 2-14, wherein the plurality of training samples comprises a third subset of the plurality of training samples.

[0299] Embodiment 16. The method embodiment 15, wherein the third subset of the plurality of training are classified as ambiguous based on the protein expression marker characteristic for one or more of the receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides).

[0300] Embodiment 17. The method of any of embodiments 1-16, wherein the predicted protein expression marker characteristic is a first predicted protein expression marker characteristic for a first receptor protein (e.g., a first cell-surface protein, first ER protein, first PR protein or first HER2 protein).

[0301] Embodiment 18. The method of embodiment 17, wherein the receptor protein (e.g., a cellsurface protein, ER protein, PR protein or HER2 protein) expression status is determined based 87MF-369983826Docket No.: 197102021140on the first predicted protein expression marker characteristic and a second predicted protein expression marker characteristic for a second receptor protein (e.g., a second cell-surface protein, second ER protein, second PR protein or second HER2 protein).

[0302] Embodiment 19. The method of any of embodiments 1-18, wherein the combined predicted protein expression marker characteristic is a combined quantitative metric or classification based on at least a first predicted protein expression marker characteristic for a first receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) and a second predicted protein expression marker characteristic for a second receptor protein (e.g., a second cell- surface protein, second ER protein, second PR protein or second HER2 protein).

[0303] Embodiment 20. The method of any of embodiments 1-19, wherein the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status is determined based on the combined predicted protein expression marker characteristic.

[0304] Embodiment 21. The method of any of embodiments 1 and 4-20, wherein the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status is a quantitative metric.

[0305] Embodiment 22. The method of any of embodiments 1 and 4-20, wherein the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status is a classification of the test sample as receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status positive or receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status negative.

[0306] Embodiment 23. The method of embodiment 22, wherein the receptor protein (e.g., a cellsurface protein, ER protein, PR protein or HER2 protein) expression status is receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status positive if the first predicted protein expression marker characteristic, the second predicted protein expression marker characteristic, and / or the combined predicted protein expression marker characteristic is positive.

[0307] Embodiment 24. The method of any of embodiments 1-23, wherein the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) comprise a progesterone receptor (PR) polypeptide, estrogen receptor (ER) polypeptide, a HER2 polypeptide, and / or a polypeptide for EGFR, a PD-1 CD20, PD-1, FOLR1, CLDN18, CA-125, ADAM9, ALCAM, AXL, CA6, CD276, CD46, CEACAM5, DLL3, ENPP3, ERBB3, F3, FOLR1, GPNMB, IGF1R, IL2RA, LY75, Met, MMP14, MSLN, NCAM1, PSMA, PTK7, ROR1, ROR2, SEZ6, SLC34A2, SLC39A6, SSTR2, TFRC, TPBG, BCMA, CD22, CD33, CD79B, EGFR, HER2, NECTIN4, and / or TROP2.88MF-369983826Docket No.: 197102021140

[0308] Embodiment 25. The method of any of embodiments 1-24, wherein the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status relates to hormone receptor (HR) status.

[0309] Embodiment 26. The method of any of embodiments 1-25, wherein the test sample has an IHC staining percentage of less than 10% for any of the one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides).

[0310] Embodiment 27. A method of determining a hormone receptor (HR) status in a test sample from a subject having cancer: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a HR expression machine learning model trained using training data for a plurality of training samples, the training data, comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) HR characteristic determined using a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides, wherein the HR expression machine learning model is trained to output a predicted HR characteristic for the test sample; outputting, using the one or more processors, from the HR expression machine learning model a predicted HR characteristic for the test sample; and determining the HR status of the test sample based on the predicted HR characteristic.

[0311] Embodiment 28. The method of embodiment 27, wherein the HR status of the test sample is HR -positive or HR-negative based on the predicted HR characteristic.

[0312] Embodiment 29. The method of embodiment 27 or 28, wherein the HR status machine learning model has been trained using a method, comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) an HR characteristic determined using a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides, wherein a first subset of the plurality of training samples are HR positive and a second subset of the plurality of training samples are HR negative; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training 89MF-369983826Docket No.: 197102021140gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the HR characteristics for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted HR characteristic of a test sample based on the training data.

[0313] Embodiment 30. A method of training a HR expression machine learning model comprising: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data, comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) an HR characteristic determined using a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides, wherein a first subset of the plurality of training samples are HR positive and a second subset of the plurality of training samples are HR negative; using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the HR characteristics for the plurality of training samples; training, by the one or more processors, a machine learning model to output a predicted HR characteristic of a test sample based on the training data.

[0314] Embodiment 31. The method of any of embodiments 27-30, wherein the HR characteristic is HR characteristic positive if the marker of expression of PR polypeptides and / or the marker of expression of ER polypeptides is positive in the training sample.

[0315] Embodiment 32. The method of any of embodiments 27-31, wherein the test sample has an IHC staining percentage of less than 1% for ER polypeptides and / or PR polypeptides.

[0316] Embodiment 33. The method of any of embodiments 1-32, wherein the gene expression values comprise transcripts per million (TPM) measurements.

[0317] Embodiment 34. The method of any of embodiments 1-33, wherein the plurality of differentially expressed genes are identified with DESeq2.

[0318] Embodiment 35. The method of any of embodiments 2-26 and 28-34, wherein the plurality of differentially expressed genes have a log2fold change in expression greater than about 1, about 2, about 3, or about 4 between the first subset of the plurality of training samples and the second subset of the plurality of training samples.90MF-369983826Docket No.: 197102021140

[0319] Embodiment 36. The method of any of embodiments 2-26 and 28-35, wherein training the machine learning model comprise optimizing lambda in a lasso regression separately or combined with training a neural network, a Random forest model or a Ridge regression.

[0320] Embodiment 37. The method of any of embodiments 2-26 and 28-36, wherein training the machine learning model comprises n-fold cross validation.

[0321] Embodiment 38. The method of any of embodiments 2-26 and 29-37, wherein the tumor purity of the plurality of training samples is less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%.

[0322] Embodiment 39. The method of any of embodiments 1-38, wherein the tumor purity of the test sample is less than about 90%, less than 80%, less than about 70%, less than about 60%, less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%.

[0323] Embodiment 40. The method of embodiment 39, wherein the tumor purity of the test sample is less than about 20%.

[0324] Embodiment 41. The method of any of embodiments 1-40, further comprising obtaining the sample from the subject.

[0325] Embodiment 42. The method of any of embodiments 1-41, wherein the test sample is a tissue biopsy sample.

[0326] Embodiment 43. The method of embodiment 42, wherein the tissue biopsy sample comprises a heterogeneous tissue biopsy sample with a tumor portion.

[0327] Embodiment 44. The method of any of embodiments 1-43, wherein the cancer is a B cell cancer (multiple myeloma), a melanoma, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine cancer, endometrial cancer, cancer of an oral cavity, cancer of a pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel cancer, appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, a cancer of hematological tissue, an adenocarcinoma, an inflammatory myofibroblastic tumor, a gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia Vera, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), soft-tissue sarcoma, fibrosarcoma, myxosarcoma,91MF-369983826Docket No.: 197102021140liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelio sarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell cancer, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familiar hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine cancers, or a carcinoid tumor.

[0328] Embodiment 45. The method of any of embodiments 1-44, wherein the cancer comprises acute lymphoblastic leukemia (Philadelphia chromosome positive), acute lymphoblastic leukemia (precursor B-cell), acute myeloid leukemia (FLT3+), acute myeloid leukemia (with an IDH2 mutation), anaplastic large cell lymphoma, basal cell carcinoma, B-cell chronic lymphocytic leukemia, bladder cancer, breast cancer (HER2 overexpressed / amplified), breast cancer (HER2+), breast cancer (HR+, HER2-), cervical cancer, cholangiocarcinoma, chronic lymphocytic leukemia, chronic lymphocytic leukemia (with 17p deletion), chronic myelogenous leukemia, chronic myelogenous leukemia (Philadelphia chromosome positive), classical Hodgkin lymphoma, colorectal cancer, colorectal cancer (dMMR / MSI-H), colorectal cancer (KRAS wild type), cryopyrin-associated periodic syndrome, a cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, a diffuse large B-cell lymphoma, fallopian tube cancer, a follicular B-cell non-Hodgkin lymphoma, a follicular lymphoma, gastric cancer, gastric cancer (HER2+), gastroesophageal junction (GEJ) adenocarcinoma, a gastrointestinal stromal tumor, a gastrointestinal stromal tumor (KIT+), a giant cell tumor of the bone, a glioblastoma, granulomatosis with polyangiitis, a head and neck squamous cell carcinoma, a hepatocellular carcinoma, Hodgkin lymphoma, juvenile idiopathic arthritis, lupus erythematosus, a mantle cell lymphoma, medullary thyroid cancer, melanoma, a melanoma with a BRAF V600 mutation, a melanoma with a BRAF V600E or V600K mutation, Merkel cell carcinoma, multicentric Castleman’s disease, multiple hematologic malignancies including Philadelphia chromosomepositive AEE and CME, multiple myeloma, myelofibrosis, a non-Hodgkin’ s lymphoma, a nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis, a non- 92MF-369983826Docket No.: 197102021140small cell lung cancer, a non-small cell lung cancer (ALK+), a non-small cell lung cancer (PD-L1+), a non-small cell lung cancer (with ALK fusion or ROS1 gene alteration), a non-small cell lung cancer (with BRAF V600E mutation), a non-small cell lung cancer (with an EGFR exon 19 deletion or exon 21 substitution (L858R) mutations), a non-small cell lung cancer (with an EGFR T790M mutation), ovarian cancer, ovarian cancer (with a BRCA mutation), pancreatic cancer, a pancreatic, gastrointestinal, or lung origin neuroendocrine tumor, a pediatric neuroblastoma, a peripheral T-cell lymphoma, peritoneal cancer, prostate cancer, a renal cell carcinoma, rheumatoid arthritis, a small lymphocytic lymphoma, a soft tissue sarcoma, a solid tumor (MSI-H / dMMR), a squamous cell cancer of the head and neck, a squamous non-small cell lung cancer, thyroid cancer, a thyroid carcinoma, urothelial cancer, a urothelial carcinoma, or Waldenstrom’s macroglobulinemia.

[0329] Embodiment 46. The method of any of embodiments 1-45, wherein the cancer is breast cancer.

[0330] Embodiment 47. The method of embodiment 46, wherein the breast cancer is breast carcinoma, invasive ductal breast cancer, or invasive lobular breast cancer.

[0331] Embodiment 48. The method of any of embodiments 2-26 and 28-47, wherein the plurality of training samples comprise tissue biopsy samples collected for a plurality of training subjects.

[0332] Embodiment 49. The method of embodiment 48, wherein the tissue biopsy samples comprises a heterogeneous tissue biopsy sample with a tumor portion.

[0333] Embodiment 50. The method of embodiment 48 or 49, wherein the plurality of training subjects have a same cancer or different cancer from the subject.

[0334] Embodiment 51. The method of any of embodiments 1-50, where in the method further comprises obtaining test gene expression data comprising: providing a plurality of RNA molecules obtained from the test sample; generating a plurality of nucleic acid molecules from the plurality of RNA molecules; ligating one or more adapters onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying the one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing amplified nucleic acid molecules from the amplified nucleic acid molecules; sequencing, by a sequencer, the captured nucleic acid molecules to obtain a plurality of sequence reads that represent the captured nucleic acid molecules; receiving, using one or more processors, sequence read data for the plurality of sequence reads; generating the test gene expression data by quantifying, using one or more processors, genes expression values for the plurality of differentially expressed genes from the sequence read data.93MF-369983826Docket No.: 197102021140

[0335] Embodiment 52. The method of embodiment 51, wherein the one or more adapters comprise amplification primers, flow cell adaptor sequences, substrate adapter sequences, or sample index sequences.

[0336] Embodiment 53. The method of embodiment 51 or 52, wherein the captured nucleic acid molecules are captured from the amplified nucleic acid molecules by hybridization to one or more bait molecules.

[0337] Embodiment 54. The method of embodiment 53, wherein the one or more bait molecules comprise one or more nucleic acid molecules, each comprising a region that is complementary to a region of a captured nucleic acid molecule.

[0338] Embodiment 55. The method of any one of embodiments 51-54, wherein amplifying nucleic acid molecules comprises performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique.

[0339] Embodiment 56. The method of any one of embodiments 51-55, wherein the sequencing comprises use of an RNA sequencing technique.

[0340] Embodiment 57. The method of embodiment 56, wherein the sequencing comprises massively parallel sequencing, and the massively parallel sequencing technique comprises next generation sequencing (NGS).

[0341] Embodiment 58. The method of any one of embodiments 51-57, wherein the sequencer comprises a next generation sequencer.

[0342] Embodiment 59. The method of any one of embodiments 51-58, wherein one or more of the plurality of sequencing reads overlap one or more gene loci within one or more subgenomic intervals in the sample.

[0343] Embodiment 60. The method of embodiment 59, wherein the one or more gene loci comprises between 10 and 20 loci, between 10 and 40 loci, between 10 and 60 loci, between 10 and 80 loci, between 10 and 100 loci, between 10 and 150 loci, between 10 and 200 loci, between 10 and 250 loci, between 10 and 300 loci, between 10 and 350 loci, between 10 and 400 loci, between 10 and 450 loci, between 10 and 500 loci, between 20 and 40 loci, between 20 and 60 loci, between 20 and 80 loci, between 20 and 100 loci, between 20 and 150 loci, between 20 and 200 loci, between 20 and 250 loci, between 20 and 300 loci, between 20 and 350 loci, between 20 and 400 loci, between 20 and 500 loci, between 40 and 60 loci, between 40 and 80 loci, between 40 and 100 loci, between 40 and 150 loci, between 40 and 200 loci, between 40 and 250 loci, between 40 and 300 loci, between 40 and 350 loci, between 40 and 400 loci, between 40 and 500 loci, between 60 and 80 loci, between 60 and 100 loci, between 60 and 150 loci, between 60 and 200 loci, between 60 and 250 loci, between 60 and 300 loci, between 60 and 350 loci,94MF-369983826Docket No.: 197102021140between 60 and 400 loci, between 60 and 500 loci, between 80 and 100 loci, between 80 and 150 loci, between 80 and 200 loci, between 80 and 250 loci, between 80 and 300 loci, between 80 and 350 loci, between 80 and 400 loci, between 80 and 500 loci, between 100 and 150 loci, between 100 and 200 loci, between 100 and 250 loci, between 100 and 300 loci, between 100 and 350 loci, between 100 and 400 loci, between 100 and 500 loci, between 150 and 200 loci, between 150 and 250 loci, between 150 and 300 loci, between 150 and 350 loci, between 150 and 400 loci, between 150 and 500 loci, between 200 and 250 loci, between 200 and 300 loci, between 200 and 350 loci, between 200 and 400 loci, between 200 and 500 loci, between 250 and 300 loci, between 250 and 350 loci, between 250 and 400 loci, between 250 and 500 loci, between 300 and 350 loci, between 300 and 400 loci, between 300 and 500 loci, between 350 and 400 loci, between 350 and 500 loci, or between 400 and 500 loci.

[0344] Embodiment 61. The method of embodiments 59 or 60, wherein the one or more gene loci comprise ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BCR, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, CAER, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUE3, CUE4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EMSY (Cllorf30), EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESRI, ETV4, ETV5, ETV6, EWSR1, EZH2, EZR, FAM46C, FANCA, FANCC, FANCG, FANCL, FAS, FBXW7, FGF10, FGF12, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, IKBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D (MLL2), KRAS, ETK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, NUTM1, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B,95MF-369983826Docket No.: 197102021140PIK3C2G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLDI, POLE, PPARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCHI, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAFI, RARA, RBI, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, RSPO2, SDC4, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SLC34A2, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SUFU, SYK, TBX3, TEK, TERC, TERT, TET2, TGFBR2, TIPARP, TMPRSS2, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSCI, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703, or any combination thereof.

[0345] Embodiment 62. The method of embodiment 59 or 60, wherein the one or more gene loci comprise ABL, ALK, ALL, B4GALNT1, BAFF, BCL2, BRAF, BRCA, BTK, CD 19, CD20, CD3, CD30, CD319, CD38, CD52, CDK4, CDK6, CML, CRACC, CS1, CTLA-4, dMMR, EGFR, ERBB1, ERBB2, FGFR1-3, FLT3, GD2, HDAC, HER1, HER2, HR, IDH2, IL-ip, IL-6, IL-6R, JAK1, JAK2, JAK3, KIT, KRAS, MEK, MET, MSLH, mTOR, PARP, PD-1, PDGFR, PDGFRa, PDGFRP, PD-L1, PI3K6, PIGF, PTCH, RAF, RANKL, RET, ROS1, SLAMF7, VEGF, VEGFA, VEGFB, or any combination thereof.

[0346] Embodiment 63. The method of any of embodiments 59 - 62, wherein the one or more gene loci comprise ABCB1, ABL1, ABL2, ACSL6, AFF1, AFF4, AKT1, AKT2, AKT3, ALK, APC, AR, ARHGAP26, ARHGDIA, ARID1A, ARID1B, ASXL1, ATIC, ATM, ATR, AXL, B2M, BAP1, BCL10, BCL11B, BCL2, BCL3, BCL6, BCOR, BCR, BRAF, BRCA1, BRCA2, BRD3, BRD4, BRIP1, BTG1, BTK, CAMTAI, CBFA2T3, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD19, CD274, CD28, CD38, CD74, CDH1, CDK4, CDK6, CDKN2A, CDKN2B, CEBPA, CIC, CIITA, CLDN18, CLDN3, CLTC, CNTRL, COL1A1, CREB3L1, CREB3L2, CREBBP, CRLF2, CSF1, CUX1, CXCR4, CYLD, DDIT3, DDR1, DDR2, DDX10, DEK, DHH, DIRC2, DLC1, DNMT3A, DUSP22, EBF1, EGFR, EIF4A2, ELF4, ELL, ELN, EML4, EP300, EPOR, EPS15, ERBB2, ERBB3, ERG, ESRI, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, FBXW7, FEV, FGFR1, FGFR1OP, FGFR2, FGFR3, FGFR4, FGR, FLU, FLT3, FOS, FOSB, FOXO1, FOXO3, FOXO4, FOXP1, FUS, GAS7, GLI1, GLIS2, HDAC10, HERPUD1, HEY1, HIP1, HLF, HMGA1, HMGA2, IGH, IGK, IGL (IGLL5), IKZF1, IKZF2, IKZF3, INSR, IRF4, ITK, JAK1, JAK2, JAK3, JAZF1, KAT6A, KIF5B, KIT, KMT2A, LATS2, LCP1, LMNA, LMO1, LMO2, LPP, LTK, MAF, MAFB, MALT1, MAML2, MAP3K7, MAP3K8, MAST1, MDS2, MECOM, MEF2C, MEF2D, MEN1, MET, MGMT, MKL1, MKL2, MLF1, MLH1, MLLT1, MLLT10, MN1, MNX1, MSH2, MSH6, MSI2, MSMB, MTAP, MTCP1, MYB, MYC, MYH11, NAB2, NBEAP1, NCOA2, NF1, NF2, NIN, NONO, NOTCH1,96MF-369983826Docket No.: 197102021140N0TCH2, N0TCH3, N0TCH4, NPM1, NR4A3, NRAS, NRG1, NRG2, NSD1, NTRK1, NTRK2, NTRK3, NUMA1, NUP214, NUP98, NUTM1, NUTM2A, P2RY8, PALB2, PAX3, PAX5, PAX7, PBX1, PBX3, PDCD1LG2, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PICALM, PIK3CA, PIK3R1, PIK3R2, PKN1, PLAG1, PMS2, PPARG, PRDM16, PRKACA, PRKCA, PRKCB, PRMT5, PTCHI, PTEN, RAFI, RARA, RASGRF1, RBI, RELA, RET, RHOH, ROS1, RPS6KB1, RSPO2, RSPO3, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SEC31A, SEPT5, SEPT6, SEPT7, SET, SH3GL1, SLC45A3, SMAD2, SMAD4, SMARCB1, SNX29, SRC, SS18, SSX1, SSX2, SSX4, STAT6, STIL, STK11, SYK, TAF15, TALI, TAL2, TBL1XR1, TCF3, TCF4, TCL1A, TCL6, TEC, TERT, TET1, TET2, TFE3, TFEB, TFG, TFPT, THADA, TLX1, TLX3, TMPRSS2, TOPI, TP53, TP63, TPM3, TPM4, TRIM24, TRIP11, TSC1, TSC2, TTL, TYK2, USP6, VHL, WHSCI, WHSC1L1, WT1, WWTR1, YAP1, YWHAE, ZAP70, ZBTB16, ZMYM2, ZNF384, ZNF750, or any combination thereof.

[0347] Embodiment 64. The method of any one of embodiments 1, 2, 4-29, and 31-63, wherein the determination indicating the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status of the sample is used to diagnose or confirm a diagnosis of disease in the subject.

[0348] Embodiment 65. The method of embodiment 64, further comprising selecting an anticancer therapy to administer to the subject based on receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status of the test sample.

[0349] Embodiment 66. The method of embodiment 64 or 65, further comprising determining an effective amount of an anti-cancer therapy to administer to the subject based on the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status of the test sample.

[0350] Embodiment 67. The method of any of embodiments 1, 2, 4-29 and 31-66, further comprising treating the subject with an anti-cancer therapy.

[0351] Embodiment 68. The method of any one of embodiments 65-67, wherein the anti-cancer therapy comprises chemotherapy, radiation therapy, immunotherapy, a targeted therapy, or surgery.

[0352] Embodiment 69. The method of any of embodiments 65-68, wherein the targeted anticancer therapy comprises abemaciclib (Verzenio), abiraterone acetate (Zytiga), acalabrutinib (Calquence), ado-trastuzumab emtansine (Kadcyla), afatinib dimaleate (Gilotrif), alectinib (Alecensa), alemtuzumab (Campath), alitretinoin (Panretin), alpelisib (Piqray), amivantamab-vmjw (Rybrevant), anastrozole (Arimidex), apalutamide (Erleada), asciminib hydrochloride 97MF-369983826Docket No.: 197102021140(Scemblix), atezolizumab (Tecentriq), avapritinib (Ayvakit), avelumab (Bavencio), axicabtagene ciloleucel (Yescarta), axitinib (Inlyta), belantamab mafodotin-blmf (Blenrep), belimumab (Benlysta), belinostat (Beleodaq), belzutifan (Welireg), bevacizumab (Avastin), bexarotene (Targretin), binimetinib (Mektovi), blinatumomab (Blincyto), bortezomib (Velcade), bosutinib (Bosulif), brentuximab vedotin (Adcetris), brexucabtagene autoleucel (Tecartus), brigatinib (Alunbrig), cabazitaxel (Jevtana), cabozantinib (Cabometyx), cabozantinib (Cabometyx, Cometriq), canakinumab (Haris), capmatinib hydrochloride (Tabrecta), carfilzomib (Kyprolis), cemiplimab-rwlc (Libtayo), ceritinib (LDK378 / Zykadia), cetuximab (Erbitux), cobimetinib (Cotellic), crizotinib (Xalkori), dabrafenib (Tafinlar), dacomitinib (Vizimpro), daratumumab (Darzalex), daratumumab and hyaluronidase-fihj (Darzalex Faspro), darolutamide (Nubeqa), dasatinib (Sprycel), denileukin diftitox (Ontak), denosumab (Xgeva), dinutuximab (Unituxin), dostarlimab-gxly (Jemperli), durvalumab (Imfinzi), duvelisib (Copiktra), elotuzumab (Empliciti), enasidenib mesylate (Idhifa), encorafenib (Braftovi), enfortumab vedotin-ejfv (Padcev), entrectinib (Rozlytrek), enzalutamide (Xtandi), erdafitinib (Bal vers a), erlotinib (Tarceva), everolimus (Afinitor), exemestane (Aromasin), fam-trastuzumab deruxtecan-nxki (Enhertu), fedratinib hydrochloride (Inrebic), fulvestrant (Faslodex), gefitinib (Iressa), gemtuzumab ozogamicin (Mylotarg), gilteritinib (Xospata), glasdegib maleate (Daurismo), hyaluronidase-zzxf (Phesgo), ibrutinib (Imbruvica), ibritumomab tiuxetan (Zevalin), idecabtagene vicleucel (Abecma), idelalisib (Zydelig), imatinib mesylate (Gleevec), infigratinib phosphate (Truseltiq), inotuzumab ozogamicin (Besponsa), ipilimumab (Yervoy), isatuximab-irfc (Sarclisa), ivosidenib (Tibsovo), ixazomib citrate (Ninlaro), lanreotide acetate (Somatuline Depot), lapatinib (Tykerb), larotrectinib sulfate (Vitrakvi), lenvatinib mesylate (Lenvima), letrozole (Femara), lisocabtagene maraleucel (Breyanzi), loncastuximab tesirine-lpyl (Zynlonta), lorlatinib (Lorbrena), lutetium Lu 177-dotatate (Lutathera), margetuximab-cmkb (Margenza), midostaurin (Rydapt), mobocertinib succinate (Exkivity), mogamulizumab-kpkc (Poteligeo), moxetumomab pasudotox-tdfk (Lumoxiti), naxitamab-gqgk (Danyelza), necitumumab (Portrazza), neratinib maleate (Nerlynx), nilotinib (Tasigna), niraparib tosylate monohydrate (Zejula), nivolumab (Opdivo), obinutuzumab (Gazyva), ofatumumab (Arzerra), olaparib (Lynparza), olaratumab (Lartruvo), osimertinib (Tagrisso), palbociclib (Ibrance), panitumumab (Vectibix), pazopanib (Votrient), pembrolizumab (Keytruda), pemigatinib (Pemazyre), pertuzumab (Perjeta), pexidartinib hydrochloride (Turalio), polatuzumab vedotin-piiq (Polivy), ponatinib hydrochloride (Iclusig), pralatrexate (Folotyn), pralsetinib (Gavreto), radium 223 dichloride (Xofigo), ramucirumab (Cyramza), regorafenib (Stivarga), ribociclib (Kisqali), ripretinib (Qinlock), rituximab (Rituxan), rituximab and hyaluronidase human (Rituxan Hycela), romidepsin (Istodax), rucaparib camsylate (Rubraca),98MF-369983826Docket No.: 197102021140ruxolitinib phosphate (Jakafi), sacituzumab govitecan-hziy (Trodelvy), seliciclib, selinexor (Xpovio), selpercatinib (Retevmo), selumetinib sulfate (Koselugo), siltuximab (Sylvant), sirolimus protein-bound particles (Fyarro), sonidegib (Odomzo), sorafenib (Nexavar), sotorasib (Lumakras), sunitinib (Sutent), tafasitamab-cxix (Monjuvi), tagraxofusp-erzs (Elzonris), talazoparib tosylate (Talzenna), tamoxifen (Nolvadex), tazemetostat hydrobromide (Tazverik), tebentafusp-tebn (Kimmtrak), temsirolimus (Torisel), tepotinib hydrochloride (Tepmetko), tisagenlecleucel (Kymriah), tisotumab vedotin-tftv (Tivdak), tocilizumab (Actemra), tofacitinib (Xeljanz), tositumomab (Bexxar), trametinib (Mekinist), trastuzumab (Herceptin), tretinoin (Vesanoid), tivozanib hydrochloride (Fotivda), toremifene (Fareston), tucatinib (Tukysa), umbralisib tosylate (Ukoniq), vandetanib (Caprelsa), vemurafenib (Zelboraf), venetoclax (Venclexta), vismodegib (Erivedge), vorinostat (Zolinza), zanubrutinib (Brukinsa), ziv-aflibercept (Zaltrap), or any combination thereof.

[0353] Embodiment 70. The method of any one of embodiments 1, 2, 4-29, and 31-69, further comprising generating, by the one or more processors, a report indicating the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status of the test sample.

[0354] Embodiment 71. The method of embodiment 70, further comprising transmitting the report to a healthcare provider.

[0355] Embodiment 72. The method of embodiment 71, wherein the report is transmitted via a computer network or a peer-to-peer connection.

[0356] Embodiment 73. A method for monitoring for switching of receptor protein (e.g., a cellsurface protein, ER protein, PR protein or HER2 protein) expression or HR status of a cancer, the method comprising; determining a first receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status in a first test sample obtained from the subject at a first time point according to the method of any one of embodiments 1, 2, 4-29 and 31-72; determining a second receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status in a second test sample obtained from the subject at a second time point according to the method of any one of embodiments 1, 2, 4-29 and 31-72; and comparing the first receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status to the second receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status, thereby monitoring for switching of receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status.

[0357] Embodiment 74. The method of embodiment 73, further comprising suggesting alternative anti-cancer treatment if a change between the first receptor protein (e.g., a cell-surface 99MF-369983826Docket No.: 197102021140protein, ER protein, PR protein or HER2 protein) expression or HR status and the second receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression or HR status is identified.

[0358] Embodiment 75. A system comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: determine a receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status of a test sample from a subject having cancer by: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2 polypeptide) expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides), wherein the receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2 polypeptide) expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression machine learning model a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

[0359] Embodiment 76. A system comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: receive, at one or more processors, expanded training data for a plurality of training samples, the expanded training data 100MF-369983826Docket No.: 197102021140comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides), wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides); using the expanded training gene expression data, by the one or more processors, identify a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generate, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) for the plurality of training samples; train, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

[0360] Embodiment 77. A non-transitory computer-readable storage medium storing one or more programs, the one or more programs comprising instructions, which when executed by one or more processors of a system, cause the system to: determine a receptor protein (e.g., a cellsurface protein, ER protein, PR protein or HER2 protein) expression status of a test sample from a subject having cancer by: receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes; inputting, using the one or more processors, the test gene expression data into a receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2 polypeptide) expression machine learning model trained using training data for a plurality of training samples, the training data comprising: (i) training gene expression data, consisting of gene expression values for the plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides), wherein the receptor polypeptide (e.g., a cell-surface polypeptide, ER polypeptide, PR polypeptide or HER2101MF-369983826Docket No.: 197102021140polypeptide) expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample; outputting, using the one or more processors, from the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression machine learning model a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) and / or a combined predicted protein expression marker characteristic for the test sample; and determining the receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

[0361] Embodiment 78. A non-transitory computer-readable storage medium storing one or more programs, the one or more programs comprising instructions, which when executed by one or more processors of a system, cause the system to: training a receptor protein (e.g., a cell-surface protein, ER protein, PR protein or HER2 protein) expression machine learning model by: receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising: (i) expanded training gene expression data, comprising gene expression values for a plurality of differentially expressed genes, (ii) a protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides), wherein plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides); using the expanded training gene expression data, by the one or more processors, identifying a plurality of differentially expressed genes between the training gene expression data for the first subset of the plurality of training samples and the training gene expression data for the second subset of the plurality of training samples; generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypeptides) for the plurality of training samples;102MF-369983826Docket No.: 197102021140training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides (e.g., cell-surface polypeptides, ER polypeptides, PR polypeptides or HER2 polypepti...

Claims

Docket No.: 197102021140CLAIMSWhat is claimed is:

1. A method of determining a receptor protein expression status of a test sample from a subject having cancer, comprising:receiving, at one or more processors, test gene expression data for the test sample, the test gene expression data comprising gene expression values for a plurality of differentially expressed genes;inputting, using the one or more processors, the test gene expression data into a receptor polypeptide expression machine learning model trained using training data for a plurality of training samples, the training data comprising:(i) training gene expression data, comprising for a plurality of genes consisting of the plurality of differentially expressed genes,(ii) a protein expression marker characteristic of one or more receptor polypeptides,wherein the receptor polypeptide expression machine learning model is trained to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of an input sample based on input gene expression data for the input sample;outputting, using the one or more processors, from the receptor protein expression machine learning model a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic for the test sample; anddetermining the receptor protein expression status of the test sample based on the predicted protein expression marker characteristic and / or a combined predicted protein expression marker characteristic for the test sample.

2. The method of claim 1, wherein the receptor protein expression machine learning model has been trained using a method, comprising:receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data comprising:(i) expanded training gene expression data, comprising gene expression values for a plurality of genes,109MF-369983826Docket No.: 197102021140(ii) a protein expression marker characteristic of one or more receptor polypeptides, wherein the plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identifying the plurality of differentially expressed genes that are differentially expressed between the expanded training gene expression data for the first subset of the plurality of training samples and the expanded training gene expression data for the second subset of the plurality of training samples;generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides for the plurality of training samples;training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

3. A method of training a receptor protein expression machine learning model comprising:receiving, at one or more processors, expanded training data for a plurality of training samples, the expanded training data, comprising:(i) expanded training gene expression data, comprising gene expression values for a plurality of genes,(ii) a protein expression marker characteristic of one or more receptor polypeptides,wherein the plurality of training samples comprise a first subset of the plurality of training samples and a second subset of the plurality of training samples based on the protein expression marker characteristic of one or more receptor polypeptides; using the expanded training gene expression data, by the one or more processors, identifying the plurality of differentially expressed genes that are differentially expressed between the expanded training gene expression data for the first subset of the plurality of training samples and the expanded training gene expression data for the second subset of the plurality of training samples;110MF-369983826Docket No.: 197102021140generating, by the one or more processors, training data comprising of a subset of the expanded training gene expression data, the subset of the expanded training gene expression data consisting of the expanded training gene expression data for the plurality of differentially expressed genes and the protein expression marker characteristic of one or more receptor polypeptides for the plurality of training samples;training, by the one or more processors, a machine learning model to output a predicted protein expression marker characteristic of one or more receptor polypeptides and / or a combined predicted protein expression marker characteristic of a test sample based on the training data.

4. The method of claim 1, wherein the training data further comprises tumor purity metrics for the plurality of training samples.

5. The method of claim 1, wherein the protein expression marker characteristic of one or more receptor polypeptides is:(i) a quantitative metric based on a percent of cells expressing the one or more receptor polypeptides in a sample of the plurality of training samples or(ii) a classification of a sample of the plurality of training samples as expressing the one or more receptor polypeptides or not expressing the one or more receptor polypeptides.

6. The method of claim 1, wherein the expression of one or more receptor polypeptides in the sample of the plurality of training samples has been measured using immunohistochemistry (IHC) staining, flow cytometry, immunofluorescence or mass spectrometry.

7. The method of claim 2, wherein the expanded training data further comprises tumor purity metrics for the plurality of training samples.

8. The method of claim 2, wherein the first subset of the plurality of training samples are classified as positive based on the protein expression marker characteristic for one or more of the receptor polypeptides.

9. The method of claim 2, wherein the second subset of the plurality of training samples are classified as negative based on the protein expression marker characteristic for all of the one or more of the receptor polypeptides.IllMF-369983826Docket No.: 19710202114010. The method of claim 1, wherein the predicted protein expression marker characteristic is a first predicted protein expression marker characteristic for a first receptor protein.

11. The method of claim 10, wherein the receptor protein expression status is determined based on the first predicted protein expression marker characteristic and a second predicted protein expression marker characteristic for a second receptor protein.

12. The method of claim 1, wherein the combined predicted protein expression marker characteristic is a combined quantitative metric or classification based on at least a first predicted protein expression marker characteristic for a first receptor protein and a second predicted protein expression marker characteristic for a second receptor protein.

13. The method of claim 1, wherein the receptor protein expression status is determined based on the combined predicted protein expression marker characteristic.

14. The method of claim 1, wherein the receptor protein expression status is:(i) a quantitative metric; or(ii) a classification of the test sample as receptor protein expression status positive or receptor protein expression status negative.

15. The method of claim 1, wherein the receptor protein expression status relates to hormone receptor (HR) status.

16. The method of claim 15, wherein the HR status is based on a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides.

17. The method of claim 3, wherein the receptor protein expression status relates to hormone receptor (HR) status.

18. The method of claim 17, wherein the HR status is based on a marker of expression of progesterone receptor (PR) polypeptides and / or a marker of expression of estrogen receptor (ER) polypeptides.112MF-369983826Docket No.: 19710202114019. The method of claim 1, wherein the test sample has an IHC staining percentage of less than 10% for any of the one or more receptor polypeptides.

20. The method of claim 16, wherein the test sample has an IHC staining percentage of less than 1% for ER polypeptides and / or PR polypeptides.MF-369983826